{"doc_id": 0, "doc": {"person_id": 115967545, "visit_occurrence_id": 168111161, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2020-10-28 00:00:00", "visit_end_datetime": "2020-10-28 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 91, "patient_first_visit_date": "2017-08-08 00:00:00", "patient_last_visit_date": "2021-12-21 10:38:54", "end_obs_date": "2021-10-28", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 43, "cumulated_visit_num": 43, "cumulated_approximate_token_count": 10330, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-08 00:00:00, ended at 2017-08-08 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-08 13:48:42, ended at 2017-08-08 15:19:30\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.323\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Disorder of kidney and/or ureter\n- Sleep apnea\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (40 mg total) by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth daily\n- rivaroxaban 20 MG Oral Tablet, started on 2017-05-14, presumably until 2017-05-14, with intended 1 refill(s). Instructions: every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-08 15:32:00, ended at 2017-08-08 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.50 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 165 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 10:56:00, ended at 2017-09-25 13:48:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-09-25, presumably until 2017-09-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 13:49:00, ended at 2017-09-25 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 08:01:39, ended at 2017-11-12 08:54:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.32\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hepatic fibrosis\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 12:31:12, ended at 2017-11-12 14:23:32\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Urogenital finding\n- Primary diagnosis: Hydronephrosis\n- Acute renal failure syndrome\n- Chronic kidney disease stage 3\n- Urinary tract obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-15 00:00:00, ended at 2017-11-15 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-27 00:00:00, ended at 2017-11-27 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-07 00:00:00, ended at 2017-12-07 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Acute non-ST segment elevation myocardial infarction\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 07:14:00, ended at 2017-12-12 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 07:56:19, ended at 2017-12-12 09:36:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Thromboembolism of vein\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 07:20:00, ended at 2017-12-28 07:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 56.8 (percent)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 09:30:00, ended at 2017-12-28 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.7 (ratio)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 67 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.4 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 69 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, started on 2018-01-10, presumably until 2018-02-06, with intended 0 refill(s). Instructions: One syringe subcu 01/15/2018 q 12 hours.  Last syringe 01/16/2018 in am.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 09:57:45, ended at 2018-01-10 12:06:21\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-10 12:13:00, ended at 2018-01-10 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Prothrombin time (PT): 15.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.39 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.1 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of kidney and/or ureter\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 13:00:12, ended at 2018-01-10 14:06:34\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; renal procedures, including upper one-third of ureter, or donor nephrectomy\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hydronephrosis\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- cefazolin 1000 MG Injection, started on 2018-01-17, presumably until 2018-01-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- ketamine 100 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- iothalamic acid, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- iothalamate, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 06:01:00, ended at 2018-01-20 13:20:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.05 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 21.5 (millimole per liter)\n- Body height: 5' 7\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -2.9 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 178.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.5 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 145 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Ultrasonic guidance, intraoperative\n- Resection of Right Kidney, Percutaneous Endoscopic Approach\n- Excision of Right Kidney, Percutaneous Endoscopic Approach, Diagnostic\n- Laparoscopy, surgical; pyeloplasty\n- Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service\n- Robotic Assisted Procedure of Trunk Region, Percutaneous Endoscopic Approach\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Laparoscopy, surgical; nephrectomy, including partial ureterectomy\n\n### Condition\n- Aortocoronary bypass graft present\n- Coagulation factor deficiency syndrome\n- Hydronephrosis\n- Anesthesia of skin\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Uncomplicated asthma\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Old myocardial infarction\n- Chronic kidney disease due to hypertension\n- Illness\n- Primary malignant neoplasm of kidney\n\n### Drug\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-01-17, presumably until 2018-01-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-20, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-01-17, presumably until 2018-01-18\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-19\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-03 00:00:00, ended at 2018-02-03 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of urinary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cellulitis of abdominal wall\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-02-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 09:57:06, ended at 2018-02-06 12:47:03\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Kidney, NOS\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 13:02:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.26 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cellulitis of abdominal wall\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 14:24:01, ended at 2018-02-06 14:57:17\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:13:00, ended at 2018-05-08 07:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:14:00, ended at 2018-05-08 10:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 10:14:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.50 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 10:31:15, ended at 2018-05-08 12:28:13\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:05:00, ended at 2018-12-26 07:20:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.66 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 09:41:30, ended at 2018-12-26 10:32:44\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-30 00:00:00, ended at 2019-09-30 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-25 06:59:00, ended at 2019-12-25 06:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Non-toxic multinodular goiter\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-08 00:00:00, ended at 2017-08-08 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-08 13:48:42, ended at 2017-08-08 15:19:30\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.323\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Disorder of kidney and/or ureter\n- Sleep apnea\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (40 mg total) by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth daily\n- rivaroxaban 20 MG Oral Tablet, started on 2017-05-14, presumably until 2017-05-14, with intended 1 refill(s). Instructions: every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-08 15:32:00, ended at 2017-08-08 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.50 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 165 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 10:56:00, ended at 2017-09-25 13:48:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-09-25, presumably until 2017-09-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 13:49:00, ended at 2017-09-25 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 08:01:39, ended at 2017-11-12 08:54:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.32\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hepatic fibrosis\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 12:31:12, ended at 2017-11-12 14:23:32\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Urogenital finding\n- Primary diagnosis: Hydronephrosis\n- Acute renal failure syndrome\n- Chronic kidney disease stage 3\n- Urinary tract obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-15 00:00:00, ended at 2017-11-15 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-27 00:00:00, ended at 2017-11-27 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-07 00:00:00, ended at 2017-12-07 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Acute non-ST segment elevation myocardial infarction\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 07:14:00, ended at 2017-12-12 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 07:56:19, ended at 2017-12-12 09:36:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Thromboembolism of vein\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 07:20:00, ended at 2017-12-28 07:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 56.8 (percent)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 09:30:00, ended at 2017-12-28 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.7 (ratio)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 67 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.4 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 69 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, started on 2018-01-10, presumably until 2018-02-06, with intended 0 refill(s). Instructions: One syringe subcu 01/15/2018 q 12 hours.  Last syringe 01/16/2018 in am.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 09:57:45, ended at 2018-01-10 12:06:21\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-10 12:13:00, ended at 2018-01-10 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Prothrombin time (PT): 15.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.39 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.1 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of kidney and/or ureter\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 13:00:12, ended at 2018-01-10 14:06:34\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; renal procedures, including upper one-third of ureter, or donor nephrectomy\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hydronephrosis\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- cefazolin 1000 MG Injection, started on 2018-01-17, presumably until 2018-01-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- ketamine 100 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- iothalamic acid, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- iothalamate, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 06:01:00, ended at 2018-01-20 13:20:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.05 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 21.5 (millimole per liter)\n- Body height: 5' 7\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -2.9 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 178.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.5 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 145 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Ultrasonic guidance, intraoperative\n- Resection of Right Kidney, Percutaneous Endoscopic Approach\n- Excision of Right Kidney, Percutaneous Endoscopic Approach, Diagnostic\n- Laparoscopy, surgical; pyeloplasty\n- Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service\n- Robotic Assisted Procedure of Trunk Region, Percutaneous Endoscopic Approach\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Laparoscopy, surgical; nephrectomy, including partial ureterectomy\n\n### Condition\n- Aortocoronary bypass graft present\n- Coagulation factor deficiency syndrome\n- Hydronephrosis\n- Anesthesia of skin\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Uncomplicated asthma\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Old myocardial infarction\n- Chronic kidney disease due to hypertension\n- Illness\n- Primary malignant neoplasm of kidney\n\n### Drug\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-01-17, presumably until 2018-01-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-20, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-01-17, presumably until 2018-01-18\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-19\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-03 00:00:00, ended at 2018-02-03 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of urinary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cellulitis of abdominal wall\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-02-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 09:57:06, ended at 2018-02-06 12:47:03\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Kidney, NOS\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 13:02:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.26 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cellulitis of abdominal wall\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 14:24:01, ended at 2018-02-06 14:57:17\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:13:00, ended at 2018-05-08 07:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:14:00, ended at 2018-05-08 10:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 10:14:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.50 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 10:31:15, ended at 2018-05-08 12:28:13\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:05:00, ended at 2018-12-26 07:20:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.66 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 09:41:30, ended at 2018-12-26 10:32:44\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-30 00:00:00, ended at 2019-09-30 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-25 06:59:00, ended at 2019-12-25 06:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Non-toxic multinodular goiter\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c7f2e67e959f3f68ead2d889c2f719e43217c79c5dd92f832286f7421c6d6d8e", "prompt_hash": "0ff44e1a8f36bcb1e982443ae0f80a3ee068af8498678be9ff4ebb06c4124794", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 1, "doc": {"person_id": 115967648, "visit_occurrence_id": 180405753, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2021-06-06 00:00:00", "visit_end_datetime": "2021-06-06 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 94, "patient_first_visit_date": "2019-12-21 00:00:00", "patient_last_visit_date": "2023-01-16 00:00:00", "end_obs_date": "2022-06-06", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 83, "cumulated_visit_num": 83, "cumulated_approximate_token_count": 13523, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "8bcd6b70cb8efffe2e11d04b49180d1e00130b055ee387b1a6780d0ca59f460f", "prompt_hash": "8d37e8da6e984b2caa158ad0eb0326ab42eb8c00dff2a2c80a0e7bb859c2ad17", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 2, "doc": {"person_id": 115967769, "visit_occurrence_id": 159320772, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2020-05-17 00:00:00", "visit_end_datetime": "2020-05-17 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n", "approximate_token_count": 123, "patient_first_visit_date": "2012-03-31 14:46:00", "patient_last_visit_date": "2023-02-06 10:56:09", "end_obs_date": "2021-05-17", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 1, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 129, "cumulated_visit_num": 129, "cumulated_approximate_token_count": 24713, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "158c09c66bbc2808a3e20c763d96a3c5eed1be8e0ff71a701fa5d42ab1404da8", "prompt_hash": "ff8b17fb56add6a822420af51aff16d9e2cb037ebc16709d65c5c7398e7f4eb7", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 3, "doc": {"person_id": 115968156, "visit_occurrence_id": 169322226, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2020-12-20 14:50:00", "visit_end_datetime": "2020-12-20 23:59:00", "visit_length_in_hours": 9.15, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 104, "patient_first_visit_date": "2009-03-14 11:00:00", "patient_last_visit_date": "2022-11-08 16:25:00", "end_obs_date": "2021-12-20", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 6, "cumulated_visit_num": 6, "cumulated_approximate_token_count": 3919, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e8f389ba77b367cd0b94b9947d1992851710e01f83c6206c3ecfe6277ecfa47d", "prompt_hash": "2421c1e25b143508f760f86236c1e871522a834d44214f35cad7788b4839d6e7", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 4, "doc": {"person_id": 115969160, "visit_occurrence_id": 110298957, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2017-10-13 10:57:00", "visit_end_datetime": "2017-10-13 12:46:00", "visit_length_in_hours": 1.8166666666666667, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-13 10:57:00, ended at 2017-10-13 12:46:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.25 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 111 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 185 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.6 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.93 (thousand per microliter)\n\n### Procedure\n- Removal of Infusion Device from Great Vessel, External Approach\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2017-10-13, presumably until 2017-10-13\n\n", "approximate_token_count": 533, "patient_first_visit_date": "2016-08-05 09:14:00", "patient_last_visit_date": "2023-01-03 00:00:00", "end_obs_date": "2018-10-13", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 90, "cumulated_visit_num": 90, "cumulated_approximate_token_count": 31036, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-05 09:14:00, ended at 2016-08-05 11:37:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, chest (excluding myocardium), with or without contrast material(s)\n- Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences\n- Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Rheumatic tricuspid valve regurgitation\n- Cardiomegaly\n- Aortic incompetence, non-rheumatic\n- Pulmonary incompetence, non-rheumatic\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-02 00:00:00, ended at 2016-09-02 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-04 11:00:00, ended at 2016-09-04 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-01 00:00:00, ended at 2016-10-01 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-01 11:00:00, ended at 2016-10-01 11:26:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-09 00:00:00, ended at 2016-10-09 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 00:00:00, ended at 2016-11-18 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac catheterization including coronary angiography and ventriculography (not to include Swan-Ganz catheter)\n\n### Condition\n- Congestive heart failure\n- Essential hypertension\n- Systolic heart failure\n- Type 2 diabetes mellitus without complication\n- Tetralogy of Fallot\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n- cefazolin 1000 MG Injection, started on 2016-11-18, presumably until 2016-11-18\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-11-18, presumably until 2016-11-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- midazolam 1 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 11:50:00, ended at 2016-11-19 11:55:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.04 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood: 53 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 18.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Base excess in Arterial blood by calculation: -6.5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 161 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 83.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 20.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 150 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 40.3 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Measurement of Cardiac Sampling and Pressure, Bilateral, Percutaneous Approach\n- Dilation of Left Pulmonary Artery, Percutaneous Approach\n- Percutaneous transluminal pulmonary artery balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)\n- Dilation of Right Pulmonary Artery, Percutaneous Approach\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Percutaneous transluminal pulmonary artery balloon angioplasty; single vessel\n- Fluoroscopy of Left Pulmonary Artery using Low Osmolar Contrast\n- Fluoroscopy of Right Pulmonary Artery using Low Osmolar Contrast\n- Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies\n- Collection of blood specimen from a completely implantable venous access device\n- Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (List separately in addition to code for primary procedure)\n\n### Condition\n- Stenosis due to any device, implant AND/OR graft\n- Postoperative state\n- Essential hypertension\n- Pulmonary artery stenosis\n- Adverse effect of prosthetic device\n- Obesity\n- Primary diagnosis: Tetralogy of Fallot\n- Complication of surgical procedure\n- Obstructive sleep apnea syndrome\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- famotidine 10 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2016-11-19, presumably until 2017-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2016-11-19, presumably until 2016-12-03, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2016-11-19, presumably until 2017-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-19 00:00:00, ended at 2016-11-19 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-22 00:00:00, ended at 2016-11-22 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take by mouth.\n- losartan potassium 100 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 100 mg by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-03 14:12:00, ended at 2016-12-03 15:37:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary perfusion imaging (eg, particulate)\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-03 15:38:00, ended at 2016-12-03 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n- Acute myeloid leukemia, disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-05 07:52:00, ended at 2016-12-05 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Ectasia of thoracic aorta\n- Complication associated with device\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-10 00:00:00, ended at 2016-12-10 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative cardiac complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-12-11, presumably until 2017-01-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-11 20:54:00, ended at 2016-12-11 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired renal cystic disease\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.3 (percent)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.1 (second)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.4 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 18.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.02 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 54.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 166 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 465 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Prothrombin time (PT): 14.0 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative cardiac complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Decompression fasciotomy, leg; anterior and/or lateral, and posterior compartment(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n\n### Condition\n- Tetralogy of Fallot\n- Transplanted heart valve present\n- Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative cardiac complication\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 08:46:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Postoperative state\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 08:46:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Cardiac arrhythmia\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-13 08:48:06, ended at 2016-12-13 14:10:03\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.882\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 13:22:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Postoperative cardiac complication\n- Tetralogy of Fallot\n- Cardiomegaly\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 175 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 36.7 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: >4.00 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 59.9 (millimeter mercury column)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 97.6 (millimeter mercury column)\n- Potassium [Moles/volume] in Blood: <2.0 (millimole per liter)\n- Prothrombin time (PT): 77.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Blood: >2.50 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 60.1 (millimeter mercury column)\n- Eosinophils [#/volume] in Blood by Manual count: 0.54 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood: <15 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- Lactate [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.26 (thousand per microliter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 44.3 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.45 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Mixed venous blood: 0.53 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.05 (million per microliter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 662 (unit per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 6 (milli-international unit per milliliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 388 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 93 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.7 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 774 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 39.0 (milligram per deciliter)\n- Fasting glucose [Mass/volume] in Serum or Plasma: 469 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1729.5 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 87.7 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 40 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 38.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.77 (thousand per microliter)\n- Vancomycin [Mass/volume] in Serum or Plasma: 3.8 (microgram per milliliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 34.3 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.61 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 99 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 50 (millimeter mercury column)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 7.40 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 7.7 (milligram per deciliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 8 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 154 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9480 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 694 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Reticulocytes [#/volume] in Blood by Automated count: 213.9 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 153 (millimole per liter)\n- Base excess in Blood by calculation: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.8 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 63.0 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 52.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.60 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative state\n- Primary diagnosis: Illness\n- Atelectasis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- thrombin alfa 1000 UNT/ML Topical Solution, through Topical route, started on 2016-12-16, presumably until 2016-12-16\n- cefazolin 1000 MG Injection, started on 2016-12-16, presumably until 2016-12-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-12-16 06:55:00, ended at 2017-01-18 10:10:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide [Partial pressure] in Venous blood: 61.7 (millimeter mercury column)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: <2.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Blood: 153 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.5 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 39.0 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9480 (unit per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 52.0 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 99 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.7 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 36.7 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: >4.00 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.60 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: <15 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Reticulocytes [#/volume] in Blood by Automated count: 213.9 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.8 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 59.9 (millimeter mercury column)\n- Carbon dioxide [Partial pressure] in Arterial blood: 60.1 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 34.3 (microgram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.05 (million per microliter)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 87.7 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 662 (unit per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.61 (thousand per microliter)\n- Prothrombin time (PT): 77.7 (second)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.45 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n- Carbon dioxide [Partial pressure] in Blood: 63.0 (millimeter mercury column)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 694 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Arterial blood: 9.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 6 (milli-international unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Oxygen [Partial pressure] in Blood: 50 (millimeter mercury column)\n- Platelets [#/volume] in Blood by Automated count: 93 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 774 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Fasting glucose [Mass/volume] in Serum or Plasma: 469 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 7.7 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.26 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 44.3 (nanogram per milliliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 7.40 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma: 3.8 (microgram per milliliter)\n- Body height: 5' 9.882\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: >2.50 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1729.5 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 40 (microgram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 388 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.77 (thousand per microliter)\n- Methemoglobin/Hemoglobin.total in Blood: <1.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 97.6 (millimeter mercury column)\n- Sodium [Moles/volume] in Serum or Plasma: 154 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.54 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 38.7 (thousand per microliter)\n- Zinc [Mass/volume] in Blood: 86 (microgram per deciliter)\n\n### Procedure\n- Medical team conference with interdisciplinary team of health care professionals, patient and/or family not present, 30 minutes or more; participation by physician\n- Closure of median sternotomy separation with or without debridement (separate procedure)\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Repair Right Pulmonary Artery, Open Approach\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Repair Atrial Septum, Open Approach\n- Repair of pulmonary artery stenosis by reconstruction with patch or graft\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Unlisted pulmonary service or procedure\n- Splitting of blood or blood products, each unit\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription\n- Controlled ventilation procedure and therapy, initiation and management\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Oxygen uptake, expired gas analysis; rest, indirect (separate procedure)\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial re\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psych\n- Supplement Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach\n- Repair Chest Wall, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Ascending aorta graft, with cardiopulmonary bypass, includes valve suspension, when performed\n- Transfusion of Nonautologous Platelets into Peripheral Vein, Percutaneous Approach\n- Repair atrial septal defect, secundum, with cardiopulmonary bypass, with or without patch\n- Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous Approach\n- Bypass Right Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach\n- Repair of complex cardiac anomaly other than pulmonary atresia with ventricular septal defect by construction or replacement of conduit from right or left ventricle to pulmonary artery\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)\n- Extirpation of Matter from Right Femoral Artery, Open Approach\n- Respiratory Ventilation, Greater than 96 Consecutive Hours\n- Release Right Lower Leg Muscle, Open Approach\n- Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Percutaneous Approach\n- Replacement, aortic valve, open, with cardiopulmonary bypass; with prosthetic valve other than homograft or stentless valve\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Replacement of Thoracic Aorta, Ascending/Arch with Synthetic Substitute, Open Approach\n- Replacement of Aortic Valve with Synthetic Substitute, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Removal of Infusion Device from Upper Vein, External Approach\n- Introduction of Nutritional Substance into Central Vein, Percutaneous Approach\n- Performance of Cardiac Output, Continuous\n- Physical therapy evaluation: high complexity, requiring these components: A history of present problem with 3 or more personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures \n- Performance of Cardiac Pacing, Continuous\n- Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours, Continuous Positive Airway Pressure\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Repair Left Pulmonary Artery, Open Approach\n- Hospital discharge day management; more than 30 minutes\n- Restoration of Cardiac Rhythm, Single\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Performance of Urinary Filtration, Multiple (Deprecated)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (eg, receptive and expressive language)\n- Drainage of Left Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Repair blood vessel, direct; lower extremity\n\n### Condition\n- Acute combined systolic and diastolic heart failure\n- Aortic incompetence, non-rheumatic\n- Finding of urine output\n- Iatrogenic hypotension\n- Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n- Obstructive sleep apnea syndrome\n- Polyneuropathy\n- Seizure\n- Supraventricular tachycardia\n- Transplanted heart valve present\n- Acute tubular necrosis\n- Bleeding\n- Disorder of pulmonary circulation\n- Drug-induced anaphylaxis\n- Low blood pressure\n- Open wound of front wall of thorax\n- Tetralogy of Fallot\n- Ulcer\n- Cardiac insufficiency following cardiac surgery\n- Compartment syndrome of lower limb\n- Gangrenous disorder\n- Iatrogenic disorder\n- Iron deficiency anemia\n- Primary diagnosis: Postoperative state\n- Postprocedural respiratory failure\n- Stenosis due to any device, implant AND/OR graft\n- Thromboembolus of artery of lower limb\n- Type 2 diabetes mellitus without complication\n- Atherosclerosis of arteries of the extremities\n- Atrial septal defect\n- Cardiac arrhythmia\n- Cardiogenic shock\n- Chronic kidney disease stage 4\n- Combined disorders of mitral, aortic and tricuspid valves\n- Congestive heart failure\n- Disseminated intravascular coagulation\n- Insomnia\n- Postoperative renal failure\n- Thromboembolism of vein\n- Acute hypoxemic respiratory failure\n- Acute renal failure syndrome\n- Atherosclerosis of artery of lower limb\n- Disorder of cardiovascular system\n- Heparin-induced thrombocytopenia\n- Open wound of ankle\n- Perioperative hemorrhage\n- Persistent pain following procedure\n- Renal failure syndrome\n- Disorder of bilirubin metabolism\n- Hepatosplenomegaly\n- Hypokalemia\n- Obesity\n- Rhabdomyolysis\n- Tonsil and/or adenoid hypertrophy\n- Abnormal breathing\n- Acute on chronic combined systolic and diastolic heart failure\n- Anemia in chronic kidney disease\n- Atresia of pulmonary valve\n- Blood coagulation disorder\n- Congenital heart disease\n- Dependence on enabling machine or device\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Late effect of complications of procedure\n- Malaise\n- Open wound of lower leg\n- Stricture of artery\n- Type 2 diabetes mellitus\n- Ventricular tachycardia\n- Atelectasis\n- Atrial flutter\n- Electroencephalogram abnormal\n- Hypertensive heart failure\n- Hypo-osmolality and or hyponatremia\n- Hypocalcemia\n- Open wound of knee\n- Pulmonary stenosis, non-rheumatic\n- Sepsis\n- Thoracic aortic aneurysm without rupture\n- Ventricular fibrillation\n- Autoimmune hemolytic anemia\n- Disorder of phosphorus metabolism\n- Heart failure\n- Hypervolemia\n- Pain in right foot\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (500 mg total) by mouth 2 (two) times a day.\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2016-12-17, presumably until 2016-12-17\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2016-12-30, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (325 mg total) by mouth 3 (three) times a day with meals.\n- 50 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-20\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2017-01-06\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-18\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-01-07, presumably until 2017-01-17\n- 150 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-25, presumably until 2016-12-27\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-12-23, presumably until 2016-12-23\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-23, presumably until 2017-01-17\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 20 mg by mouth daily.\n- 50 ML albumin human, USP 250 MG/ML Injection, through Intravenous route, started on 2016-12-24, presumably until 2016-12-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2016-12-27, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (5 mg total) by mouth nightly as needed for sleep.\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2017-01-09, presumably until 2017-01-17\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2016-12-24, presumably until 2016-12-27\n- melatonin 5 MG Oral Tablet, through Oral route, started on 2016-12-26, presumably until 2016-12-26\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2016-12-19, presumably until 2016-12-19\n- folic acid, through Oral route, started on 2017-01-01, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet by mouth daily.\n- mineral oil 0.15 MG/MG / petrolatum 0.83 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2016-12-17, presumably until 2016-12-23\n- 50 ML argatroban 1 MG/ML Injection, through Intravenous route, started on 2016-12-21, presumably until 2017-01-14\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-12-28, presumably until 2016-12-28\n- oxycodone hydrochloride 15 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (15 mg total) by mouth daily.\n- heparin sodium, porcine 10 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-31, presumably until 2017-01-09\n- iodixanol, through Intravenous route, started on 2016-12-20, presumably until 2016-12-20\n- vecuronium bromide 1 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-17, presumably until 2016-12-17\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2016-12-20, presumably until 2016-12-20\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2017-01-04, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 capsule (250 mg total) by mouth 2 (two) times a day as needed for constipation.\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-18\n- 10 ML calcium chloride 100 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-16, presumably until 2016-12-23\n- sevelamer carbonate 800 MG Oral Tablet, through Oral route, started on 2016-12-30, presumably until 2017-01-01\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-01-01, presumably until 2017-01-01\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 2 tablets (8 mg total) by mouth every evening.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-01-09, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 2 tablets by mouth 2 (two) times a day.\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take by mouth daily.\n- ketamine 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-26, presumably until 2016-12-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-01-09, presumably until 2017-01-09\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2016-12-31, presumably until 2017-01-06\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-01-04, presumably until 2017-01-18\n- 100 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-12-24, presumably until 2016-12-27\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-16, presumably until 2016-12-17\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-02, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 2 capsules (1,334 mg total) by mouth 3 (three) times a day with meals.\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 81 mg by mouth daily.\n- 1 ML epoetin alfa 4000 UNT/ML Injection, through Subcutaneous route, started on 2017-01-07, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Inject 1 mL (4,000 Units total) into the skin Tuesday, Thursday and Saturday.\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-19\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-20, presumably until 2016-12-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-17, presumably until 2017-01-14\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-17, presumably until 2017-01-14\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2016-12-24, presumably until 2016-12-24\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth 3 (three) times a day.\n- ketamine 100 MG/ML Injectable Solution, started on 2016-12-17, presumably until 2016-12-17\n- melatonin 1 MG/ML Oral Solution, through Oral route, started on 2016-12-27, presumably until 2017-01-17, with intended 0 refill(s). Instructions: 10 mLs (10 mg total) by NG-Tube route at bedtime.\n- collagenase 0.25 UNT/MG Topical Ointment, through Topical route, started on 2017-01-01, presumably until 2017-01-17\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-10, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 capsule (100 mg total) by mouth 2 (two) times a day.\n- 500 ML glucose 100 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-19\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2017-01-04, presumably until 2017-01-06\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-01-10, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (5 mg total) by mouth every 4 (four) hours as needed.\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2016-12-19, presumably until 2016-12-29\n- midazolam 1 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-17, presumably until 2017-01-06\n- 50 ML glucose 500 MG/ML Injection, through Intravenous route, started on 2016-12-26, presumably until 2016-12-27\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-15, presumably until 2017-01-17\n- phenylephrine hydrochloride 5 MG/ML Nasal Spray, through Nasal route, started on 2016-12-24, presumably until 2016-12-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of artery of lower limb\n- Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of artery of lower limb\n- Primary diagnosis: Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-12-20, presumably until 2016-12-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Compartment syndrome of upper limb\n- Pain in toe\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thromboembolus of artery of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Edema\n- Localized swelling, mass and lump, lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Intermittent claudication due to atherosclerosis of artery of limb\n- Thromboembolus of artery of upper limb\n- Atherosclerosis of arteries of the extremities\n- Thrombophlebitis\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Compartment syndrome of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 09:09:00, ended at 2016-12-24 14:44:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Localized swelling, mass and lump, lower limb\n- Pain in right foot\n- Intermittent claudication due to atherosclerosis of artery of limb\n- Pain in toe\n- Atherosclerosis of arteries of the extremities\n- Thrombophlebitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-02 00:00:00, ended at 2017-01-02 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-02 13:00:00, ended at 2017-01-02 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-09 00:00:00, ended at 2017-01-09 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-20 00:00:00, ended at 2017-01-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-24 13:29:49, ended at 2017-01-24 15:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-01-24 17:46:00, ended at 2017-02-13 14:30:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: -1.5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.88 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.25 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Osmolality of Urine: 257 (milliosmole per kilogram)\n- Oxygen [Partial pressure] in Arterial blood: 231.0 (millimeter mercury column)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Prothrombin time (PT): 21.9 (second)\n- C reactive protein [Mass/volume] in Serum or Plasma: 21.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.13 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 110 (millimeter per hour)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 184 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 495 (thousand per microliter)\n- Sodium/Creatinine [Molar ratio] in Urine: 17 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 9.8 (microgram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 98.5 (second)\n- Neutrophils [#/volume] in Blood by Automated count: 7.92 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 23.6 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 53.69 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.75 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 6.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.21 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 34.6 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lidocaine [Mass/volume] in Serum or Plasma: <0.5 (microgram per milliliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n\n### Procedure\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less\n- Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Extraction of Right Lower Leg Subcutaneous Tissue and Fascia, Open Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Excision of Right Tibia, Open Approach\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Excision of Right Lower Leg Muscle, Open Approach\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Detachment at Right Lower Leg, Mid, Open Approach\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Amputation, leg, through tibia and fibula; open, circular (guillotine)\n- Splitting of blood or blood products, each unit\n- Radiologic examination, chest; single view, frontal\n- Excision of Right Fibula, Open Approach\n- Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours, Continuous Positive Airway Pressure\n- Amputation, leg, through tibia and fibula; re-amputation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Bacterial infection due to Pseudomonas\n- Hypokalemia\n- Necrosis of amputation stump\n- Rhabdomyolysis\n- Absence of lower limb\n- Postoperative state\n- Right bundle branch block\n- Type 2 diabetes mellitus without complication\n- Acquired absence of organ\n- Complication following amputation of limb\n- Infection by methicillin sensitive Staphylococcus aureus\n- Phantom limb syndrome with pain\n- Tachycardia\n- Transplanted heart valve present\n- Complication of procedure\n- Gangrenous disorder\n- Hypo-osmolality and or hyponatremia\n- Obesity\n- Primary diagnosis: Compartment syndrome of lower limb\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Essential hypertension\n- Gangrene due to type 2 diabetes mellitus\n- Peripheral angiopathy due to diabetes mellitus\n- Cardiomegaly\n- Electrocardiogram abnormal\n- Persistent pain following procedure\n- Acute renal failure syndrome\n- Obstructive sleep apnea syndrome\n- Type 2 diabetes mellitus\n- Anemia\n\n### Drug\n- 1000 ML potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 500 mg by mouth\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-01-28, presumably until 2017-02-06\n- ascorbic acid 250 MG Oral Tablet, through Oral route, started on 2017-02-06, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 325 mg by mouth\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-11\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-02-08\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-31\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-31, presumably until 2017-02-05\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-01-24, presumably until 2017-01-29\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-01-24, presumably until 2017-02-12\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 5 mg by mouth daily\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2017-01-25, presumably until 2017-02-05\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2017-01-29, presumably until 2017-02-05\n- sodium hypochlorite 1.25 MG/ML Topical Solution, started on 2017-01-31, presumably until 2017-02-11\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours\n- folic acid, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2017-02-09, presumably until 2017-02-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-01-24, presumably until 2017-02-09\n- oxycodone hydrochloride 15 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 15 mg by mouth daily\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-01-25, presumably until 2017-02-13\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-01-29, presumably until 2017-04-29, with intended 0 refill(s). Instructions: take 1 Peaslee by mouth every bedtime\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-02-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 2 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-01-27, presumably until 2017-01-27\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-01-25, presumably until 2017-02-05\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-02-06, presumably until 2017-02-11\n- sodium hypochlorite 0.125 MG/ML Topical Solution, through Topical route, started on 2017-02-03, presumably until 2017-06-17, with intended 0 refill(s). Instructions: by Topical route 2 times a day\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-08-14, with intended 0 refill(s). Instructions: take 10 mg by mouth \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 2 Tabs by mouth\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2017-01-25, presumably until 2017-01-28\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-01-29, presumably until 2017-02-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-02-07\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-02-08, presumably until 2017-02-17, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-01-24, presumably until 2017-01-24\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 1,334 mg by mouth 2 times a day\n- 1 ML epoetin alfa 4000 UNT/ML Injection, through Subcutaneous route, started on 2017-01-18, presumably until 2017-02-13, with intended 0 refill(s). Instructions: inject 4,000 Units subcutaneous (under the skin)\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-25, presumably until 2017-02-05\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-01-25, presumably until 2017-02-07\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-02-01, presumably until 2017-02-01\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-01-30, presumably until 2017-01-30\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-02-03\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2017-01-31, presumably until 2017-02-06\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 80 mg by mouth\n- melatonin 1 MG/ML Oral Solution, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: 10 mg\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 6 Caps by mouth 3 times a day\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-06-17, with intended 0 refill(s). Instructions: take 5 mg by mouth every 4 hours\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-02-12, presumably until 2017-08-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2017-02-05, presumably until 2017-02-05\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-01-27, presumably until 2017-02-13\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-02-01, presumably until 2017-02-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-01-25 00:00:00, ended at 2017-01-25 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-01-25, presumably until 2017-01-25\n- sodium hypochlorite 0.125 MG/ML Topical Solution, through Topical route, started on 2017-01-25, presumably until 2017-01-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-25 00:00:00, ended at 2017-01-25 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of upper leg\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Transplanted heart valve present\n- Gangrenous disorder\n- Compartment syndrome of lower limb\n- Tetralogy of Fallot\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-25, presumably until 2017-01-25\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- cefazolin 1000 MG Injection, started on 2017-01-25, presumably until 2017-01-25\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-29 00:00:00, ended at 2017-01-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; radical resection (including below knee amputation)\n\n### Condition\n- Heart failure\n- Gangrenous disorder\n- Transplanted heart valve present\n- Compartment syndrome of lower limb\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- ketamine 100 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-29 00:00:00, ended at 2017-01-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), anesthetic agent(s) and/or steroid; brachial plexus\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; femoral nerve\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n- midazolam 1 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; radical resection (including below knee amputation)\n\n### Condition\n- Compartment syndrome of lower limb\n- Peripheral vascular disease\n- Essential hypertension\n- Gangrenous disorder\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2017-02-05, presumably until 2017-02-05\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; femoral nerve\n- Injection(s), anesthetic agent(s) and/or steroid; sciatic nerve\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- midazolam 1 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-17 14:52:51, ended at 2017-02-17 16:16:11\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of organ\n- Acute renal failure syndrome\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-17 16:22:24, ended at 2017-02-17 16:22:37\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Absence of lower limb\n- Acute renal failure syndrome\n- Primary diagnosis: Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-24 15:03:43, ended at 2017-02-24 16:26:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Primary diagnosis: Acquired absence of organ\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 14:00:00, ended at 2017-03-17 16:45:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 54.7 (percent)\n\n### Procedure\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-17 15:00:31, ended at 2017-03-17 16:34:55\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of organ\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-17 15:02:20, ended at 2017-03-17 16:35:29\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Transplanted heart valve present\n- Electrocardiogram abnormal\n- Right bundle branch block\n- Tetralogy of Fallot\n- Postoperative state\n\n### Drug\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-03-17, presumably until 2017-07-17, with intended 3 refill(s). Instructions: take 2 Caps by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 16:46:00, ended at 2017-03-17 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.48 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.1 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.83 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 336 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2017-04-28, presumably until 2017-04-28, with intended 0 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-29 00:00:00, ended at 2017-04-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-04-29, presumably until 2018-06-04, with intended 6 refill(s). Instructions: take 1 Fleischner by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-17 00:00:00, ended at 2017-06-17 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-17 15:04:14, ended at 2017-06-17 16:50:01\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-18 00:00:00, ended at 2017-06-18 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired absence of organ\n- Absence of lower limb\n- Transplanted heart valve present\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chest pain\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- gabapentin 100 MG Oral Capsule, started on 2017-07-17, presumably until 2017-08-14, with intended 3 refill(s). Instructions: Take 2 caps by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-12 00:00:00, ended at 2017-08-12 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Primary diagnosis: Right lower quadrant pain\n- Injury of femoral artery\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-13 13:43:00, ended at 2017-08-13 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Right lower quadrant pain\n- Tetralogy of Fallot\n- Injury of femoral artery\n- Localized edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-14 00:00:00, ended at 2017-08-14 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iothalamic acid, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-08-14, presumably until 2017-08-14\n- iothalamate, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-14 00:00:00, ended at 2017-08-14 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for procedures on arteries of lower leg, including bypass graft; not otherwise specified\n\n### Condition\n- Cellulitis of groin\n- Tetralogy of Fallot\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-08-14, presumably until 2017-08-14\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-14, presumably until 2017-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-14, presumably until 2017-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-08-14 12:09:00, ended at 2017-08-20 11:28:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.70 (thousand per microliter)\n- Base excess in Arterial blood by calculation: -2.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 21.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 167 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 325 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- Base excess in Blood by calculation: 3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Prothrombin time (PT): 25.3 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.11 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 34.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 18.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.9 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 206.0 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n\n### Procedure\n- Repair blood vessel, direct; lower extremity\n- Insertion of Infusion Device into Upper Vein, Percutaneous Approach\n- Revision, femoral anastomosis of synthetic arterial bypass graft in groin, open; with autogenous vein patch graft\n- Collection of venous blood by venipuncture\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquire\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Excision of infected graft; extremity\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Replacement of Right Femoral Artery with Autologous Tissue Substitute, Open Approach\n- Excision of Left Saphenous Vein, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Postoperative state\n- Tetralogy of Fallot\n- Traumatic or non-traumatic injury\n- Abscess of groin\n- Abscess of skin and/or subcutaneous tissue\n- Complication associated with device\n- Complication of surgical procedure\n- Infection by methicillin sensitive Staphylococcus aureus\n- Infection of amputation stump\n- Postprocedural infection\n- Absence of lower limb\n- Aneurysm of artery of lower extremity\n- Primary diagnosis: Cellulitis of groin\n- Complication following amputation of limb\n- Transplanted heart valve present\n- Acquired absence of organ\n- Localized infection of skin AND/OR subcutaneous tissue\n- Obesity\n- Obstructive sleep apnea syndrome\n- Sepsis\n- Secondary pulmonary hypertension\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-08-15, presumably until 2017-08-19\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2022-04-24, with intended 0 refill(s). Instructions: take 10 mg by mouth every Wednesday\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-05-27, presumably until 2022-04-24, with intended 1 refill(s). Instructions: take 5 mg by mouth every Monday\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-08-17, presumably until 2017-08-17\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2017-08-17, presumably until 2017-10-13, with intended 2 refill(s). Instructions: 2 g by Intravenous route every 8 hours\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-08-15, presumably until 2017-08-19\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-08-16, presumably until 2017-08-18\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-15\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-08-14, presumably until 2017-08-16\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-08-15, presumably until 2017-08-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2018-01-24, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day \n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2017-08-14, presumably until 2017-08-17\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-09-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-08-17, presumably until 2017-08-20, with intended 3 refill(s). Instructions: 100 mL by Intravenous route every 8 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-19 00:00:00, ended at 2017-08-19 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n\n### Condition\n- Tetralogy of Fallot\n- Cellulitis of groin\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-08-19, presumably until 2017-08-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-08-19, presumably until 2017-08-19\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-19, presumably until 2017-08-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-26 09:09:25, ended at 2017-08-26 10:59:39\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less th\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 500 mg by Swish & Swallow route\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, through Topical route, started on 2017-03-10, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 1 Application by Topical route\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-08-26, with intended 0 refill(s). Instructions: 20 mg by Swish & Swallow route\n- aspirin 81 MG / calcium carbonate 777 MG Oral Tablet, through Oral route, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 81 mg by Swish & Swallow route\n- gabapentin 300 MG Oral Capsule, started on 2017-07-17, presumably until 2017-08-26, with intended 0 refill(s). Instructions: One qhs\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 1,334 mg by Swish & Swallow route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-26 13:30:00, ended at 2017-08-26 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Laceration - injury\n- Cellulitis of groin\n- Transplanted heart valve present\n- Open wound of anterior abdominal wall\n- Injury to blood vessels of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-02 08:10:47, ended at 2017-09-02 09:04:28\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less th\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Open wound of inguinal region\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-05 00:00:00, ended at 2017-09-05 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 09:31:07, ended at 2017-09-09 10:26:49\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 12:19:51, ended at 2017-09-09 16:25:24\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Open wound of anterior abdominal wall\n- Tetralogy of Fallot\n- Right bundle branch block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 12:20:09, ended at 2017-09-09 16:25:32\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-10 09:06:39, ended at 2017-09-10 10:05:44\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abscess of groin\n- Infection by methicillin sensitive Staphylococcus aureus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-16 09:57:09, ended at 2017-09-16 11:04:59\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-23 09:52:28, ended at 2017-09-23 10:25:55\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound\n\n### Condition\n- Primary diagnosis: Late effect of open wound of head, neck and trunk\n- Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-30 09:55:42, ended at 2017-09-30 10:51:41\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Late effect of open wound of head, neck and trunk\n- Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-01 10:51:35, ended at 2017-10-01 12:00:55\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Traumatic or non-traumatic injury\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Traumatic or non-traumatic injury\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-13 10:57:00, ended at 2017-10-13 12:46:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.25 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 111 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 185 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.6 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.93 (thousand per microliter)\n\n### Procedure\n- Removal of Infusion Device from Great Vessel, External Approach\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2017-10-13, presumably until 2017-10-13\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-05 09:14:00, ended at 2016-08-05 11:37:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, chest (excluding myocardium), with or without contrast material(s)\n- Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences\n- Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Rheumatic tricuspid valve regurgitation\n- Cardiomegaly\n- Aortic incompetence, non-rheumatic\n- Pulmonary incompetence, non-rheumatic\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-02 00:00:00, ended at 2016-09-02 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-04 11:00:00, ended at 2016-09-04 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-01 00:00:00, ended at 2016-10-01 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-01 11:00:00, ended at 2016-10-01 11:26:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-09 00:00:00, ended at 2016-10-09 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 00:00:00, ended at 2016-11-18 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac catheterization including coronary angiography and ventriculography (not to include Swan-Ganz catheter)\n\n### Condition\n- Congestive heart failure\n- Essential hypertension\n- Systolic heart failure\n- Type 2 diabetes mellitus without complication\n- Tetralogy of Fallot\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n- cefazolin 1000 MG Injection, started on 2016-11-18, presumably until 2016-11-18\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-11-18, presumably until 2016-11-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- midazolam 1 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 11:50:00, ended at 2016-11-19 11:55:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.04 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood: 53 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 18.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Base excess in Arterial blood by calculation: -6.5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 161 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 83.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 20.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 150 (milligram per deciliter)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 40.3 (millimeter mercury column)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Measurement of Cardiac Sampling and Pressure, Bilateral, Percutaneous Approach\n- Dilation of Left Pulmonary Artery, Percutaneous Approach\n- Percutaneous transluminal pulmonary artery balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)\n- Dilation of Right Pulmonary Artery, Percutaneous Approach\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Percutaneous transluminal pulmonary artery balloon angioplasty; single vessel\n- Fluoroscopy of Left Pulmonary Artery using Low Osmolar Contrast\n- Fluoroscopy of Right Pulmonary Artery using Low Osmolar Contrast\n- Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies\n- Collection of blood specimen from a completely implantable venous access device\n- Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (List separately in addition to code for primary procedure)\n\n### Condition\n- Stenosis due to any device, implant AND/OR graft\n- Postoperative state\n- Essential hypertension\n- Pulmonary artery stenosis\n- Adverse effect of prosthetic device\n- Obesity\n- Primary diagnosis: Tetralogy of Fallot\n- Complication of surgical procedure\n- Obstructive sleep apnea syndrome\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- famotidine 10 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2016-11-19, presumably until 2017-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2016-11-19, presumably until 2016-12-03, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2016-11-19, presumably until 2017-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-19 00:00:00, ended at 2016-11-19 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-22 00:00:00, ended at 2016-11-22 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take by mouth.\n- losartan potassium 100 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 100 mg by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-03 14:12:00, ended at 2016-12-03 15:37:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary perfusion imaging (eg, particulate)\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-03 15:38:00, ended at 2016-12-03 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 89 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-05 00:00:00, ended at 2016-12-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n- Acute myeloid leukemia, disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-05 07:52:00, ended at 2016-12-05 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Ectasia of thoracic aorta\n- Complication associated with device\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-10 00:00:00, ended at 2016-12-10 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative cardiac complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2016-12-11, presumably until 2017-01-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-11 00:00:00, ended at 2016-12-11 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-11 20:54:00, ended at 2016-12-11 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired renal cystic disease\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.3 (percent)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.1 (second)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.4 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 18.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.02 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 54.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 166 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 465 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.79 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Prothrombin time (PT): 14.0 (second)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative cardiac complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Decompression fasciotomy, leg; anterior and/or lateral, and posterior compartment(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n\n### Condition\n- Tetralogy of Fallot\n- Transplanted heart valve present\n- Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative cardiac complication\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 08:46:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Postoperative state\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 08:46:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Cardiac arrhythmia\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-13 08:48:06, ended at 2016-12-13 14:10:03\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.882\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-13 13:22:00, ended at 2016-12-13 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Postoperative cardiac complication\n- Tetralogy of Fallot\n- Cardiomegaly\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 175 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 36.7 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: >4.00 (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 59.9 (millimeter mercury column)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 97.6 (millimeter mercury column)\n- Potassium [Moles/volume] in Blood: <2.0 (millimole per liter)\n- Prothrombin time (PT): 77.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.4 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Blood: >2.50 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 60.1 (millimeter mercury column)\n- Eosinophils [#/volume] in Blood by Manual count: 0.54 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood: <15 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- Lactate [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.26 (thousand per microliter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 44.3 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.45 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Mixed venous blood: 0.53 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.05 (million per microliter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 662 (unit per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 6 (milli-international unit per milliliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 388 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 93 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.7 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 774 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 39.0 (milligram per deciliter)\n- Fasting glucose [Mass/volume] in Serum or Plasma: 469 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1729.5 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 87.7 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 40 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 38.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.77 (thousand per microliter)\n- Vancomycin [Mass/volume] in Serum or Plasma: 3.8 (microgram per milliliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 34.3 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.61 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 99 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 50 (millimeter mercury column)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 7.40 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 7.7 (milligram per deciliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 8 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 154 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9480 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 694 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Reticulocytes [#/volume] in Blood by Automated count: 213.9 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 153 (millimole per liter)\n- Base excess in Blood by calculation: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.8 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 63.0 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 52.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.60 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Postoperative state\n- Primary diagnosis: Illness\n- Atelectasis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-16 00:00:00, ended at 2016-12-16 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- thrombin alfa 1000 UNT/ML Topical Solution, through Topical route, started on 2016-12-16, presumably until 2016-12-16\n- cefazolin 1000 MG Injection, started on 2016-12-16, presumably until 2016-12-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-12-16 06:55:00, ended at 2017-01-18 10:10:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide [Partial pressure] in Venous blood: 61.7 (millimeter mercury column)\n- Hemoglobin [Mass/volume] in Blood by calculation: 9.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: <2.0 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Blood: 153 (millimole per liter)\n- Base excess in Arterial blood by calculation: 4.4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.5 (percent)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 39.0 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 9480 (unit per liter)\n- Glucose [Mass/volume] in Blood: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 52.0 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 99 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.7 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 36.7 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: >4.00 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.60 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: <15 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Reticulocytes [#/volume] in Blood by Automated count: 213.9 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.8 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 59.9 (millimeter mercury column)\n- Carbon dioxide [Partial pressure] in Arterial blood: 60.1 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 34.3 (microgram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.05 (million per microliter)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 87.7 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 662 (unit per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.61 (thousand per microliter)\n- Prothrombin time (PT): 77.7 (second)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.45 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.5 (microgram per milliliter)\n- Carbon dioxide [Partial pressure] in Blood: 63.0 (millimeter mercury column)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 694 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Arterial blood: 9.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 6 (milli-international unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Oxygen [Partial pressure] in Blood: 50 (millimeter mercury column)\n- Platelets [#/volume] in Blood by Automated count: 93 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 774 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Fasting glucose [Mass/volume] in Serum or Plasma: 469 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 7.7 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.26 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Procalcitonin [Mass/volume] in Serum or Plasma: 44.3 (nanogram per milliliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 7.40 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma: 3.8 (microgram per milliliter)\n- Body height: 5' 9.882\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: >2.50 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1729.5 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 40 (microgram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 388 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.77 (thousand per microliter)\n- Methemoglobin/Hemoglobin.total in Blood: <1.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 97.6 (millimeter mercury column)\n- Sodium [Moles/volume] in Serum or Plasma: 154 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.54 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 38.7 (thousand per microliter)\n- Zinc [Mass/volume] in Blood: 86 (microgram per deciliter)\n\n### Procedure\n- Medical team conference with interdisciplinary team of health care professionals, patient and/or family not present, 30 minutes or more; participation by physician\n- Closure of median sternotomy separation with or without debridement (separate procedure)\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Repair Right Pulmonary Artery, Open Approach\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Repair Atrial Septum, Open Approach\n- Repair of pulmonary artery stenosis by reconstruction with patch or graft\n- Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Unlisted pulmonary service or procedure\n- Splitting of blood or blood products, each unit\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription\n- Controlled ventilation procedure and therapy, initiation and management\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Oxygen uptake, expired gas analysis; rest, indirect (separate procedure)\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial re\n- Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\n- Hemodialysis procedure with single evaluation by a physician or other qualified health care professional\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psych\n- Supplement Right Femoral Artery with Nonautologous Tissue Substitute, Open Approach\n- Repair Chest Wall, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n- Ascending aorta graft, with cardiopulmonary bypass, includes valve suspension, when performed\n- Transfusion of Nonautologous Platelets into Peripheral Vein, Percutaneous Approach\n- Repair atrial septal defect, secundum, with cardiopulmonary bypass, with or without patch\n- Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous Approach\n- Bypass Right Ventricle to Pulmonary Trunk with Zooplastic Tissue, Open Approach\n- Repair of complex cardiac anomaly other than pulmonary atresia with ventricular septal defect by construction or replacement of conduit from right or left ventricle to pulmonary artery\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)\n- Extirpation of Matter from Right Femoral Artery, Open Approach\n- Respiratory Ventilation, Greater than 96 Consecutive Hours\n- Release Right Lower Leg Muscle, Open Approach\n- Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Percutaneous Approach\n- Replacement, aortic valve, open, with cardiopulmonary bypass; with prosthetic valve other than homograft or stentless valve\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Replacement of Thoracic Aorta, Ascending/Arch with Synthetic Substitute, Open Approach\n- Replacement of Aortic Valve with Synthetic Substitute, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Removal of Infusion Device from Upper Vein, External Approach\n- Introduction of Nutritional Substance into Central Vein, Percutaneous Approach\n- Performance of Cardiac Output, Continuous\n- Physical therapy evaluation: high complexity, requiring these components: A history of present problem with 3 or more personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures \n- Performance of Cardiac Pacing, Continuous\n- Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours, Continuous Positive Airway Pressure\n- Collection of venous blood by venipuncture\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Repair Left Pulmonary Artery, Open Approach\n- Hospital discharge day management; more than 30 minutes\n- Restoration of Cardiac Rhythm, Single\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Performance of Urinary Filtration, Multiple (Deprecated)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (eg, receptive and expressive language)\n- Drainage of Left Lower Lobe Bronchus, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Repair blood vessel, direct; lower extremity\n\n### Condition\n- Acute combined systolic and diastolic heart failure\n- Aortic incompetence, non-rheumatic\n- Finding of urine output\n- Iatrogenic hypotension\n- Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n- Obstructive sleep apnea syndrome\n- Polyneuropathy\n- Seizure\n- Supraventricular tachycardia\n- Transplanted heart valve present\n- Acute tubular necrosis\n- Bleeding\n- Disorder of pulmonary circulation\n- Drug-induced anaphylaxis\n- Low blood pressure\n- Open wound of front wall of thorax\n- Tetralogy of Fallot\n- Ulcer\n- Cardiac insufficiency following cardiac surgery\n- Compartment syndrome of lower limb\n- Gangrenous disorder\n- Iatrogenic disorder\n- Iron deficiency anemia\n- Primary diagnosis: Postoperative state\n- Postprocedural respiratory failure\n- Stenosis due to any device, implant AND/OR graft\n- Thromboembolus of artery of lower limb\n- Type 2 diabetes mellitus without complication\n- Atherosclerosis of arteries of the extremities\n- Atrial septal defect\n- Cardiac arrhythmia\n- Cardiogenic shock\n- Chronic kidney disease stage 4\n- Combined disorders of mitral, aortic and tricuspid valves\n- Congestive heart failure\n- Disseminated intravascular coagulation\n- Insomnia\n- Postoperative renal failure\n- Thromboembolism of vein\n- Acute hypoxemic respiratory failure\n- Acute renal failure syndrome\n- Atherosclerosis of artery of lower limb\n- Disorder of cardiovascular system\n- Heparin-induced thrombocytopenia\n- Open wound of ankle\n- Perioperative hemorrhage\n- Persistent pain following procedure\n- Renal failure syndrome\n- Disorder of bilirubin metabolism\n- Hepatosplenomegaly\n- Hypokalemia\n- Obesity\n- Rhabdomyolysis\n- Tonsil and/or adenoid hypertrophy\n- Abnormal breathing\n- Acute on chronic combined systolic and diastolic heart failure\n- Anemia in chronic kidney disease\n- Atresia of pulmonary valve\n- Blood coagulation disorder\n- Congenital heart disease\n- Dependence on enabling machine or device\n- Electrocardiogram abnormal\n- Hyperglycemia due to type 2 diabetes mellitus\n- Late effect of complications of procedure\n- Malaise\n- Open wound of lower leg\n- Stricture of artery\n- Type 2 diabetes mellitus\n- Ventricular tachycardia\n- Atelectasis\n- Atrial flutter\n- Electroencephalogram abnormal\n- Hypertensive heart failure\n- Hypo-osmolality and or hyponatremia\n- Hypocalcemia\n- Open wound of knee\n- Pulmonary stenosis, non-rheumatic\n- Sepsis\n- Thoracic aortic aneurysm without rupture\n- Ventricular fibrillation\n- Autoimmune hemolytic anemia\n- Disorder of phosphorus metabolism\n- Heart failure\n- Hypervolemia\n- Pain in right foot\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (500 mg total) by mouth 2 (two) times a day.\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2016-12-17, presumably until 2016-12-17\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2016-12-30, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (325 mg total) by mouth 3 (three) times a day with meals.\n- 50 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-20\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2017-01-06\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-18\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-01-07, presumably until 2017-01-17\n- 150 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-25, presumably until 2016-12-27\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-12-23, presumably until 2016-12-23\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-23, presumably until 2017-01-17\n- furosemide 20 MG Oral Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 20 mg by mouth daily.\n- 50 ML albumin human, USP 250 MG/ML Injection, through Intravenous route, started on 2016-12-24, presumably until 2016-12-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2016-12-27, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (5 mg total) by mouth nightly as needed for sleep.\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2017-01-09, presumably until 2017-01-17\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2016-12-24, presumably until 2016-12-27\n- melatonin 5 MG Oral Tablet, through Oral route, started on 2016-12-26, presumably until 2016-12-26\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2016-12-19, presumably until 2016-12-19\n- folic acid, through Oral route, started on 2017-01-01, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet by mouth daily.\n- mineral oil 0.15 MG/MG / petrolatum 0.83 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2016-12-17, presumably until 2016-12-23\n- 50 ML argatroban 1 MG/ML Injection, through Intravenous route, started on 2016-12-21, presumably until 2017-01-14\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2016-12-28, presumably until 2016-12-28\n- oxycodone hydrochloride 15 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (15 mg total) by mouth daily.\n- heparin sodium, porcine 10 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-31, presumably until 2017-01-09\n- iodixanol, through Intravenous route, started on 2016-12-20, presumably until 2016-12-20\n- vecuronium bromide 1 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-17, presumably until 2016-12-17\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2016-12-20, presumably until 2016-12-20\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2017-01-04, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 capsule (250 mg total) by mouth 2 (two) times a day as needed for constipation.\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-18\n- 10 ML calcium chloride 100 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-16, presumably until 2016-12-23\n- sevelamer carbonate 800 MG Oral Tablet, through Oral route, started on 2016-12-30, presumably until 2017-01-01\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-01-01, presumably until 2017-01-01\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 2 tablets (8 mg total) by mouth every evening.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-01-09, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 2 tablets by mouth 2 (two) times a day.\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take by mouth daily.\n- ketamine 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-26, presumably until 2016-12-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-01-09, presumably until 2017-01-09\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2016-12-31, presumably until 2017-01-06\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-01-04, presumably until 2017-01-18\n- 100 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2016-12-24, presumably until 2016-12-27\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-16, presumably until 2016-12-17\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-02, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 2 capsules (1,334 mg total) by mouth 3 (three) times a day with meals.\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 81 mg by mouth daily.\n- 1 ML epoetin alfa 4000 UNT/ML Injection, through Subcutaneous route, started on 2017-01-07, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Inject 1 mL (4,000 Units total) into the skin Tuesday, Thursday and Saturday.\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2016-12-19, presumably until 2016-12-19\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2016-12-20, presumably until 2016-12-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-17, presumably until 2017-01-14\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2016-12-17, presumably until 2017-01-14\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2016-12-24, presumably until 2016-12-24\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-01-17, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth 3 (three) times a day.\n- ketamine 100 MG/ML Injectable Solution, started on 2016-12-17, presumably until 2016-12-17\n- melatonin 1 MG/ML Oral Solution, through Oral route, started on 2016-12-27, presumably until 2017-01-17, with intended 0 refill(s). Instructions: 10 mLs (10 mg total) by NG-Tube route at bedtime.\n- collagenase 0.25 UNT/MG Topical Ointment, through Topical route, started on 2017-01-01, presumably until 2017-01-17\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-10, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 capsule (100 mg total) by mouth 2 (two) times a day.\n- 500 ML glucose 100 MG/ML Injection, through Intravenous route, started on 2016-12-18, presumably until 2016-12-19\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2017-01-04, presumably until 2017-01-06\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-01-10, presumably until 2017-01-18, with intended 0 refill(s). Instructions: Take 1 tablet (5 mg total) by mouth every 4 (four) hours as needed.\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2016-12-19, presumably until 2016-12-29\n- midazolam 1 MG/ML Injectable Solution, through Intravenous route, started on 2016-12-17, presumably until 2017-01-06\n- 50 ML glucose 500 MG/ML Injection, through Intravenous route, started on 2016-12-26, presumably until 2016-12-27\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-15, presumably until 2017-01-17\n- phenylephrine hydrochloride 5 MG/ML Nasal Spray, through Nasal route, started on 2016-12-24, presumably until 2016-12-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of artery of lower limb\n- Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of artery of lower limb\n- Primary diagnosis: Intermittent claudication of right lower limb co-occurrent and due to atherosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-12-20 00:00:00, ended at 2016-12-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2016-12-20, presumably until 2016-12-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Compartment syndrome of upper limb\n- Pain in toe\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thromboembolus of artery of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Edema\n- Localized swelling, mass and lump, lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Intermittent claudication due to atherosclerosis of artery of limb\n- Thromboembolus of artery of upper limb\n- Atherosclerosis of arteries of the extremities\n- Thrombophlebitis\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Compartment syndrome of upper limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-24 00:00:00, ended at 2016-12-24 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-24 09:09:00, ended at 2016-12-24 14:44:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Localized swelling, mass and lump, lower limb\n- Pain in right foot\n- Intermittent claudication due to atherosclerosis of artery of limb\n- Pain in toe\n- Atherosclerosis of arteries of the extremities\n- Thrombophlebitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-02 00:00:00, ended at 2017-01-02 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Primary diagnosis: Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-02 13:00:00, ended at 2017-01-02 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure\n\n### Condition\n- Peripheral vascular disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-09 00:00:00, ended at 2017-01-09 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-20 00:00:00, ended at 2017-01-20 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-24 13:29:49, ended at 2017-01-24 15:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-01-24 17:46:00, ended at 2017-02-13 14:30:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: -1.5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.88 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.25 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Osmolality of Urine: 257 (milliosmole per kilogram)\n- Oxygen [Partial pressure] in Arterial blood: 231.0 (millimeter mercury column)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Prothrombin time (PT): 21.9 (second)\n- C reactive protein [Mass/volume] in Serum or Plasma: 21.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 3.13 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 110 (millimeter per hour)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 184 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 495 (thousand per microliter)\n- Sodium/Creatinine [Molar ratio] in Urine: 17 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 9.8 (microgram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 98.5 (second)\n- Neutrophils [#/volume] in Blood by Automated count: 7.92 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Base excess in Blood by calculation: 4 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 23.6 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 53.69 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.75 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 6.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 82 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.21 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 34.6 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lidocaine [Mass/volume] in Serum or Plasma: <0.5 (microgram per milliliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7 (percent)\n\n### Procedure\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less\n- Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Extraction of Right Lower Leg Subcutaneous Tissue and Fascia, Open Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Excision of Right Tibia, Open Approach\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Excision of Right Lower Leg Muscle, Open Approach\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Detachment at Right Lower Leg, Mid, Open Approach\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Amputation, leg, through tibia and fibula; open, circular (guillotine)\n- Splitting of blood or blood products, each unit\n- Radiologic examination, chest; single view, frontal\n- Excision of Right Fibula, Open Approach\n- Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours, Continuous Positive Airway Pressure\n- Amputation, leg, through tibia and fibula; re-amputation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Bacterial infection due to Pseudomonas\n- Hypokalemia\n- Necrosis of amputation stump\n- Rhabdomyolysis\n- Absence of lower limb\n- Postoperative state\n- Right bundle branch block\n- Type 2 diabetes mellitus without complication\n- Acquired absence of organ\n- Complication following amputation of limb\n- Infection by methicillin sensitive Staphylococcus aureus\n- Phantom limb syndrome with pain\n- Tachycardia\n- Transplanted heart valve present\n- Complication of procedure\n- Gangrenous disorder\n- Hypo-osmolality and or hyponatremia\n- Obesity\n- Primary diagnosis: Compartment syndrome of lower limb\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Essential hypertension\n- Gangrene due to type 2 diabetes mellitus\n- Peripheral angiopathy due to diabetes mellitus\n- Cardiomegaly\n- Electrocardiogram abnormal\n- Persistent pain following procedure\n- Acute renal failure syndrome\n- Obstructive sleep apnea syndrome\n- Type 2 diabetes mellitus\n- Anemia\n\n### Drug\n- 1000 ML potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 500 mg by mouth\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-01-28, presumably until 2017-02-06\n- ascorbic acid 250 MG Oral Tablet, through Oral route, started on 2017-02-06, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 325 mg by mouth\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-11\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-02-08\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-31\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-31, presumably until 2017-02-05\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-01-24, presumably until 2017-01-29\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-01-24, presumably until 2017-02-12\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 5 mg by mouth daily\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2017-01-25, presumably until 2017-02-05\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2017-01-29, presumably until 2017-02-05\n- sodium hypochlorite 1.25 MG/ML Topical Solution, started on 2017-01-31, presumably until 2017-02-11\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours\n- folic acid, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2017-02-09, presumably until 2017-02-09\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-01-24, presumably until 2017-02-09\n- oxycodone hydrochloride 15 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 15 mg by mouth daily\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-01-25, presumably until 2017-02-13\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-01-29, presumably until 2017-04-29, with intended 0 refill(s). Instructions: take 1 Peaslee by mouth every bedtime\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2017-02-07, presumably until 2017-02-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 2 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-01-27, presumably until 2017-01-27\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-01-25, presumably until 2017-02-05\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2017-02-06, presumably until 2017-02-11\n- sodium hypochlorite 0.125 MG/ML Topical Solution, through Topical route, started on 2017-02-03, presumably until 2017-06-17, with intended 0 refill(s). Instructions: by Topical route 2 times a day\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-08-14, with intended 0 refill(s). Instructions: take 10 mg by mouth \n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 2 Tabs by mouth\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2017-01-25, presumably until 2017-01-28\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2017-01-29, presumably until 2017-02-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-02-07\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-02-08, presumably until 2017-02-17, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-01-24, presumably until 2017-01-24\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 1,334 mg by mouth 2 times a day\n- 1 ML epoetin alfa 4000 UNT/ML Injection, through Subcutaneous route, started on 2017-01-18, presumably until 2017-02-13, with intended 0 refill(s). Instructions: inject 4,000 Units subcutaneous (under the skin)\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-25, presumably until 2017-02-05\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-01-25, presumably until 2017-02-07\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-02-01, presumably until 2017-02-01\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-01-30, presumably until 2017-01-30\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-02-03\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2017-01-31, presumably until 2017-02-06\n- furosemide 80 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: take 80 mg by mouth\n- melatonin 1 MG/ML Oral Solution, started on 2017-01-17, presumably until 2017-02-13, with intended 0 refill(s). Instructions: 10 mg\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-03-17, with intended 0 refill(s). Instructions: take 6 Caps by mouth 3 times a day\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-06-17, with intended 0 refill(s). Instructions: take 5 mg by mouth every 4 hours\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-02-12, presumably until 2017-08-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2017-02-05, presumably until 2017-02-05\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-01-27, presumably until 2017-02-13\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-02-01, presumably until 2017-02-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-01-25 00:00:00, ended at 2017-01-25 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bacitracin 5000 UNT/ML Injectable Solution, through Intramuscular route, started on 2017-01-25, presumably until 2017-01-25\n- sodium hypochlorite 0.125 MG/ML Topical Solution, through Topical route, started on 2017-01-25, presumably until 2017-01-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-25 00:00:00, ended at 2017-01-25 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of upper leg\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Transplanted heart valve present\n- Gangrenous disorder\n- Compartment syndrome of lower limb\n- Tetralogy of Fallot\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-25, presumably until 2017-01-25\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- cefazolin 1000 MG Injection, started on 2017-01-25, presumably until 2017-01-25\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-25, presumably until 2017-01-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-29 00:00:00, ended at 2017-01-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; radical resection (including below knee amputation)\n\n### Condition\n- Heart failure\n- Gangrenous disorder\n- Transplanted heart valve present\n- Compartment syndrome of lower limb\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2017-01-29, presumably until 2017-01-29\n- ketamine 100 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-01-29 00:00:00, ended at 2017-01-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), anesthetic agent(s) and/or steroid; brachial plexus\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; femoral nerve\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-01-29, presumably until 2017-01-29\n- midazolam 1 MG/ML Injectable Solution, started on 2017-01-29, presumably until 2017-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; radical resection (including below knee amputation)\n\n### Condition\n- Compartment syndrome of lower limb\n- Peripheral vascular disease\n- Essential hypertension\n- Gangrenous disorder\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2017-02-05, presumably until 2017-02-05\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Illness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Injection(s), anesthetic agent(s) and/or steroid; femoral nerve\n- Injection(s), anesthetic agent(s) and/or steroid; sciatic nerve\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2017-02-05, presumably until 2017-02-05\n- midazolam 1 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-17 14:52:51, ended at 2017-02-17 16:16:11\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of organ\n- Acute renal failure syndrome\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-17 16:22:24, ended at 2017-02-17 16:22:37\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Absence of lower limb\n- Acute renal failure syndrome\n- Primary diagnosis: Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-24 15:03:43, ended at 2017-02-24 16:26:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nervous system due to type 2 diabetes mellitus\n- Primary diagnosis: Acquired absence of organ\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 14:00:00, ended at 2017-03-17 16:45:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 54.7 (percent)\n\n### Procedure\n- Transthoracic echocardiography for congenital cardiac anomalies; complete\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-17 15:00:31, ended at 2017-03-17 16:34:55\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired absence of organ\n- Primary diagnosis: Absence of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-17 15:02:20, ended at 2017-03-17 16:35:29\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Transplanted heart valve present\n- Electrocardiogram abnormal\n- Right bundle branch block\n- Tetralogy of Fallot\n- Postoperative state\n\n### Drug\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-03-17, presumably until 2017-07-17, with intended 3 refill(s). Instructions: take 2 Caps by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-17 16:46:00, ended at 2017-03-17 23:59:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.48 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.1 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.83 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 336 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-28 00:00:00, ended at 2017-04-28 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, started on 2017-04-28, presumably until 2017-04-28, with intended 0 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH AT BEDTIME\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-29 00:00:00, ended at 2017-04-29 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-04-29, presumably until 2018-06-04, with intended 6 refill(s). Instructions: take 1 Fleischner by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-17 00:00:00, ended at 2017-06-17 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-17 15:04:14, ended at 2017-06-17 16:50:01\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-18 00:00:00, ended at 2017-06-18 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired absence of organ\n- Absence of lower limb\n- Transplanted heart valve present\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chest pain\n- Primary diagnosis: Compartment syndrome of lower limb\n\n### Drug\n- gabapentin 100 MG Oral Capsule, started on 2017-07-17, presumably until 2017-08-14, with intended 3 refill(s). Instructions: Take 2 caps by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-12 00:00:00, ended at 2017-08-12 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tetralogy of Fallot\n- Primary diagnosis: Right lower quadrant pain\n- Injury of femoral artery\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-13 13:43:00, ended at 2017-08-13 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Right lower quadrant pain\n- Tetralogy of Fallot\n- Injury of femoral artery\n- Localized edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-14 00:00:00, ended at 2017-08-14 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- iothalamic acid, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-08-14, presumably until 2017-08-14\n- iothalamate, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-14 00:00:00, ended at 2017-08-14 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for procedures on arteries of lower leg, including bypass graft; not otherwise specified\n\n### Condition\n- Cellulitis of groin\n- Tetralogy of Fallot\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-08-14, presumably until 2017-08-14\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-14, presumably until 2017-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-14, presumably until 2017-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2017-08-14 12:09:00, ended at 2017-08-20 11:28:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.70 (thousand per microliter)\n- Base excess in Arterial blood by calculation: -2.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 21.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Glucose [Mass/volume] in Blood: 167 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 325 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- Base excess in Blood by calculation: 3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Prothrombin time (PT): 25.3 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.11 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 34.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 18.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.9 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 206.0 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n\n### Procedure\n- Repair blood vessel, direct; lower extremity\n- Insertion of Infusion Device into Upper Vein, Percutaneous Approach\n- Revision, femoral anastomosis of synthetic arterial bypass graft in groin, open; with autogenous vein patch graft\n- Collection of venous blood by venipuncture\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n- Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquire\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Excision of infected graft; extremity\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Replacement of Right Femoral Artery with Autologous Tissue Substitute, Open Approach\n- Excision of Left Saphenous Vein, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Postoperative state\n- Tetralogy of Fallot\n- Traumatic or non-traumatic injury\n- Abscess of groin\n- Abscess of skin and/or subcutaneous tissue\n- Complication associated with device\n- Complication of surgical procedure\n- Infection by methicillin sensitive Staphylococcus aureus\n- Infection of amputation stump\n- Postprocedural infection\n- Absence of lower limb\n- Aneurysm of artery of lower extremity\n- Primary diagnosis: Cellulitis of groin\n- Complication following amputation of limb\n- Transplanted heart valve present\n- Acquired absence of organ\n- Localized infection of skin AND/OR subcutaneous tissue\n- Obesity\n- Obstructive sleep apnea syndrome\n- Sepsis\n- Secondary pulmonary hypertension\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-08-15, presumably until 2017-08-19\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2022-04-24, with intended 0 refill(s). Instructions: take 10 mg by mouth every Wednesday\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2017-05-27, presumably until 2022-04-24, with intended 1 refill(s). Instructions: take 5 mg by mouth every Monday\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-08-17, presumably until 2017-08-17\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2017-08-17, presumably until 2017-10-13, with intended 2 refill(s). Instructions: 2 g by Intravenous route every 8 hours\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, started on 2017-08-15, presumably until 2017-08-19\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-08-16, presumably until 2017-08-18\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-15\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-08-14, presumably until 2017-08-16\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-08-15, presumably until 2017-08-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-14, presumably until 2017-08-14\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2018-01-24, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day \n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2017-08-14, presumably until 2017-08-17\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-08-20\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2017-08-15, presumably until 2017-09-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-08-17, presumably until 2017-08-20, with intended 3 refill(s). Instructions: 100 mL by Intravenous route every 8 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-19 00:00:00, ended at 2017-08-19 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older\n\n### Condition\n- Tetralogy of Fallot\n- Cellulitis of groin\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-08-19, presumably until 2017-08-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-08-19, presumably until 2017-08-19\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-19, presumably until 2017-08-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-26 09:09:25, ended at 2017-08-26 10:59:39\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less th\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- chlorothiazide 500 MG Oral Tablet, through Oral route, started on 2017-01-17, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 500 mg by Swish & Swallow route\n- triamcinolone acetonide 0.001 MG/MG Topical Ointment, through Topical route, started on 2017-03-10, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 1 Application by Topical route\n- duloxetine 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-08-26, with intended 0 refill(s). Instructions: 20 mg by Swish & Swallow route\n- aspirin 81 MG / calcium carbonate 777 MG Oral Tablet, through Oral route, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 81 mg by Swish & Swallow route\n- gabapentin 300 MG Oral Capsule, started on 2017-07-17, presumably until 2017-08-26, with intended 0 refill(s). Instructions: One qhs\n- calcium acetate 667 MG Oral Capsule, through Oral route, started on 2017-01-17, presumably until 2017-09-09, with intended 0 refill(s). Instructions: 1,334 mg by Swish & Swallow route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-26 13:30:00, ended at 2017-08-26 23:59:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study\n\n### Condition\n- Laceration - injury\n- Cellulitis of groin\n- Transplanted heart valve present\n- Open wound of anterior abdominal wall\n- Injury to blood vessels of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-02 08:10:47, ended at 2017-09-02 09:04:28\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less th\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Open wound of inguinal region\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-05 00:00:00, ended at 2017-09-05 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 09:31:07, ended at 2017-09-09 10:26:49\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 12:19:51, ended at 2017-09-09 16:25:24\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Open wound of anterior abdominal wall\n- Tetralogy of Fallot\n- Right bundle branch block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-09 12:20:09, ended at 2017-09-09 16:25:32\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tetralogy of Fallot\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-10 09:06:39, ended at 2017-09-10 10:05:44\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abscess of groin\n- Infection by methicillin sensitive Staphylococcus aureus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-16 09:57:09, ended at 2017-09-16 11:04:59\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less\n\n### Condition\n- Primary diagnosis: Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-23 09:52:28, ended at 2017-09-23 10:25:55\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound\n\n### Condition\n- Primary diagnosis: Late effect of open wound of head, neck and trunk\n- Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-30 09:55:42, ended at 2017-09-30 10:51:41\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Late effect of open wound of head, neck and trunk\n- Open wound of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-01 10:51:35, ended at 2017-10-01 12:00:55\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Traumatic or non-traumatic injury\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Traumatic or non-traumatic injury\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-13 10:57:00, ended at 2017-10-13 12:46:00\nThe patient in this visit was 40 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.25 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Glucose [Mass/volume] in Blood: 111 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n- Body height: 5' 10\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 185 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.6 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.93 (thousand per microliter)\n\n### Procedure\n- Removal of Infusion Device from Great Vessel, External Approach\n- Removal of tunneled central venous catheter, without subcutaneous port or pump\n\n### Condition\n- Tetralogy of Fallot\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2017-10-13, presumably until 2017-10-13\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "6608c77a8df64af106484f8202d60c2955aca5e016266c3b6f3901d4f43c855d", "prompt_hash": "45184c435db804ecc8ab212a8b6df0bec347bc2160d1ef661ed9b9ba494b2258", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 5, "doc": {"person_id": 115969163, "visit_occurrence_id": 123629933, "death_date": null, "visit_concept_name": "Office Visit", "visit_start_datetime": "2018-09-26 13:59:08", "visit_end_datetime": "2018-09-26 15:02:23", "visit_length_in_hours": 1.0541666666666667, "integrated_visit_record": "## Visit\nThis visit record, was from Office Visit, started at 2018-09-26 13:59:08, ended at 2018-09-26 15:02:23\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemorrhage of rectum and anus\n- Primary diagnosis: Nausea\n\n### Drug\n- colesevelam hydrochloride 625 MG Oral Tablet, through Oral route, started on 2018-09-26, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n", "approximate_token_count": 139, "patient_first_visit_date": "2015-01-29 07:01:00", "patient_last_visit_date": "2022-10-23 09:37:25", "end_obs_date": "2019-09-26", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 8, "cumulated_visit_num": 8, "cumulated_approximate_token_count": 7349, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2015-01-29 07:01:00, ended at 2015-01-30 16:25:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.95 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 182 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 320 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 53.3 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Body height: 5' 7\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial vein\n- Injection procedure for extremity venography (including introduction of needle or intracatheter)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Transcatheter therapy, arterial or venous infusion for thrombolysis other than coronary, any method, including radiological supervision and interpretation, continued treatment on subsequent day during course of thrombolytic therapy, including follow-up ca\n- Procedure on single vessel\n- Angioplasty of other non-coronary vessel(s)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Injection or infusion of thrombolytic agent\n- Introduction of catheter, superior or inferior vena cava\n- Insertion of one vascular stent\n- Venography, extremity, unilateral, radiological supervision and interpretation\n- Transcatheter therapy, venous infusion for thrombolysis, any method, including radiological supervision and interpretation, initial treatment day\n- Collection of venous blood by venipuncture\n- Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)\n\n### Condition\n- Cardiac arrhythmia\n- Electrocardiogram abnormal\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n- Swelling of limb\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2015-01-29\n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth Patient takes every day\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2015-01-29\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 50 mcg by mouth every morning before breakfast. Take 100 mcg by mouth daily.\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-01-30, presumably until 2015-01-30\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 25 mg by mouth every 6 hours as needed.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-29, presumably until 2015-01-29\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2015-01-29, presumably until 2015-01-29\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2015-01-22, presumably until 2019-02-06, with intended 0 refill(s). Instructions: take 20 mg by mouth 2 times a day.\n- paroxetine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2017-04-01, with intended 0 refill(s). Instructions: take  by mouth.\n- 0.6 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-01-30, presumably until 2015-05-22, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) every 12 hours.\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2015-01-30, presumably until 2015-01-30\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2015-01-29, presumably until 2015-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-22 10:11:49, ended at 2015-05-22 10:58:25\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling of limb\n\n### Drug\n- warfarin sodium 3 MG Oral Tablet, through Oral route, presumably until 2017-04-01, with intended 0 refill(s). Instructions: take 3 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 13:35:00, ended at 2017-04-01 13:53:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Abnormal urine\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-04-19 00:00:00, ended at 2017-04-19 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Anesthesia for procedures on heart, pericardial sac, and great vessels of chest; with pump oxygenator, age 1 year or older, for all noncoronary bypass procedures (eg, valve procedures) or for re-operation for coronary bypass more than 1 month after origin\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Dyspnea\n- Hypothyroidism\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-04-19, presumably until 2017-04-19\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- cefazolin 1000 MG Injection, started on 2017-04-19, presumably until 2017-04-19\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-04-19, presumably until 2017-04-19\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2017-04-19, presumably until 2017-04-19\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-04-19 06:24:00, ended at 2017-04-28 11:39:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.55 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.17 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.48 (thousand per microliter)\n- Base excess in Blood by calculation: 2 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.5 (millimeter mercury column)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.47 (million per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.73 (thousand per microliter)\n- Oxygen [Partial pressure] in Arterial blood: >500.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.0 (second)\n- Bicarbonate [Moles/volume] in Specimen: 26.5 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 48.2 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.66 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.1 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 83 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 99 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 5.984\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Left ventricular Ejection fraction: 38.9 (percent)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Base excess in Arterial blood by calculation: 1.7 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 155 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Prothrombin time (PT): 20.4 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 5.1 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 61 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 19.1 (nanogram per milliliter)\n\n### Procedure\n- Repair Atrial Septum, Open Approach\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Radiologic examination, abdomen; single anteroposterior view\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour\n- Excision of Right Saphenous Vein, Open Approach\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary procedure)\n- Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Supplement Mitral Valve with Synthetic Substitute, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Controlled ventilation procedure and therapy, initiation and management\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Performance of Cardiac Output, Continuous\n\n### Condition\n- Chronic kidney disease stage 1\n- Congestive heart failure\n- Angina co-occurrent and due to coronary arteriosclerosis\n- Atrial premature complex\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Abdominal pain\n- Low back pain\n- Rheumatic disease of mitral valve\n- Right bundle branch block\n- Acute posthemorrhagic anemia\n- Ascorbic acid deficiency\n- Combined systolic and diastolic dysfunction\n- Compression of vein\n- Gastroesophageal reflux disease without esophagitis\n- Mitral valve prolapse\n- Pneumothorax\n- Conduction disorder of the heart\n- Hypothyroidism\n- Major depression, single episode\n- Anxiety disorder\n- Atrial fibrillation\n- Chronic pain\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n- Urinary tract infectious disease\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial septal defect\n- Bifascicular block\n- Chronic atrial fibrillation\n- Chronic combined systolic and diastolic heart failure\n- Headache\n- Nausea\n- Non-rheumatic mitral valve disease\n- Paroxysmal atrial fibrillation\n- Pleural effusion\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-23\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- rivaroxaban 15 MG Oral Tablet, through Oral route, started on 2017-04-28, presumably until 2017-04-28\n- 100 ML milrinone lactate 0.2 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-21\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2017-04-27, presumably until 2017-05-03, with intended 0 refill(s). Instructions: take 1 Aminian by mouth every 12 hours for 5 days , first dose was on 3-28 at night, last dose will be 4-3\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-23\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2017-04-19, presumably until 2017-04-22\n- 250 ML dobutamine 2 MG/ML Injection, through Intravenous route, started on 2017-04-20, presumably until 2017-04-22\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2017-04-28, presumably until 2018-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-27\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2018-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-27\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-21\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-04-22\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- rivaroxaban, started on 2017-04-27, presumably until 2017-05-20, with intended 0 refill(s). Instructions: Take 1 round (15 mg) tab twice daily with food for 21 days then 1 triangle tab (20 mg) daily with food\n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- lisinopril 2.5 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-27\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2017-04-20, presumably until 2017-04-21\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-28\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2017-04-22, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every morning before breakfast\n- ferrous sulfate 140 MG Extended Release Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-04-20, presumably until 2017-04-25\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2017-04-21, presumably until 2017-04-21\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Daily at night\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-04-20, presumably until 2017-04-24\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2017-04-20, presumably until 2017-04-23\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Daily at night\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2017-04-26, presumably until 2017-04-27\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2017-04-22, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-21\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-04-20, presumably until 2017-04-21\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-26\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-26\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-23\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- 100 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- 0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2017-04-20, presumably until 2017-04-27\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2017-04-20, presumably until 2017-04-20\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-04-24, presumably until 2017-04-26\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-27 00:00:00, ended at 2017-04-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Compression of vein\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2017-04-27, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 5 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-20 11:02:41, ended at 2017-05-20 12:11:36\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- rivaroxaban 20 MG Oral Tablet, through Oral route, presumably until 2020-07-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 81 mg by mouth every Monday, Wednesday and Friday\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-26 13:59:08, ended at 2018-09-26 15:02:23\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemorrhage of rectum and anus\n- Primary diagnosis: Nausea\n\n### Drug\n- colesevelam hydrochloride 625 MG Oral Tablet, through Oral route, started on 2018-09-26, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-01-29 07:01:00, ended at 2015-01-30 16:25:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.95 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 182 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 320 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 53.3 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Body height: 5' 7\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial vein\n- Injection procedure for extremity venography (including introduction of needle or intracatheter)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Transcatheter therapy, arterial or venous infusion for thrombolysis other than coronary, any method, including radiological supervision and interpretation, continued treatment on subsequent day during course of thrombolytic therapy, including follow-up ca\n- Procedure on single vessel\n- Angioplasty of other non-coronary vessel(s)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Injection or infusion of thrombolytic agent\n- Introduction of catheter, superior or inferior vena cava\n- Insertion of one vascular stent\n- Venography, extremity, unilateral, radiological supervision and interpretation\n- Transcatheter therapy, venous infusion for thrombolysis, any method, including radiological supervision and interpretation, initial treatment day\n- Collection of venous blood by venipuncture\n- Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)\n\n### Condition\n- Cardiac arrhythmia\n- Electrocardiogram abnormal\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n- Swelling of limb\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2015-01-29\n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth Patient takes every day\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2015-01-29, presumably until 2015-01-29\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 50 mcg by mouth every morning before breakfast. Take 100 mcg by mouth daily.\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-01-30, presumably until 2015-01-30\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 25 mg by mouth every 6 hours as needed.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-29, presumably until 2015-01-29\n- 250 ML heparin sodium, porcine 100 UNT/ML Injection, through Intravenous route, started on 2015-01-29, presumably until 2015-01-29\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2015-01-22, presumably until 2019-02-06, with intended 0 refill(s). Instructions: take 20 mg by mouth 2 times a day.\n- paroxetine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2017-04-01, with intended 0 refill(s). Instructions: take  by mouth.\n- 0.6 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-01-30, presumably until 2015-05-22, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) every 12 hours.\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2015-01-30, presumably until 2015-01-30\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2015-01-29, presumably until 2015-01-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-22 10:11:49, ended at 2015-05-22 10:58:25\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Swelling of limb\n\n### Drug\n- warfarin sodium 3 MG Oral Tablet, through Oral route, presumably until 2017-04-01, with intended 0 refill(s). Instructions: take 3 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-01 13:35:00, ended at 2017-04-01 13:53:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Abnormal urine\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-04-19 00:00:00, ended at 2017-04-19 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Anesthesia for procedures on heart, pericardial sac, and great vessels of chest; with pump oxygenator, age 1 year or older, for all noncoronary bypass procedures (eg, valve procedures) or for re-operation for coronary bypass more than 1 month after origin\n- Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Dyspnea\n- Hypothyroidism\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-04-19, presumably until 2017-04-19\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- cefazolin 1000 MG Injection, started on 2017-04-19, presumably until 2017-04-19\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-04-19, presumably until 2017-04-19\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2017-04-19, presumably until 2017-04-19\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-04-19 06:24:00, ended at 2017-04-28 11:39:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.55 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n- Glucose [Mass/volume] in Blood: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.17 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.48 (thousand per microliter)\n- Base excess in Blood by calculation: 2 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.5 (millimeter mercury column)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.47 (million per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.73 (thousand per microliter)\n- Oxygen [Partial pressure] in Arterial blood: >500.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 5.6 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 96.0 (second)\n- Bicarbonate [Moles/volume] in Specimen: 26.5 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 48.2 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.66 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.1 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 83 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 99 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 5.984\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: <0.10 (unit per milliliter)\n- Left ventricular Ejection fraction: 38.9 (percent)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Base excess in Arterial blood by calculation: 1.7 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 155 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Prothrombin time (PT): 20.4 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Lactate [Moles/volume] in Blood: 5.1 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 61 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 19.1 (nanogram per milliliter)\n\n### Procedure\n- Repair Atrial Septum, Open Approach\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Radiologic examination, abdomen; single anteroposterior view\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour\n- Excision of Right Saphenous Vein, Open Approach\n- Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary procedure)\n- Bypass Coronary Artery, One Artery from Aorta with Autologous Venous Tissue, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Supplement Mitral Valve with Synthetic Substitute, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Controlled ventilation procedure and therapy, initiation and management\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Performance of Cardiac Output, Continuous\n\n### Condition\n- Chronic kidney disease stage 1\n- Congestive heart failure\n- Angina co-occurrent and due to coronary arteriosclerosis\n- Atrial premature complex\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Abdominal pain\n- Low back pain\n- Rheumatic disease of mitral valve\n- Right bundle branch block\n- Acute posthemorrhagic anemia\n- Ascorbic acid deficiency\n- Combined systolic and diastolic dysfunction\n- Compression of vein\n- Gastroesophageal reflux disease without esophagitis\n- Mitral valve prolapse\n- Pneumothorax\n- Conduction disorder of the heart\n- Hypothyroidism\n- Major depression, single episode\n- Anxiety disorder\n- Atrial fibrillation\n- Chronic pain\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n- Urinary tract infectious disease\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial septal defect\n- Bifascicular block\n- Chronic atrial fibrillation\n- Chronic combined systolic and diastolic heart failure\n- Headache\n- Nausea\n- Non-rheumatic mitral valve disease\n- Paroxysmal atrial fibrillation\n- Pleural effusion\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-23\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- rivaroxaban 15 MG Oral Tablet, through Oral route, started on 2017-04-28, presumably until 2017-04-28\n- 100 ML milrinone lactate 0.2 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-21\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2017-04-27, presumably until 2017-05-03, with intended 0 refill(s). Instructions: take 1 Aminian by mouth every 12 hours for 5 days , first dose was on 3-28 at night, last dose will be 4-3\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-23\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2017-04-19, presumably until 2017-04-22\n- 250 ML dobutamine 2 MG/ML Injection, through Intravenous route, started on 2017-04-20, presumably until 2017-04-22\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2017-04-28, presumably until 2018-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-27\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2018-04-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed\n- trazodone hydrochloride 50 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-27\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-21\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-04-22\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- rivaroxaban, started on 2017-04-27, presumably until 2017-05-20, with intended 0 refill(s). Instructions: Take 1 round (15 mg) tab twice daily with food for 21 days then 1 triangle tab (20 mg) daily with food\n- acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-04-28\n- lisinopril 2.5 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-27\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2017-04-20, presumably until 2017-04-21\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-28\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2017-04-22, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every morning before breakfast\n- ferrous sulfate 140 MG Extended Release Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-04-20, presumably until 2017-04-25\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2017-04-21, presumably until 2017-04-21\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Daily at night\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-04-20, presumably until 2017-04-24\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2017-04-20, presumably until 2017-04-23\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Daily at night\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2017-04-26, presumably until 2017-04-27\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2017-04-22, presumably until 2018-04-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-21\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-04-20, presumably until 2017-04-21\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-19\n- 100 ML amiodarone hydrochloride 1.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-26\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-26\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2017-04-21, presumably until 2017-04-23\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain\n- 100 ML clevidipine 0.5 MG/ML Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n- 0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspension, through Intraocular route, started on 2017-04-20, presumably until 2017-04-27\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2017-04-23, presumably until 2017-04-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-04-24, presumably until 2017-05-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- 100 ML dexmedetomidine 0.004 MG/ML Injection, through Intravenous route, started on 2017-04-20, presumably until 2017-04-20\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-04-20, presumably until 2017-04-22\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2017-04-24, presumably until 2017-04-26\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-04-19, presumably until 2017-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-27 00:00:00, ended at 2017-04-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Compression of vein\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2017-04-27, presumably until 2017-04-28, with intended 0 refill(s). Instructions: take 5 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-20 11:02:41, ended at 2017-05-20 12:11:36\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.22\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-rheumatic mitral valve stenosis with regurgitation\n\n### Drug\n- rivaroxaban 20 MG Oral Tablet, through Oral route, presumably until 2020-07-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 81 mg by mouth every Monday, Wednesday and Friday\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-26 13:59:08, ended at 2018-09-26 15:02:23\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hemorrhage of rectum and anus\n- Primary diagnosis: Nausea\n\n### Drug\n- colesevelam hydrochloride 625 MG Oral Tablet, through Oral route, started on 2018-09-26, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every bedtime\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "8666d13960d637ca8d9e0a450d06902e03da589b9f9a6d5672eeac0b5b040c36", "prompt_hash": "8f76e0d8fbfdda0ee6c589b81131c2b9afde6548a0789acd4cdfa3cd860a5975", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 6, "doc": {"person_id": 115969204, "visit_occurrence_id": 64206805, "death_date": "2015-07-20", "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2014-07-15 08:52:00", "visit_end_datetime": "2014-07-15 23:59:00", "visit_length_in_hours": 15.116666666666667, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-15 08:52:00, ended at 2014-07-15 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, elastography (List separately in addition to code for primary procedure)\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Chronic kidney disease\n- Chronic hepatitis C\n- Viral hepatitis C\n- Transplanted kidney present\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 169, "patient_first_visit_date": "2008-12-24 00:00:00", "patient_last_visit_date": "2015-07-20 00:00:00", "end_obs_date": "2015-07-15", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 1, "visit_sequence_number": 6, "cumulated_visit_num": 6, "cumulated_approximate_token_count": 1596, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-24 00:00:00, ended at 2008-12-24 00:00:00\nThe patient in this visit was 44 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-29 00:00:00, ended at 2008-12-29 00:00:00\nThe patient in this visit was 44 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection: 6.10 (log copies per milliliter)\n- Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 iU/mL: [000000] (international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-12 10:28:42, ended at 2012-07-12 10:47:29\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-20 00:00:00, ended at 2014-05-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-17 09:45:00, ended at 2014-06-17 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.6 (milligram per deciliter)\n- Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection: 6.42 (log copies per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 308 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.39 (thousand per microliter)\n- Prothrombin time (PT): 14.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 iU/mL: [000000] (international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-15 08:52:00, ended at 2014-07-15 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, elastography (List separately in addition to code for primary procedure)\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Chronic kidney disease\n- Chronic hepatitis C\n- Viral hepatitis C\n- Transplanted kidney present\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-24 00:00:00, ended at 2008-12-24 00:00:00\nThe patient in this visit was 44 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-29 00:00:00, ended at 2008-12-29 00:00:00\nThe patient in this visit was 44 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection: 6.10 (log copies per milliliter)\n- Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 iU/mL: [000000] (international unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-12 10:28:42, ended at 2012-07-12 10:47:29\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-20 00:00:00, ended at 2014-05-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-17 09:45:00, ended at 2014-06-17 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.6 (milligram per deciliter)\n- Hepatitis C virus RNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection: 6.42 (log copies per milliliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 308 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.39 (thousand per microliter)\n- Prothrombin time (PT): 14.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 iU/mL: [000000] (international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 92 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-15 08:52:00, ended at 2014-07-15 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, elastography (List separately in addition to code for primary procedure)\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Chronic kidney disease\n- Chronic hepatitis C\n- Viral hepatitis C\n- Transplanted kidney present\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "1cfe6003a58908767dd9c91e8d9ad94e488cbc950fe865d17f2b222f228cda17", "prompt_hash": "95fdd638e1dc1fcc387388fddd2b1b9fc71091ad5388aaf7eac58439973be79b", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 1.0, "f1_gu_yn": [1, 1], "recall_gu_yn": [1, 1]}
{"doc_id": 7, "doc": {"person_id": 115969314, "visit_occurrence_id": 128640450, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2018-11-20 00:00:00", "visit_end_datetime": "2018-11-20 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-20 00:00:00, ended at 2018-11-20 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, started on 2018-11-20, presumably until 2018-11-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n", "approximate_token_count": 119, "patient_first_visit_date": "2017-08-01 13:17:23", "patient_last_visit_date": "2021-05-12 00:00:00", "end_obs_date": "2019-11-20", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 13, "cumulated_visit_num": 13, "cumulated_approximate_token_count": 9336, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2017-08-01 13:17:23, ended at 2017-08-01 14:50:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thoracoabdominal aortic aneurysm\n\n### Drug\n- folic acid 1 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 mg by mouth daily\n- prednisone 10 MG Oral Tablet, through Oral route, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 5 mg by mouth daily \n- amoxicillin 120 MG/ML / clavulanate 8.58 MG/ML Oral Suspension, through Oral route, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take by mouth\n- alprazolam 0.25 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 0.25 mg by mouth every 4 hours as needed for Insomnia or Anxiety \n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 25 mg by mouth as needed Takes when systolic is greater than 120\n- omeprazole 20 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 20 mg by mouth daily \n- fluoxetine 40 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 40 mg by mouth daily \n- methotrexate 2.5 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 2.5 mg by mouth every 7 days 2.5 mg tabs. Patient takes 8 tabs  Every Wednesday. Totally of 20 mg.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-03 13:38:00, ended at 2017-08-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.5 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-06 15:50:00, ended at 2017-08-10 15:02:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.01 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 193 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 319 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 211 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide [Partial pressure] in Arterial blood: 40.1 (millimeter mercury column)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.2 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lactate [Moles/volume] in Blood: 2.3 (millimole per liter)\n- Lactate [Moles/volume] in Serum or Plasma: 2.5 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Prothrombin time (PT): 15.3 (second)\n- Base excess in Blood by calculation: 0 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Oxygen [Partial pressure] in Arterial blood: 215.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.1 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.6 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Base excess in Arterial blood by calculation: -1.9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Body height: 5' 0\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Restriction of Thoracic Aorta, Descending with Intraluminal Device, Percutaneous Approach\n- Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological super\n- Radiologic examination, chest; single view, frontal\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Open femoral artery exposure for delivery of endovascular prosthesis, by groin incision, unilateral (List separately in addition to code for primary procedure)\n- Open brachial artery exposure for delivery of endovascular prosthesis, unilateral (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquire\n- Radiologic examination, abdomen; single anteroposterior view\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Dilation of Superior Mesenteric Artery with Intraluminal Device, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); each additional proximal extension (List separatel\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Selective catheter placement, arterial system; each first order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); initial extension\n- Endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); not involving coverage of left subclavian artery origin, initial endoprosthesis plus descending t\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperglycemia\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Acute posthemorrhagic anemia\n- Congestive heart failure\n- Chronic kidney disease stage 3\n- Major depression, single episode\n- Anxiety disorder\n- Temporal arteritis\n- Acute pancreatitis\n- Asthenia\n- Atelectasis\n- Chronic combined systolic and diastolic heart failure\n- Persistent pain following procedure\n- Thoracoabdominal aortic aneurysm\n- Atrial premature complex\n- Essential hypertension\n- Intraventricular conduction defect\n- Abdominal distension, gaseous\n- Anemia of chronic disease\n- Postoperative state\n- Thoracic aortic aneurysm without rupture\n- Complication associated with device\n- Electrocardiogram abnormal\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effects of poliomyelitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-08-07, presumably until 2017-08-10\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-09\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-10\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2017-08-10\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2017-08-09, presumably until 2017-08-10\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-08-10\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2017-08-06, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-07\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-08-10, presumably until 2018-08-10, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed for Constipation\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2017-08-08, presumably until 2017-08-09\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-06, presumably until 2017-08-06\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-08-06, presumably until 2017-08-06\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-07\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-08-06, presumably until 2017-08-10\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-08-08, presumably until 2017-08-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-08-07, presumably until 2017-08-07\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-08-08, presumably until 2017-08-08\n- methotrexate 2.5 MG Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-08-09\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2017-08-10\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2018-08-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-08-08, presumably until 2017-08-08\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-08-08, presumably until 2017-08-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-07 00:00:00, ended at 2017-08-07 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for therapeutic interventional radiological procedures involving the arterial system; intracranial, intracardiac, or aortic\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Temporal arteritis\n- Thoracoabdominal aortic aneurysm\n- Essential hypertension\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-08-07, presumably until 2017-08-07\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- cefazolin 1000 MG Injection, started on 2017-08-07, presumably until 2017-08-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-08-07, presumably until 2017-08-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-07\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-07, presumably until 2017-08-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-08-15 00:00:00, ended at 2017-08-15 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-15 11:15:17, ended at 2017-09-15 12:05:28\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal aortic aneurysm without rupture\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-15 11:54:00, ended at 2017-09-15 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 83 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- MCV [Entitic volume] by Automated count: 88.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-25 15:26:00, ended at 2017-10-31 18:47:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Prothrombin time (PT): 13.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.7 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Base excess in Arterial blood by calculation: 0.3 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.08 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 229.0 (millimeter mercury column)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Body height: 5' 0\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Lactate [Moles/volume] in Serum or Plasma: 2.2 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 263 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 24.1 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.9 (second)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.17 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 37.3 (millimeter mercury column)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 89 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of capillary blood specimen (eg, finger, heel, ear stick)\n- Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel\n- Radiologic examination, chest; single view, frontal\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Collection of venous blood by venipuncture\n- Fluoroscopy of Thoraco-Abdominal Aorta using Low Osmolar Contrast\n- Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modula\n- Radiologic examination, abdomen; single anteroposterior view\n- Open femoral artery exposure for delivery of endovascular prosthesis, by groin incision, unilateral (List separately in addition to code for primary procedure)\n- Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal aortic or iliac artery aneurysm, pseudoaneurysm, or dissection, radiological supervision and interpretation\n- Restriction of Abdominal Aorta with Branched or Fenestrated Intraluminal Device, One or Two Arteries, Percutaneous Approach\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Restriction of Thoracic Aorta, Descending with Branched or Fenestrated Intraluminal Device, One or Two Arteries, Percutaneous Approach\n\n### Condition\n- Intestinal obstruction co-occurrent and due to decreased peristalsis\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Constipation\n- Electrocardiogram abnormal\n- Nausea and vomiting\n- Chronic congestive heart failure\n- Thoracoabdominal aortic aneurysm\n- Temporal arteritis\n- Chronic pain\n- Chronic systolic heart failure\n- Monoplegia of lower limb affecting non-dominant side\n- Nausea\n- Persistent pain following procedure\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Acute posthemorrhagic anemia\n- Anemia of chronic disease\n- Chronic kidney disease stage 3\n- Late effects of poliomyelitis\n- Mechanical complication of aortic graft\n- Abdominal aortic aneurysm without rupture\n\n### Drug\n- glycerin, started on 2017-10-28, presumably until 2017-10-28\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-10-28, presumably until 2017-10-30\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2017-10-28, presumably until 2017-10-30\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-31\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-10-28, presumably until 2017-10-28\n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2017-10-28, presumably until 2017-10-30\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2017-10-26, presumably until 2017-10-28\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2017-10-28, presumably until 2017-10-28\n- amoxicillin 500 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 500 mg by mouth every day\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2017-10-27, presumably until 2017-10-31\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-10-26, presumably until 2018-11-01, with intended 1 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2017-10-28, presumably until 2017-10-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-10-29, presumably until 2017-10-29\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-25, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2017-10-26, presumably until 2017-10-31\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-27\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-25\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2017-10-28, presumably until 2017-10-31\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2018-10-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-28, presumably until 2017-10-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-10-27, presumably until 2017-10-31\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-29\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 5 mg by mouth daily\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-28\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-10-28, presumably until 2017-10-29\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-31\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2017-10-26, presumably until 2017-10-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-25, presumably until 2017-10-27\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2017-10-28, presumably until 2017-10-28\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2017-10-26, presumably until 2017-10-30\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2017-10-26, presumably until 2017-10-26\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2017-10-28, presumably until 2017-10-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2017-10-31\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-10-28, presumably until 2017-10-30\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-27, presumably until 2017-10-27\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-26 00:00:00, ended at 2017-10-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for therapeutic interventional radiological procedures involving the arterial system; intracranial, intracardiac, or aortic\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n- Essential hypertension\n- Anemia\n- Chronic kidney disease\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-26\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- cefazolin 1000 MG Injection, started on 2017-10-26, presumably until 2017-10-26\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-26\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-26 00:00:00, ended at 2017-10-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-10-26, presumably until 2017-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-11-02 00:00:00, ended at 2017-11-02 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-29 00:00:00, ended at 2018-06-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, started on 2018-07-02, presumably until 2018-07-02, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-20 00:00:00, ended at 2018-11-20 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, started on 2018-11-20, presumably until 2018-11-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-01 13:17:23, ended at 2017-08-01 14:50:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thoracoabdominal aortic aneurysm\n\n### Drug\n- folic acid 1 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 mg by mouth daily\n- prednisone 10 MG Oral Tablet, through Oral route, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 5 mg by mouth daily \n- amoxicillin 120 MG/ML / clavulanate 8.58 MG/ML Oral Suspension, through Oral route, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take by mouth\n- alprazolam 0.25 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 0.25 mg by mouth every 4 hours as needed for Insomnia or Anxiety \n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 25 mg by mouth as needed Takes when systolic is greater than 120\n- omeprazole 20 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 20 mg by mouth daily \n- fluoxetine 40 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 40 mg by mouth daily \n- methotrexate 2.5 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 2.5 mg by mouth every 7 days 2.5 mg tabs. Patient takes 8 tabs  Every Wednesday. Totally of 20 mg.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-03 13:38:00, ended at 2017-08-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.5 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-06 15:50:00, ended at 2017-08-10 15:02:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.01 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 193 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 319 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 211 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 100 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide [Partial pressure] in Arterial blood: 40.1 (millimeter mercury column)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.2 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lactate [Moles/volume] in Blood: 2.3 (millimole per liter)\n- Lactate [Moles/volume] in Serum or Plasma: 2.5 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Prothrombin time (PT): 15.3 (second)\n- Base excess in Blood by calculation: 0 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Oxygen [Partial pressure] in Arterial blood: 215.0 (millimeter mercury column)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.1 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.6 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Base excess in Arterial blood by calculation: -1.9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Body height: 5' 0\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Restriction of Thoracic Aorta, Descending with Intraluminal Device, Percutaneous Approach\n- Transcatheter placement of an intravascular stent(s) (except lower extremity artery(s) for occlusive disease, cervical carotid, extracranial vertebral or intrathoracic carotid, intracranial, or coronary), open or percutaneous, including radiological super\n- Radiologic examination, chest; single view, frontal\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Open femoral artery exposure for delivery of endovascular prosthesis, by groin incision, unilateral (List separately in addition to code for primary procedure)\n- Open brachial artery exposure for delivery of endovascular prosthesis, unilateral (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquire\n- Radiologic examination, abdomen; single anteroposterior view\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Dilation of Superior Mesenteric Artery with Intraluminal Device, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); each additional proximal extension (List separatel\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Selective catheter placement, arterial system; each first order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); initial extension\n- Endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); not involving coverage of left subclavian artery origin, initial endoprosthesis plus descending t\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperglycemia\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Acute posthemorrhagic anemia\n- Congestive heart failure\n- Chronic kidney disease stage 3\n- Major depression, single episode\n- Anxiety disorder\n- Temporal arteritis\n- Acute pancreatitis\n- Asthenia\n- Atelectasis\n- Chronic combined systolic and diastolic heart failure\n- Persistent pain following procedure\n- Thoracoabdominal aortic aneurysm\n- Atrial premature complex\n- Essential hypertension\n- Intraventricular conduction defect\n- Abdominal distension, gaseous\n- Anemia of chronic disease\n- Postoperative state\n- Thoracic aortic aneurysm without rupture\n- Complication associated with device\n- Electrocardiogram abnormal\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Late effects of poliomyelitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-08-07, presumably until 2017-08-10\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-09\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-10\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2017-08-10\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2017-08-09, presumably until 2017-08-10\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-08-10\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2017-08-06, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-07\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-08-10, presumably until 2018-08-10, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day as needed for Constipation\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2017-08-08, presumably until 2017-08-09\n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-06, presumably until 2017-08-06\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-08\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2017-08-06, presumably until 2017-08-06\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-07\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-08-06, presumably until 2017-08-10\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-08-07, presumably until 2017-08-10\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-08-08, presumably until 2017-08-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2017-08-07, presumably until 2017-08-07\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2017-08-08, presumably until 2017-08-08\n- methotrexate 2.5 MG Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-08-09\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2017-08-10\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-08-09, presumably until 2017-10-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-08-10, presumably until 2018-08-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-08-08, presumably until 2017-08-08\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2017-08-08, presumably until 2017-08-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-08-07 00:00:00, ended at 2017-08-07 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for therapeutic interventional radiological procedures involving the arterial system; intracranial, intracardiac, or aortic\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Temporal arteritis\n- Thoracoabdominal aortic aneurysm\n- Essential hypertension\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-08-07, presumably until 2017-08-07\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 10 ML epinephrine 0.1 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- cefazolin 1000 MG Injection, started on 2017-08-07, presumably until 2017-08-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-08-07, presumably until 2017-08-07\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-07, presumably until 2017-08-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-07, presumably until 2017-08-07\n- midazolam 1 MG/ML Injectable Solution, started on 2017-08-07, presumably until 2017-08-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-08-15 00:00:00, ended at 2017-08-15 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-15 11:15:17, ended at 2017-09-15 12:05:28\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal aortic aneurysm without rupture\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-15 11:54:00, ended at 2017-09-15 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 83 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- MCV [Entitic volume] by Automated count: 88.5 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n- Thoracoabdominal aortic aneurysm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-25 15:26:00, ended at 2017-10-31 18:47:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Prothrombin time (PT): 13.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.7 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Base excess in Arterial blood by calculation: 0.3 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.08 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Oxygen [Partial pressure] in Arterial blood: 229.0 (millimeter mercury column)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Body height: 5' 0\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 0.45 (milligram per deciliter)\n- Lactate [Moles/volume] in Serum or Plasma: 2.2 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 263 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 24.1 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.9 (second)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.17 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 37.3 (millimeter mercury column)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 89 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of capillary blood specimen (eg, finger, heel, ear stick)\n- Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal abdominal aortic or iliac aneurysm, false aneurysm, or dissection; initial vessel\n- Radiologic examination, chest; single view, frontal\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Collection of venous blood by venipuncture\n- Fluoroscopy of Thoraco-Abdominal Aorta using Low Osmolar Contrast\n- Endovascular repair of visceral aorta and infrarenal abdominal aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption) with a fenestrated visceral aortic endograft and concomitant unibody or modula\n- Radiologic examination, abdomen; single anteroposterior view\n- Open femoral artery exposure for delivery of endovascular prosthesis, by groin incision, unilateral (List separately in addition to code for primary procedure)\n- Placement of proximal or distal extension prosthesis for endovascular repair of infrarenal aortic or iliac artery aneurysm, pseudoaneurysm, or dissection, radiological supervision and interpretation\n- Restriction of Abdominal Aorta with Branched or Fenestrated Intraluminal Device, One or Two Arteries, Percutaneous Approach\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach\n- Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Restriction of Thoracic Aorta, Descending with Branched or Fenestrated Intraluminal Device, One or Two Arteries, Percutaneous Approach\n\n### Condition\n- Intestinal obstruction co-occurrent and due to decreased peristalsis\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Constipation\n- Electrocardiogram abnormal\n- Nausea and vomiting\n- Chronic congestive heart failure\n- Thoracoabdominal aortic aneurysm\n- Temporal arteritis\n- Chronic pain\n- Chronic systolic heart failure\n- Monoplegia of lower limb affecting non-dominant side\n- Nausea\n- Persistent pain following procedure\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Acute posthemorrhagic anemia\n- Anemia of chronic disease\n- Chronic kidney disease stage 3\n- Late effects of poliomyelitis\n- Mechanical complication of aortic graft\n- Abdominal aortic aneurysm without rupture\n\n### Drug\n- glycerin, started on 2017-10-28, presumably until 2017-10-28\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-10-28, presumably until 2017-10-30\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2017-10-28, presumably until 2017-10-30\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-31\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-10-28, presumably until 2017-10-28\n- acetaminophen 650 MG Rectal Suppository, through Rectal route, started on 2017-10-28, presumably until 2017-10-30\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2017-10-26, presumably until 2017-10-28\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2017-10-28, presumably until 2017-10-28\n- amoxicillin 500 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 500 mg by mouth every day\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2017-10-27, presumably until 2017-10-31\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-10-26, presumably until 2018-11-01, with intended 1 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2017-10-28, presumably until 2017-10-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-10-29, presumably until 2017-10-29\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-10-25, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2017-10-26, presumably until 2017-10-31\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-27\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-25\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2017-10-28, presumably until 2017-10-31\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2018-10-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-28, presumably until 2017-10-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-10-27, presumably until 2017-10-31\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-29\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-10-25, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 5 mg by mouth daily\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2017-10-28\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2017-10-28, presumably until 2017-10-29\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2018-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-31\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2017-10-26, presumably until 2017-10-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-25, presumably until 2017-10-27\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2017-10-28, presumably until 2017-10-28\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2017-10-26, presumably until 2017-10-30\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2017-10-26, presumably until 2017-10-26\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2017-10-28, presumably until 2017-10-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2017-10-27, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2017-10-31\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-10-28, presumably until 2017-10-30\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-27, presumably until 2017-10-27\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-10-26 00:00:00, ended at 2017-10-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for therapeutic interventional radiological procedures involving the arterial system; intracranial, intracardiac, or aortic\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n- Essential hypertension\n- Anemia\n- Chronic kidney disease\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-26\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- cefazolin 1000 MG Injection, started on 2017-10-26, presumably until 2017-10-26\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-10-26, presumably until 2017-10-26\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-26, presumably until 2017-10-26\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-10-26, presumably until 2017-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-26 00:00:00, ended at 2017-10-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2017-10-26, presumably until 2017-10-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-11-02 00:00:00, ended at 2017-11-02 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-29 00:00:00, ended at 2018-06-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, started on 2018-07-02, presumably until 2018-07-02, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-20 00:00:00, ended at 2018-11-20 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, started on 2018-11-20, presumably until 2018-11-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "49aefc9e33b6bb70b18a78dde8b76d6061c348249460fdc49cd670c64f6afe38", "prompt_hash": "be9af52f9ce691abd6f3b8457fb32f5ec60fab2d12a8b1fc0859a7ec16a926be", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 8, "doc": {"person_id": 115969466, "visit_occurrence_id": 173590087, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2021-01-27 00:00:00", "visit_end_datetime": "2021-01-27 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-27 00:00:00, ended at 2021-01-27 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated moderate persistent asthma\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2021-01-27, presumably until 2021-02-09, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n", "approximate_token_count": 137, "patient_first_visit_date": "2014-03-21 01:58:00", "patient_last_visit_date": "2023-02-02 00:00:00", "end_obs_date": "2022-01-27", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "recurrent", "ischemic_stroke_one_year_diagnosis": 1, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 379, "cumulated_visit_num": 379, "cumulated_approximate_token_count": 81213, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2014-03-21 01:58:00, ended at 2014-03-29 16:27:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.6 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 338 (milligram per deciliter)\n- Osmolality of Urine: 574 (milliosmole per kilogram)\n- Thrombin time: 15.7 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 229 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.31 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.25 (milli-international unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Body height: 5' 4\" (inch (US))\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 83 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.3 (percent)\n- Prothrombin time (PT): 16.0 (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.3 (nanogram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 61 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 9.82 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 357 (thousand per microliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 94 (milligram per deciliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 12.4 (microgram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 55 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 25 (millimeter per hour)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Magnetic resonance angiography, head; without contrast material(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time int\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Hospital discharge day management; more than 30 minutes\n- Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professio\n- Nerve conduction studies; 5-6 studies\n- Occupational therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Magnetic resonance angiography, neck; without contrast material(s)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Lumbar puncture\n- Open biopsy of cranial or peripheral nerve or ganglion\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Open biopsy of soft tissue\n- Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and prepari\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Acute renal failure syndrome\n- Arteritis\n- Diffuse cerebrovascular disease\n- Acquired deformity of ankle AND/OR foot\n- Altered mental status\n- Congestive heart failure\n- Disorder of brain\n- Eosinophil count raised\n- Eruption\n- Hyperkalemia\n- Cardiomegaly\n- Cerebral ischemia\n- Disorder of lower extremity\n- Disorder of posterior pituitary\n- Granulomatosis with polyangiitis\n- Hypo-osmolality and or hyponatremia\n- Polyarteritis nodosa\n- Primary diagnosis: Visual field defect\n- Disorder of skeletal muscle\n- Essential hypertension\n- Primary cardiomyopathy\n- Anemia in chronic kidney disease\n- First degree atrioventricular block\n- Renal function tests abnormal\n- Spontaneous ecchymosis\n- Organic mental disorder\n- Abnormal findings on diagnostic imaging of skull and head\n- Backache\n- Cardiomyopathy associated with another disorder\n- Chronic diastolic heart failure\n- Chronic kidney disease\n- Disorder of nervous system\n- Herpes simplex without complication\n- Electrocardiogram abnormal\n- Mononeuritis\n- Subarachnoid hemorrhage\n\n### Drug\n- ramipril 5 MG Oral Capsule, through Oral route, started on 2014-03-21, presumably until 2014-03-23\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-21\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2014-03-25, presumably until 2014-05-14, with intended 0 refill(s). Instructions: 3 mL by Nebulization route every 4 hours as needed for Bronchospasm/Wheezing.\n- calcium carbonate 625 MG / cholecalciferol 125 UNT Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2023-01-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2014-03-22, presumably until 2017-12-26, with intended 0 refill(s). Instructions: 2 Sprays by Nasal route daily.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2014-03-23, presumably until 2014-05-14, with intended 0 refill(s). Instructions: 40 mg by Intravenous route daily.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-03-22, presumably until 2014-07-31, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed (pain or fever).\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-03-21, presumably until 2014-03-21\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2014-03-21, presumably until 2014-03-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-03-24, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- citalopram 20 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-23\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-03-23, presumably until 2015-03-29, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 12 hours as needed.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2014-03-21, presumably until 2014-05-14, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2014-03-23, presumably until 2014-07-31, with intended 0 refill(s). Instructions: take 1 Singhal by mouth every bedtime.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-03-27, presumably until 2014-03-29\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2014-03-24\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2014-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every Monday, Wednesday and Friday.\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2014-03-25, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2014-03-29, presumably until 2014-03-29\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-03-26, presumably until 2014-03-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-23, presumably until 2014-03-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-03-26, presumably until 2014-03-26\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-03-25 00:00:00, ended at 2014-03-25 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-03-25 00:00:00, ended at 2014-03-25 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nerves, muscles, tendons, and fascia of lower leg, ankle, and foot; not otherwise specified\n\n### Condition\n- Muscle weakness\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2014-03-25, presumably until 2014-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-25, presumably until 2014-03-25\n- midazolam 1 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-09 10:06:18, ended at 2014-04-09 16:27:50\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-24 11:44:00, ended at 2014-04-24 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-04-24, presumably until 2014-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-24, presumably until 2014-04-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-04-24, presumably until 2014-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-24 15:16:36, ended at 2014-04-24 15:16:45\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-14 00:00:00, ended at 2014-05-14 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 2.1EF(MOD-sp4) (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-14 09:16:31, ended at 2014-05-14 10:23:33\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2014-05-14, presumably until 2014-09-04, with intended 6 refill(s). Instructions: take 4 Tabs by mouth daily.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2014-05-14, presumably until 2015-01-06, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-14 09:30:00, ended at 2014-05-14 10:28:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n\n### Condition\n- Localized swelling, mass and lump, trunk\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-14 10:29:00, ended at 2014-05-14 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.13 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.17 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-27 11:59:00, ended at 2014-05-27 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.5\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-05-27, presumably until 2014-05-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-05-27, presumably until 2014-05-27\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-05-27, presumably until 2014-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-27 12:40:23, ended at 2014-05-27 12:41:49\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-06-11 00:00:00, ended at 2014-06-11 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arteritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-26 09:44:00, ended at 2014-06-26 10:55:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 12.65 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Ulcerative colitis\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-26 10:56:00, ended at 2014-06-26 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.488\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Ulcerative colitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-06-26\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-06-26, presumably until 2014-06-26\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-06-26, presumably until 2014-06-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-26 12:33:34, ended at 2014-06-26 12:34:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Ulcerative colitis\n\n### Drug\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2014-06-26, presumably until 2014-10-14, with intended 3 refill(s). Instructions: take 40 mg by mouth daily.\n- prednisone 5 MG Oral Tablet, started on 2014-06-26, presumably until 2014-07-31, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- cyclophosphamide 25 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-08-01, with intended 1 refill(s). Instructions: take 4 Tabs by mouth daily.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-10-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 09:56:00, ended at 2014-07-31 11:17:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 240 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 12.59 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 34 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Age related macular degeneration\n- Cataract\n- Presbyopia\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-31 10:22:03, ended at 2014-07-31 11:10:54\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2018-09-06, with intended 0 refill(s). Instructions: take 81 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 11:18:00, ended at 2014-07-31 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 10 (milligram per gram)\n- Albumin [Mass/volume] in Urine: 10 (milligram per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-05 09:30:00, ended at 2014-08-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-08-05, presumably until 2014-08-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-08-05, presumably until 2014-08-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-08-05, presumably until 2014-08-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-08-05 14:28:42, ended at 2014-08-05 17:01:53\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Arteritis\n- Inflammatory and toxic neuropathy\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-18 00:00:00, ended at 2014-08-18 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-08-18, presumably until 2014-09-04, with intended 3 refill(s). Instructions: take 2 tablets by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-04 00:00:00, ended at 2014-09-04 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-09-04, presumably until 2014-11-11, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- prednisone 10 MG Oral Tablet, started on 2014-09-04, presumably until 2014-11-06, with intended 6 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-22 00:00:00, ended at 2014-09-22 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-14 11:53:00, ended at 2014-10-14 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 17 (milligram per gram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 335 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.90 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cataract\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-14 15:17:41, ended at 2014-10-14 16:01:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- 0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Ma..., through Intramuscular route, started on 2014-10-14, presumably until 2014-10-15, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- ciprofloxacin 250 MG Oral Tablet, through Oral route, presumably until 2014-11-11, with intended 0 refill(s). Instructions: take  by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-04 00:00:00, ended at 2014-11-04 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute myocardial infarction of anterior wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-05 00:00:00, ended at 2014-11-05 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-05 12:34:00, ended at 2014-11-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Erythrocyte sedimentation rate: 13 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.23 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.2 (thousand per microliter)\n- Albumin/Creatinine [Mass Ratio] in Urine: 9 (milligram per gram)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 294 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- MCV [Entitic volume] by Automated count: 92.7 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-05 13:51:43, ended at 2014-11-05 14:20:57\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation\n\n### Condition\n- Primary diagnosis: Cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-06 00:00:00, ended at 2014-11-06 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2014-11-06, presumably until 2015-01-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. Taper as instructed by MD.\n- prednisone 5 MG Oral Tablet, started on 2014-11-06, presumably until 2015-01-06, with intended 3 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-11-10 00:00:00, ended at 2014-11-10 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- chondroitin sulfates, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- chondroitin 4-sulfate, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- cefazolin 1000 MG Injection, started on 2014-11-10, presumably until 2014-11-10\n- 1 ML epinephrine 1 MG/ML Injection, started on 2014-11-10, presumably until 2014-11-10\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-11-10, presumably until 2014-11-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-10 11:50:00, ended at 2014-11-10 14:31:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- One stage extracapsular extraction of lens and insertion of prosthetic intraocular lens\n- Aspiration of cataract by phacoemulsification\n\n### Condition\n- Visual field defect\n- Hypermetropia\n- Presbyopia\n- Cataract\n- Asthma\n- Gastroesophageal reflux disease\n- Age related macular degeneration\n- Cardiac arrhythmia\n- Chronic kidney disease\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- moxifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-11 13:56:14, ended at 2014-11-11 14:39:52\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-11-11, presumably until 2015-01-06, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-18 10:24:00, ended at 2014-11-18 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 19 (milligram per gram)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Neutrophils [#/volume] in Blood by Automated count: 7.61 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 331 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Urine: 11 (milligram per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.25 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-12-15 00:00:00, ended at 2014-12-15 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- chondroitin sulfates, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- chondroitin 4-sulfate, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- cefazolin 1000 MG Injection, started on 2014-12-15, presumably until 2014-12-15\n- 1 ML epinephrine 1 MG/ML Injection, started on 2014-12-15, presumably until 2014-12-15\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-12-15, presumably until 2014-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-15 11:18:00, ended at 2014-12-15 14:40:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Aspiration of cataract by phacoemulsification\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- One stage extracapsular extraction of lens and insertion of prosthetic intraocular lens\n\n### Condition\n- Asthma\n- Chronic kidney disease\n- Cataract\n- Heart failure\n- Disorder of kidney and/or ureter\n- Granulomatosis with polyangiitis\n- Age related macular degeneration\n- Allergic disposition\n- Chronic sinusitis\n- Allergic rhinitis\n- Gastroesophageal reflux disease\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-12-15, presumably until 2014-12-15\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- moxifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-12-24 00:00:00, ended at 2014-12-24 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-24 12:07:00, ended at 2014-12-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.76 (thousand per microliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 305 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Age related macular degeneration\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-06 09:29:01, ended at 2015-01-06 10:29:13\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n- Intraocular pressure of right eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Age related macular degeneration\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-06 11:18:21, ended at 2015-01-06 12:06:39\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Age related macular degeneration\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-01-06, presumably until 2015-04-30, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- prednisone 1 MG Oral Tablet, started on 2015-01-06, presumably until 2015-05-05, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- prednisone 5 MG Oral Tablet, started on 2015-01-06, presumably until 2015-03-27, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- carvedilol 6.25 MG Oral Tablet, through Oral route, presumably until 2016-10-20, with intended 0 refill(s). Instructions: take 6.25 mg by mouth 2 times a day with meals \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-10 00:00:00, ended at 2015-02-10 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 10:04:24, ended at 2015-02-10 12:34:34\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n\n### Condition\n- Eruption\n- Primary diagnosis: Chronic rhinitis\n- Chronic sinusitis\n- Asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 14:51:30, ended at 2015-02-10 16:38:58\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Chronic rhinitis\n- Eruption\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 16:11:09, ended at 2015-02-10 17:15:16\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-03 00:00:00, ended at 2015-03-03 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 09:01:58, ended at 2015-03-03 10:32:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 11 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Age related macular degeneration\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 11:10:19, ended at 2015-03-03 13:37:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Granulomatosis with polyangiitis\n- IgE-mediated allergic asthma\n- Primary diagnosis: Allergic rhinitis due to pollen\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-03-03, presumably until 2015-05-05, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-03 12:47:00, ended at 2015-03-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Acute myocardial infarction of anterior wall\n- Cerebral infarction due to embolism of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 15:08:13, ended at 2015-03-03 16:51:51\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-03-25 00:00:00, ended at 2015-03-25 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2015-04-16, presumably until 2015-06-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-27 00:00:00, ended at 2015-03-27 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2015-03-31, presumably until 2015-08-25, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-17 00:00:00, ended at 2015-04-17 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2015-04-17, presumably until 2015-04-17, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE A DAY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-04-30 00:00:00, ended at 2015-04-30 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Allergic rhinitis due to animal hair and dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-04-30, presumably until 2015-06-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-05-05 00:00:00, ended at 2015-05-05 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-05 09:35:00, ended at 2015-05-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 18 (milligram per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 129.70 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.73 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.7 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCV [Entitic volume] by Automated count: 94.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypokalemia\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-05 10:09:27, ended at 2015-05-05 10:55:28\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypokalemia\n\n### Drug\n- potassium chloride 25 MEQ Effervescent Oral Tablet, through Oral route, started on 2015-05-05, presumably until 2016-02-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-24 10:42:00, ended at 2015-06-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 10.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Creatinine [Mass/volume] in Urine: 32.50 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-24 12:52:33, ended at 2015-06-24 14:33:10\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 1\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-24 14:50:21, ended at 2015-06-24 15:40:13\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Allergic rhinitis due to animal hair and dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-06-24, presumably until 2015-08-25, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-07 00:00:00, ended at 2015-07-07 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-21 10:22:00, ended at 2015-07-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.06 (million per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 79.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 11 (millimeter per hour)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 257 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n- Chronic sinusitis\n- Chronic kidney disease stage 1\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-07-21 13:38:44, ended at 2015-07-21 14:47:40\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-07-21, presumably until 2016-05-19, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n- cephalexin 500 MG Oral Capsule, through Oral route, presumably until 2015-07-21, with intended 0 refill(s). Instructions: take by mouth 4 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-25 10:45:00, ended at 2015-08-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Erythrocyte sedimentation rate: 9 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Creatinine [Mass/volume] in Urine: 55.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.85 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of muscle\n- Allergic rhinitis due to animal hair and dander\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-25 11:35:10, ended at 2015-08-25 12:35:45\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis due to pollen\n- Asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2015-08-25, presumably until 2016-08-24, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-25 14:05:22, ended at 2015-08-25 15:02:39\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Body height: 5' 4\" (inch (US))\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.04 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Disorder of muscle\n- Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-08-25, presumably until 2016-04-20, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, started on 2015-08-25, presumably until 2015-12-23, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-26 00:00:00, ended at 2015-08-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-09-28 00:00:00, ended at 2015-09-28 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-12 00:00:00, ended at 2015-11-12 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-11-17 00:00:00, ended at 2015-11-17 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-18 10:21:00, ended at 2015-11-18 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.6 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 168 (picogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 120.7 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.83 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-18 11:04:02, ended at 2015-11-18 11:46:02\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-23 10:30:00, ended at 2015-12-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 8 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 255 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 123.8 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.64 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of bone\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-23 11:24:15, ended at 2015-12-23 11:52:17\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-01-05 00:00:00, ended at 2016-01-05 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-04 14:12:49, ended at 2016-02-04 16:12:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-04 16:10:44, ended at 2016-02-04 16:53:21\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, presumably until 2019-04-30, with intended 0 refill(s). Instructions: take 20 mEq by mouth 2 times a day Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-19 00:00:00, ended at 2016-04-19 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-20 11:37:00, ended at 2016-04-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 59.99 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.40 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 292 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Osteoporosis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-20 12:00:20, ended at 2016-04-20 12:18:01\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2016-04-20, presumably until 2016-09-20, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 1 MG Oral Tablet, started on 2016-04-20, presumably until 2016-09-19, with intended 2 refill(s). Instructions: Take 3mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-29 00:00:00, ended at 2016-04-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-05-18 00:00:00, ended at 2016-05-18 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-19 10:46:24, ended at 2016-05-19 12:06:35\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, started on 2016-05-19, presumably until 2017-04-12, with intended 0 refill(s). Instructions: Take 2 tablets by mouth initially then 1 tablet by mouth following each loose stool. Not to exceed 8 tablets per day\n- 1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection, through Intramuscular route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: inject 1,440 Units into a muscle One Time\n- azithromycin 500 MG Oral Tablet, through Oral route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 3 days\n- typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution, through Intramuscular route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n- atovaquone 250 MG / proguanil hydrochloride 100 MG Oral Tablet, through Oral route, started on 2016-05-19, presumably until 2017-01-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily Take one tablet daily, starting 1-2 days prior to travel to malarious area. Continue daily while in malarious area and for 7 days after leaving area\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-19 13:25:31, ended at 2016-05-19 14:01:55\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2016-05-19, presumably until 2016-10-10, with intended 6 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n- fexofenadine hydrochloride 180 MG Oral Tablet, through Oral route, presumably until 2018-09-06, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-09 00:00:00, ended at 2016-06-09 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 15:45:46, ended at 2016-06-09 16:14:23\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypokalemia\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-13 00:00:00, ended at 2016-06-13 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-14 00:00:00, ended at 2016-07-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-14 12:20:00, ended at 2016-07-14 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 287 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Creatinine [Mass/volume] in Urine: 32.09 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-14 14:04:01, ended at 2016-07-14 14:32:54\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-07-14, presumably until 2016-09-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-07-14, presumably until 2016-10-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-08-09 00:00:00, ended at 2016-08-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-06 00:00:00, ended at 2016-09-06 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-15 00:00:00, ended at 2016-09-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2016-09-15, presumably until 2016-09-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-16 00:00:00, ended at 2016-09-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Urine: 24 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Globulin [Mass/volume] in Serum: 2.1 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 199 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 21 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10635 (cells per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Protein [Mass/volume] in Urine: 5 (milligram per deciliter)\n- Bacteria [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Basophils [#/volume] in Blood by Automated count: 0 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 445 (cells per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 208 (milligram per gram of creatinine)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 2.0 (calculated)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- MCV [Entitic volume] by Automated count: 94.3 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.13 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.05 (milligram per deciliter)\n- Epithelial cells.squamous [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 421 (cells per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hyaline casts [#/area] in Urine sediment by Microscopy low power field: NONE SEEN (per low powered field)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.9 (percent)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 8.6 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-19 00:00:00, ended at 2016-09-19 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Essential hypertension\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-09-19, presumably until 2017-04-12, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-20 00:00:00, ended at 2016-09-20 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2016-09-20, presumably until 2017-01-19, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2016-09-28, presumably until 2017-01-19, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-30 00:00:00, ended at 2016-09-30 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-10-10 00:00:00, ended at 2016-10-10 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, started on 2016-10-10, presumably until 2017-01-19, with intended 3 refill(s). Instructions: SPRAY 1 SPRAY NASALLY 2 TIMES A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-14 00:00:00, ended at 2016-10-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-20 12:33:00, ended at 2016-10-20 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 18.05 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.39 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-20 14:20:04, ended at 2016-10-20 14:56:33\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-28 00:00:00, ended at 2016-10-28 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-11 00:00:00, ended at 2016-11-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-12 00:00:00, ended at 2016-11-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2016-11-14, presumably until 2017-01-19, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-14 00:00:00, ended at 2016-12-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-14 11:39:00, ended at 2016-12-14 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 94.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.9 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.8 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 10.31 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-14 14:17:25, ended at 2016-12-14 15:07:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-19 10:48:04, ended at 2017-01-19 10:48:30\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis due to pollen\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Inhalation, started on 2017-01-19, presumably until 2017-12-26, with intended 3 refill(s). Instructions: 1 Spray by Inhalation route 2 times a day as needed (rhinitis)\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-01-19, presumably until 2017-07-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- beclomethasone dipropionate 0.08 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-01-19, presumably until 2017-04-12, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-19 14:07:24, ended at 2017-01-19 14:50:33\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-01-19, presumably until 2017-04-12, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n- prednisone 1 MG Oral Tablet, started on 2017-01-19, presumably until 2017-04-12, with intended 3 refill(s). Instructions: Take 4mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-07 00:00:00, ended at 2017-02-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-09 00:00:00, ended at 2017-02-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-02-14, presumably until 2017-03-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-09 11:18:15, ended at 2017-02-09 12:28:04\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.913\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-09 12:38:08, ended at 2017-02-09 13:15:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Disorder of nasal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-14 00:00:00, ended at 2017-02-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2017-02-23, presumably until 2017-02-23, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-21 00:00:00, ended at 2017-03-21 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-03-21, presumably until 2017-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-12 10:51:00, ended at 2017-04-12 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 26.74 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Erythrocyte sedimentation rate: 14 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 10.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 284 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Osteoporosis\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-12 11:17:25, ended at 2017-04-12 12:11:15\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.795\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2017-04-12, presumably until 2018-01-03, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 7 days\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2017-01-04, presumably until 2017-08-10, with intended 0 refill(s). Instructions:   </br>1 Puff Aerosol, INH, BID, 6 gm, 0, Maintenance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-12 14:58:04, ended at 2017-04-12 15:24:37\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-04-12, presumably until 2017-07-17, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n- prednisone 1 MG Oral Tablet, started on 2017-04-12, presumably until 2017-09-05, with intended 3 refill(s). Instructions: Take 3mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-24 00:00:00, ended at 2017-05-24 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n\n### Drug\n- levalbuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2017-05-31, presumably until 2017-12-26, with intended 0 refill(s). Instructions: 3 mL by Nebulization route 4 times a day as needed\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2017-05-31, presumably until 2017-06-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 7 days\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2017-05-31, presumably until 2018-02-01, with intended 1 refill(s). Instructions: 2 mL by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-07 00:00:00, ended at 2017-06-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2017-06-07, presumably until 2018-06-07, with intended 1 refill(s). Instructions: TAPER AS PRESCRIBED BY DR\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-07-17, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily Or as directed by MD.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-06-12, presumably until 2017-09-05, with intended 0 refill(s). Instructions: Take as directed by MD for tapering\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-06-13, presumably until 2017-06-13, with intended 6 refill(s). Instructions: TAKE 4 TABLETS ORALLY DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 12:56:20, ended at 2017-06-15 15:15:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Allergic rhinitis due to pollen\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 14:25:08, ended at 2017-06-15 15:08:23\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Exacerbation of mild persistent asthma\n- Allergic rhinitis due to pollen\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-16 00:00:00, ended at 2017-06-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2017-06-22, presumably until 2017-06-22, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-06 00:00:00, ended at 2017-07-06 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-07-06, presumably until 2017-12-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-07-17, presumably until 2017-09-05, with intended 0 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2017-07-17, presumably until 2017-07-18, with intended 1 refill(s). Instructions: TAPER AS PRESCRIBED BY MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-07-18 00:00:00, ended at 2017-07-18 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-07-18, presumably until 2018-01-04, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-08-02 00:00:00, ended at 2017-08-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-10 11:38:00, ended at 2017-08-10 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 11.83 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.63 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-10 13:51:08, ended at 2017-08-10 15:20:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2017-01-04, presumably until 2018-09-06, with intended 0 refill(s). Instructions: 1 Cris Burt, Oliver, every 12 hours, PRN, as needed for pain, 0, Maintenance\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-08-10, presumably until 2017-12-26, with intended 11 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-01-04, presumably until 2019-10-22, with intended 0 refill(s). Instructions: take 3.125 mg by mouth daily as needed\n- citalopram 10 MG Oral Tablet, through Oral route, presumably until 2019-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-08-22, presumably until 2018-08-22, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-24 15:25:49, ended at 2017-08-24 16:47:09\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 00:00:00, ended at 2017-08-25 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nose and accessory sinuses; not otherwise specified\n\n### Condition\n- Heart failure\n- Transient cerebral ischemia\n- Deviated nasal septum\n- Hypertrophy of nasal turbinates\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- cefazolin 1000 MG Injection, started on 2017-08-25, presumably until 2017-08-25\n- remifentanil 2 MG Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-08-25, presumably until 2017-08-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-25 00:00:00, ended at 2017-08-25 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-08-25, presumably until 2017-08-25\n- fluorescein dilaurate, through Intraocular route, started on 2017-08-25, presumably until 2017-08-25\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- fluorescein, through Intraocular route, started on 2017-08-25, presumably until 2017-08-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 05:47:00, ended at 2017-08-25 12:19:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- Replacement of Nasal Septum with Autologous Tissue Substitute, Open Approach\n- Submucous resection inferior turbinate, partial or complete, any method\n- Excision of Nasal Turbinate, Percutaneous Approach\n- Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed\n- Nasal/sinus endoscopy, surgical, with maxillary antrostomy\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Computer Assisted Procedure of Head and Neck Region\n- Excision of Right Sphenoid Sinus, Percutaneous Endoscopic Approach\n- Excision of Left Ethmoid Sinus, Percutaneous Endoscopic Approach\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Nasal/sinus endoscopy, surgical, with sphenoidotomy\n- Repair Right Maxillary Sinus, Percutaneous Endoscopic Approach\n- Excision of Left Sphenoid Sinus, Percutaneous Endoscopic Approach\n- Excision of Right Frontal Sinus, Percutaneous Endoscopic Approach\n- Repair Left Maxillary Sinus, Percutaneous Endoscopic Approach\n- Septoplasty or submucous resection, with or without cartilage scoring, contouring or replacement with graft\n- Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)\n- Excision of Left Frontal Sinus, Percutaneous Endoscopic Approach\n- Excision of Right Ethmoid Sinus, Percutaneous Endoscopic Approach\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Degenerative disorder of macula\n- Deviated nasal septum\n- Hypertrophy of nasal turbinates\n- Osteoporosis\n- Seasonal allergic rhinitis\n- Presbyopia\n- Allergic rhinitis\n- Disorder of nasal cavity\n- Chronic sinusitis\n- Disorder of kidney and/or ureter\n- Essential hypertension\n- Heart failure\n- Uncomplicated asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 12:31:57, ended at 2017-09-05 13:01:26\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2018-01-04, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 15:21:00, ended at 2017-09-05 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of nasal cavity\n- Allergic rhinitis due to animal dander\n- Disorder of bone\n- Chronic sinusitis\n- Osteoporosis\n- Uncomplicated asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 13:12:56, ended at 2017-09-28 14:17:14\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure)\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-12 11:00:00, ended at 2017-10-12 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.1 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 332 (picogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 94.2 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.11 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.6 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 24.94 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Hypo-osmolality and or hyponatremia\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 11:34:28, ended at 2017-10-12 12:34:37\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Hypo-osmolality and or hyponatremia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 13:54:53, ended at 2017-10-12 15:07:57\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Eosinophilic asthma\n- Allergic rhinitis due to pollen\n- Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-10-12, presumably until 2017-10-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 15:15:57, ended at 2017-10-12 16:10:38\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.99\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-10-19 00:00:00, ended at 2017-10-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n- Acute asthma\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-10-19, presumably until 2017-12-26, with intended 0 refill(s). Instructions: Take 20 mg PO Qday x 7 days, then 10 mg PO Qday x 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-02 12:54:42, ended at 2017-11-02 13:31:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Allergic rhinitis due to pollen\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Disorder of nasal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-26 12:07:41, ended at 2017-12-26 12:43:08\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to pollen\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated mild persistent asthma\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-12-26, presumably until 2018-10-09, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-12-26, presumably until 2018-02-01, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-12-26, presumably until 2018-10-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-12-26, presumably until 2019-01-01, with intended 3 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-12-26, presumably until 2019-03-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-26 13:09:03, ended at 2017-12-26 14:24:20\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 14:27:00, ended at 2017-12-26 14:49:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 51.71 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- IgE [Units/volume] in Serum or Plasma by Immunoassay: 19 (kilounit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 14:50:00, ended at 2017-12-26 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Uncomplicated asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-03 00:00:00, ended at 2018-01-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-03-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-03 00:00:00, ended at 2018-01-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperparathyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-04 12:55:22, ended at 2018-01-04 13:29:56\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-04 15:01:13, ended at 2018-01-04 16:10:33\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-01-04, presumably until 2018-03-21, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-01-04, presumably until 2018-03-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-01 11:22:54, ended at 2018-02-01 12:51:04\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Allergic rhinitis due to pollen\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic maxillary sinusitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n\n### Drug\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2018-02-01, presumably until 2018-09-06, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2018-02-01, presumably until 2018-09-06, with intended 1 refill(s). Instructions: 2 mL by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-01 13:32:31, ended at 2018-02-01 14:52:49\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Mononeuritis multiplex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-10 00:00:00, ended at 2018-03-10 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2018-03-12, presumably until 2019-03-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 10:25:18, ended at 2018-03-21 10:50:18\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-03-21, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-03-21, presumably until 2018-07-19, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 11:12:00, ended at 2018-03-21 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.30 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Urine: <5.0 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.27 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 282 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Creatinine [Mass/volume] in Urine: 60.51 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 8 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.17 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.13 (milligram per milligram)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- IgE [Units/volume] in Serum or Plasma by Immunoassay: 16 (kilounit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- MCV [Entitic volume] by Automated count: 93.5 (femtoliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 182 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Osteoporosis\n- Allergic rhinitis\n- Hyperparathyroidism\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 11:22:44, ended at 2018-03-21 12:13:39\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 10:49:00, ended at 2018-04-24 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Chronic sinusitis\n- Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-24 14:54:36, ended at 2018-04-24 16:30:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-05-09 00:00:00, ended at 2018-05-09 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-26 13:43:37, ended at 2018-06-26 14:46:12\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2018-07-12, presumably until 2018-07-12, with intended 0 refill(s). Instructions: TAKE 2 TABLETS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-19 14:18:37, ended at 2018-07-19 14:45:47\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-10-11, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-10-11, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-19 15:26:30, ended at 2018-07-19 16:01:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Exacerbation of mild persistent asthma\n- Allergic rhinitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-14 11:59:13, ended at 2018-08-14 13:15:54\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-04 00:00:00, ended at 2018-09-04 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe, started on 2018-09-05, presumably until 2018-09-05, with intended 0 refill(s). Instructions: LA:[000000]:05/18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-06 12:58:46, ended at 2018-09-06 14:41:57\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Visual field defect\n\n### Drug\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2019-03-20, with intended 0 refill(s). Instructions: take 81 mg by mouth every morning with breakfast Takes 2-3 a day for pain \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-06 14:15:00, ended at 2018-09-06 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Cerebral infarction\n- Visual field defect\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-10-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-09-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-08, presumably until 2018-10-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-08, presumably until 2018-10-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-09 00:00:00, ended at 2018-10-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Anemia in chronic kidney disease\n- Primary diagnosis: Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-09 00:00:00, ended at 2018-10-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to pollen\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2018-10-09, presumably until 2019-01-31, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 10:40:45, ended at 2018-10-11 11:28:07\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n- Acute upper respiratory infection\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 12:08:12, ended at 2018-10-11 12:34:03\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 14:10:39, ended at 2018-10-11 14:36:43\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2019-01-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2019-01-24, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Visual field defect\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-15 00:00:00, ended at 2018-10-15 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-18, presumably until 2018-10-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 4 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-24 00:00:00, ended at 2018-10-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2018-10-29, presumably until 2019-01-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 14 days\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2018-12-13, presumably until 2019-12-13, with intended 1 refill(s). Instructions: TAKE 2 TABLETS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 11:00:00, ended at 2018-12-12 14:56:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 58.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Chronic kidney disease\n- Cerebral infarction\n- Anemia in chronic kidney disease\n- Valvular endocarditis\n- Visual field defect\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 14:57:00, ended at 2018-12-12 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Protein [Mass/volume] in Urine collected for unspecified duration: 13.0 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.15 (milligram per milligram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.0 (ratio)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 255 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 88.78 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 5 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 152 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.14 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.93 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.8 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 108.0 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 259 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-01 10:43:30, ended at 2019-01-01 12:48:12\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic pansinusitis\n- Uncomplicated mild persistent asthma\n- Primary diagnosis: Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2019-01-01, presumably until 2020-02-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-01-01, presumably until 2019-04-04, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-01 12:52:22, ended at 2019-01-01 15:15:25\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Uncomplicated asthma\n- Chronic sinusitis\n- Primary diagnosis: Loss of sense of smell\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, started on 2019-01-01, presumably until 2019-03-20, with intended 11 refill(s). Instructions: Use 1 ampule as directed BID.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-24 14:46:39, ended at 2019-01-24 15:22:41\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-01-29, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-06-18, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-29 00:00:00, ended at 2019-01-29 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-01-29, presumably until 2019-08-13, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-31 00:00:00, ended at 2019-01-31 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to pollen\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2019-01-31, presumably until 2020-03-02, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-12 15:03:19, ended at 2019-02-12 16:29:50\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dysphonia\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-07 11:37:58, ended at 2019-03-07 12:21:35\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Chronic rhinitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- fexofenadine hydrochloride 60 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-03-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2019-03-07, presumably until 2019-05-13, with intended 11 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-07-29, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-07 15:33:11, ended at 2019-03-07 17:03:08\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-19 12:17:38, ended at 2019-03-19 14:02:29\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n- Disorder of the larynx\n\n### Drug\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2019-03-19, presumably until 2019-05-13, with intended 3 refill(s). Instructions: take 5 mL by mouth 4 times a day\n- fluconazole 150 MG Oral Tablet, started on 2019-03-19, presumably until 2019-03-20, with intended 0 refill(s). Instructions: 150mg orally once and may repeat one tablet in 4 days if symptoms persist.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 07:23:00, ended at 2019-03-20 15:22:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 07:23:00, ended at 2019-03-20 15:22:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Hypertrophic condition of skin\n- Essential hypertension\n- Osteoporosis\n- Pain in right foot\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- gadobenate, through Intravenous route, started on 2019-03-20, presumably until 2019-03-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-20 09:56:33, ended at 2019-03-20 10:25:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2019-03-20, presumably until 2020-03-04, with intended 3 refill(s). Instructions: take 1 Tab (70 mg total) by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-20 13:31:38, ended at 2019-03-20 15:07:49\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Hypertrophic condition of skin\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-03-20, presumably until 2019-03-20, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (81 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-03-26 00:00:00, ended at 2019-03-26 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-03-27, presumably until 2019-03-27, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-04 11:42:40, ended at 2019-04-04 12:33:34\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.81\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-04 14:09:00, ended at 2019-04-04 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.63 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 282 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.17 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 30.13 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.0 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 5.0 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.1 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-24 00:00:00, ended at 2019-04-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2019-05-01, presumably until 2019-09-23, with intended 12 refill(s). Instructions: take 1 Packet (20 mEq total) by mouth daily Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-30 12:05:26, ended at 2019-04-30 15:57:31\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 0.6 to 1.0 cm\n\n### Condition\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n- Neoplasm of uncertain behavior of skin\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-30 13:14:52, ended at 2019-04-30 14:18:49\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.81\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated moderate persistent asthma\n- Dysphonia\n- Neoplasm of uncertain behavior of skin\n- Senile hyperkeratosis\n- Neoplastic disease of uncertain behavior\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-13 10:55:27, ended at 2019-05-13 12:12:51\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- olopatadine 1 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-05-08, presumably until 2019-05-08, with intended 0 refill(s). Instructions: Instill 1 drop to both eyes as needed\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-05-13, presumably until 2019-05-13, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2019-04-14, presumably until 2019-05-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-13 12:15:00, ended at 2019-05-13 12:29:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Tailor's bunion\n- Pain in right foot\n- Talipes planus\n- Acquired hallux varus\n- Essential hypertension\n- Pain in left foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-13 12:30:00, ended at 2019-05-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in left foot\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-15 00:00:00, ended at 2019-05-15 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-05-15, presumably until 2020-05-11, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-18 10:57:51, ended at 2019-06-18 12:08:03\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2019-06-18, presumably until 2019-10-09, with intended 3 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n- gabapentin 100 MG Oral Capsule, through Oral route, presumably until 2019-08-13, with intended 0 refill(s). Instructions: take 100 mg by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-09 11:00:00, ended at 2019-07-09 11:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-16 00:00:00, ended at 2019-07-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-17 00:00:00, ended at 2019-07-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n\n### Drug\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-07-29, presumably until 2019-12-25, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-13 10:36:00, ended at 2019-08-13 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.16 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 295 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 26.70 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <4.0 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Bunion\n- Follicular cysts of skin and subcutaneous tissue\n- Low back pain\n- Pain of left knee region\n- Chronic pain\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-13 13:18:06, ended at 2019-08-13 13:37:04\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pain\n- Primary diagnosis: Follicular cysts of skin and subcutaneous tissue\n- Low back pain\n- Pain of left knee region\n- Bunion\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-08-13, presumably until 2019-09-20, with intended 2 refill(s). Instructions: take 1 Tab (50 mg total) by mouth as needed for pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-13 14:05:12, ended at 2019-08-13 14:51:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-08-13, presumably until 2020-02-04, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-26 00:00:00, ended at 2019-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 1000 MG Oral Tablet, through Oral route, started on 2019-08-26, presumably until 2019-08-27, with intended 2 refill(s). Instructions: take 2 Tabs (2,000 mg total) by mouth 2 times a day for 1 day PRN cold sores\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-09-05 00:00:00, ended at 2019-09-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-12 09:26:05, ended at 2019-09-12 14:45:38\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- valacyclovir 1000 MG Oral Tablet, started on 2019-08-30, presumably until 2019-09-13, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-12 11:31:14, ended at 2019-09-12 13:11:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n- Eosinophilic asthma\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-13 07:30:00, ended at 2019-09-13 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Supraventricular tachycardia\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-09-20 00:00:00, ended at 2019-09-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-09-20, presumably until 2019-10-25, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every bedtime as needed for pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-09-23, presumably until 2020-04-07, with intended 12 refill(s). Instructions: take 20 Tabs by mouth every day\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2019-09-23, presumably until 2019-09-23, with intended 12 refill(s). Instructions: take 1 Packet (20 mEq total) by mouth daily Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-09 00:00:00, ended at 2019-10-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-09 08:15:00, ended at 2019-10-09 11:14:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Osteoarthritis of knee\n- Acquired genu valgum\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-09 08:55:12, ended at 2019-10-09 09:27:51\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2019-10-09, presumably until 2020-02-04, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-09 11:15:00, ended at 2019-10-09 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Osteoporosis\n- Disorder of bone\n- Pain in thoracic spine\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Acquired hallux varus\n- Pain of left knee region\n- Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-09 15:03:15, ended at 2019-10-09 15:53:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in thoracic spine\n- Primary diagnosis: Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pansinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-10-17, presumably until 2019-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-21 00:00:00, ended at 2019-10-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2019-10-22, presumably until 2020-04-07, with intended 12 refill(s). Instructions: take 1 Tab (3.125 mg total) by mouth daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-25 00:00:00, ended at 2019-10-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2019-10-28, presumably until 2019-12-05, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pansinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-10-29, presumably until 2019-11-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-04 00:00:00, ended at 2019-11-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 09:50:06, ended at 2019-11-05 10:25:56\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 11:12:09, ended at 2019-11-05 12:04:23\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Uncomplicated severe persistent asthma\n- Chronic rhinitis\n- Primary diagnosis: Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 12:22:32, ended at 2019-11-05 14:38:39\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 13:22:35, ended at 2019-11-05 14:31:38\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Chronic kidney disease stage 3\n- Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-05 13:50:00, ended at 2019-11-05 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: 15 (milligram per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 20 (milligram per gram)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 74.10 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Dysphonia\n- Anemia in chronic kidney disease\n- Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-08 00:00:00, ended at 2019-11-08 08:07:41\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-25 00:00:00, ended at 2019-11-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-11-25, presumably until 2019-12-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-02 00:00:00, ended at 2019-12-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2019-12-05, presumably until 2019-12-10, with intended 1 refill(s). Instructions: 3 mL (1.25 mg total) by Nebulization route every 4 hours as needed for Bronchospasm/Wheezing (cough)\n- prednisone 5 MG Oral Tablet, started on 2019-12-05, presumably until 2020-02-04, with intended 0 refill(s). Instructions: Take 10 mg x 1 week, then 5 mg x 1 week\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2019-12-05, presumably until 2020-02-20, with intended 2 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-05 00:00:00, ended at 2019-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2019-12-05, presumably until 2020-01-22, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-10 00:00:00, ended at 2019-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2019-12-10, presumably until 2021-02-09, with intended 1 refill(s). Instructions: 1 Dose by Injection route every 4 hours as needed Use as directed\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2019-12-10, presumably until 2020-01-09, with intended 1 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-11 08:59:06, ended at 2019-12-11 09:45:31\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute sinusitis\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Acute bronchitis\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-11 10:29:00, ended at 2019-12-11 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Melanocytic nevus of trunk\n- Acute sinusitis\n- Disorder of immune function\n- Hyperpigmentation of skin\n- Melanocytic nevus of lower limb\n- Temporomandibular joint disorder\n- Scar conditions and fibrosis of skin\n- Essential hypertension\n- Acute bronchitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n- Melanocytic nevus of upper limb\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-11 12:17:22, ended at 2019-12-11 13:40:55\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Scar conditions and fibrosis of skin\n- Hyperpigmentation of skin\n- Primary diagnosis: Melanocytic nevus of lower limb\n- Disorder of immune function\n- Primary diagnosis: Melanocytic nevus of trunk\n- Primary diagnosis: Melanocytic nevus of upper limb\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-19 00:00:00, ended at 2019-12-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n\n### Drug\n- levocetirizine dihydrochloride 5 MG Oral Tablet, started on 2019-12-25, presumably until 2020-10-06, with intended 10 refill(s). Instructions: TAKE ONE TABLET (5MG) BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-01-22, presumably until 2020-02-29, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated mild persistent asthma\n- Eosinophilic asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2020-01-22, presumably until 2020-07-21, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-04 09:13:00, ended at 2020-02-04 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 264 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 20 (milligram per gram)\n- Basophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.96 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 6.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 39.80 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocyte sedimentation rate: 5 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 73.8 (picogram per milliliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.15 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Dysphonia\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 09:50:25, ended at 2020-02-04 10:17:09\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 10:45:37, ended at 2020-02-04 12:08:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Joint pain\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 12:20:34, ended at 2020-02-04 13:04:58\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-05-19, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-13 00:00:00, ended at 2020-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Reduced mobility\n- Primary diagnosis: Closed fracture of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-13 00:00:00, ended at 2020-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture of lower leg\n- Primary diagnosis: Loss of consciousness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-20 12:15:00, ended at 2020-02-20 13:41:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Closed bimalleolar fracture\n- Closed fracture of lower leg\n- Arthralgia of the ankle and/or foot\n- Closed fracture of fibula\n- Closed fracture of medial malleolus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-20 13:42:00, ended at 2020-02-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; 2 views\n\n### Condition\n- Closed fracture of lateral malleolus\n- Closed fracture of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-21 00:00:00, ended at 2020-02-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nonunion of fracture\n- Primary diagnosis: Closed bimalleolar fracture\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2020-02-21, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; not otherwise specified\n\n### Condition\n- Closed fracture of lateral malleolus\n- Sprain of deltoid ligament of ankle\n- Sprain of ankle\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- cefazolin 1000 MG Injection, started on 2020-02-27, presumably until 2020-02-27\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- ketamine 100 MG/ML Injectable Solution, started on 2020-02-27, presumably until 2020-02-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 30 ML ropivacaine hydrochloride 5 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed\n- Manual application of stress performed by physician or other qualified health care professional for joint radiography, including contralateral joint if indicated\n- Open treatment of distal tibiofibular joint (syndesmosis) disruption, includes internal fixation, when performed\n\n### Condition\n- Closed fracture of lateral malleolus\n- Sprain of ankle\n- Sprain of deltoid ligament of ankle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-02-27 07:19:00, ended at 2020-02-29 13:20:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Left ventricular Ejection fraction: 61.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Body height: 5' 2\" (inch (US))\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n\n### Procedure\n- Repair Right Ankle Bursa and Ligament, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Reposition Right Fibula with Internal Fixation Device, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n\n### Condition\n- Chronic congestive heart failure\n- Hypertensive heart failure\n- Pain\n- Closed bimalleolar fracture\n- Primary diagnosis: Loss of consciousness\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated asthma\n- Essential hypertension\n- First degree atrioventricular block\n- Illness\n- Persistent pain following procedure\n- Chronic systolic heart failure\n- Gastroesophageal reflux disease without esophagitis\n- Closed fracture of lower leg\n- Sprain of deltoid ligament of ankle\n- Electrocardiogram abnormal\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2020-02-28, presumably until 2020-02-29\n- calcium carbonate 625 MG / cholecalciferol 125 UNT Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2020-02-27, presumably until 2020-03-10, with intended 0 refill(s). Instructions: take 2 Caps (200 mg total) by mouth 2 times a day as needed for Constipation\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-28\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-02-29, presumably until 2020-02-29\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-02-28, presumably until 2020-03-10, with intended 1 refill(s). Instructions: take 1 Packet (17 g total) by mouth daily as needed\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-03-10, with intended 0 refill(s). Instructions: take 1 Tab (650 mg total) by mouth every 6 hours\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-02-27, presumably until 2020-02-28\n- carboxymethylcellulose sodium 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2020-02-28, presumably until 2020-02-29\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-04-07, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed for Pain\n- 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2020-02-29, presumably until 2020-02-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-02 00:00:00, ended at 2020-03-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-04 00:00:00, ended at 2020-03-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2020-03-04, presumably until 2021-05-21, with intended 3 refill(s). Instructions: take 1 Tab (70 mg total) by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-10 09:00:00, ended at 2020-03-10 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Closed fracture of medial malleolus\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-16 00:00:00, ended at 2020-03-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in left foot\n- Pain in right foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-04-07 10:41:24, ended at 2020-04-07 12:14:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic pansinusitis\n- Primary diagnosis: Eosinophilic asthma\n- Chronic rhinitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-04-07 12:40:59, ended at 2020-04-07 13:56:39\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed bimalleolar fracture\n- Primary diagnosis: Loss of consciousness\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-04-07, presumably until 2020-12-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2020-04-07, presumably until 2020-10-23, with intended 0 refill(s). Instructions: take 1 Tab (3.125 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-07 13:56:18, ended at 2020-04-07 13:56:28\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Loss of consciousness\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-08 00:00:00, ended at 2020-04-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-13 00:00:00, ended at 2020-04-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-20 00:00:00, ended at 2020-04-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-04-28, presumably until 2020-05-26, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-23 09:50:00, ended at 2020-04-23 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Closed fracture of lateral malleolus\n- Tailor's bunion\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed bimalleolar fracture\n- Arthralgia of the ankle and/or foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-09 00:00:00, ended at 2020-05-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2020-05-11, presumably until 2020-08-11, with intended 2 refill(s). Instructions: INHALE TWO PUFFS BY MOUTH TWICE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 00:00:00, ended at 2020-05-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-05-19, presumably until 2020-12-23, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-05-26, presumably until 2020-06-02, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2020-05-25, presumably until 2020-06-01, with intended 5 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-26 00:00:00, ended at 2020-05-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n- Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-01 00:00:00, ended at 2020-06-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-01, presumably until 2020-06-16, with intended 5 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-02 00:00:00, ended at 2020-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-06-02, presumably until 2020-07-13, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-04 00:00:00, ended at 2020-06-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-16 09:23:00, ended at 2020-06-16 15:41:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Late effect of fracture of lower extremities\n- Melanocytic nevus\n- Postoperative state\n- Closed bimalleolar fracture\n- Supraventricular tachycardia\n- Arthralgia of the ankle and/or foot\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 11:49:33, ended at 2020-06-16 13:26:49\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nasal cavity\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-16, presumably until 2020-06-25, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n- mupirocin 0.02 MG/MG Nasal Ointment, through Nasal route, started on 2020-06-16, presumably until 2020-06-18, with intended 0 refill(s). Instructions: by Nasal route 2 times a day\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2020-06-16, presumably until 2020-06-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 13:05:45, ended at 2020-06-16 15:41:51\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Melanocytic nevus\n- Primary diagnosis: Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 14:48:32, ended at 2020-06-16 15:36:44\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-16 15:42:00, ended at 2020-06-16 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9.0 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.12 (milligram per milligram)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Creatinine [Mass/volume] in Urine: 77.29 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-17 00:00:00, ended at 2020-06-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-18 00:00:00, ended at 2020-06-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nasal cavity\n\n### Drug\n- mupirocin 0.02 MG/MG Nasal Ointment, through Nasal route, started on 2020-06-18, presumably until 2020-08-21, with intended 0 refill(s). Instructions: by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-19 00:00:00, ended at 2020-06-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 0.83 MG/ML Inhalation Solution, started on 2020-06-19, presumably until 2021-11-19, with intended 0 refill(s). Instructions: USE ONE VIAL BY INHALATION ROUTE EVERY 4 HOURS AS NEEDED FOR COUGH/WHEEZE\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-25 00:00:00, ended at 2020-06-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-25, presumably until 2020-08-20, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-25 00:00:00, ended at 2020-06-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-25, presumably until 2020-07-07, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-02 00:00:00, ended at 2020-07-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n- Primary diagnosis: Bacterial infectious disease\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2020-07-02, presumably until 2020-08-27, with intended 1 refill(s). Instructions: Apply to affected areas BID x 5-7 days until improved\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-02 00:00:00, ended at 2020-07-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-07 11:06:14, ended at 2020-07-07 16:16:38\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated mild persistent asthma\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-07-07, presumably until 2020-08-17, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n- prednisone 5 MG Oral Tablet, started on 2020-07-07, presumably until 2020-07-09, with intended 0 refill(s). Instructions: Take 20 mg by mouth x 5 days, 15 mg x 5 days, 10 mg x 5 days, 5 mg x 5 days\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2020-07-07, presumably until 2020-11-03, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-09 00:00:00, ended at 2020-07-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-09 00:00:00, ended at 2020-07-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2020-07-09, presumably until 2020-07-21, with intended 0 refill(s). Instructions: Take 20 mg by mouth x 5 days, 15 mg x 5 days, 10 mg x 5 days, 5 mg x 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-10 00:00:00, ended at 2020-07-10 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-07-13, presumably until 2020-10-23, with intended 2 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-14 12:46:03, ended at 2020-07-14 13:10:35\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eosinophilic asthma\n- Recurrent acute sinusitis\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Acute pansinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-21 00:00:00, ended at 2020-07-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2020-07-21, presumably until 2020-10-06, with intended 11 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-21 00:00:00, ended at 2020-07-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2020-07-21, presumably until 2020-08-13, with intended 0 refill(s). Instructions: 30 mg x 7 days, 20 mg x 7 days, 10 mg x 7 days, 5 mg x 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-10 00:00:00, ended at 2020-08-10 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2020-08-11, presumably until 2021-01-26, with intended 0 refill(s). Instructions: INHALE TWO PUFFS BY MOUTH TWICE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-13 11:05:59, ended at 2020-08-13 15:45:04\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eosinophilic asthma\n- Uncomplicated severe persistent asthma\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2020-08-13, presumably until 2020-12-07, with intended 0 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-17 00:00:00, ended at 2020-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated severe persistent asthma\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-08-17, presumably until 2020-08-20, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-08-20, presumably until 2021-05-21, with intended 1 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-18 00:00:00, ended at 2020-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-20 00:00:00, ended at 2020-08-20 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, started on 2020-08-20, presumably until 2020-08-21, with intended 0 refill(s). Instructions: 3mL mixed with budesonide by inhalation route BID PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-20 10:05:43, ended at 2020-08-20 11:13:04\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pansinusitis\n- Spasm\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Blood chemistry abnormal\n- Primary diagnosis: Disorder of bone\n- Lymphocytopenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-20 10:45:00, ended at 2020-08-20 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Arthralgia of the ankle and/or foot\n- Metatarsalgia\n- Pain in right foot\n- Postoperative state\n- Closed bimalleolar fracture\n- Closed fracture of lateral malleolus\n- Acquired hallux varus\n- Hammer toe\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-21 00:00:00, ended at 2020-08-21 08:04:46\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Eosinophilic asthma\n- Primary diagnosis: Insomnia\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- 0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 M..., through Intramuscular route, started on 2020-08-21, presumably until 2020-08-21, with intended 0 refill(s). Instructions: inject into a muscle\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-08-21, with intended 12 refill(s). Instructions: take 1 Tab (3 mg total) by mouth every bedtime as needed (insomnia)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-21 00:00:00, ended at 2020-08-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, started on 2020-08-21, presumably until 2020-12-07, with intended 3 refill(s). Instructions: 3mL mixed with budesonide by inhalation route BID PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-24 00:00:00, ended at 2020-08-24 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis due to pollen\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-24 00:00:00, ended at 2020-08-24 10:20:37\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Candidiasis of mouth\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2020-08-27, presumably until 2020-12-07, with intended 0 refill(s). Instructions: APPLY TO THE AFFECTED AREA(S) TWICE DAILY FOR 5 TO 7 DAYS UNTIL IMPROVED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-08 11:04:53, ended at 2020-09-08 12:09:27\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lymphocytopenia\n- Uncomplicated severe persistent asthma\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-10 11:26:40, ended at 2020-09-10 13:35:18\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary diagnosis: Tailor's bunion\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-17 00:00:00, ended at 2020-09-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-09-17, presumably until 2020-12-07, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Open bimalleolar fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-23 00:00:00, ended at 2020-09-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-23 11:15:00, ended at 2020-09-23 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Dysphonia\n- Pain in right foot\n- Chronic pansinusitis\n- Disorder of bone\n- Spasm\n- Lymphocytopenia\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-24 00:00:00, ended at 2020-09-24 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2020-09-24, presumably until 2020-09-24\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-09-24, presumably until 2020-09-24\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-09-24, presumably until 2020-09-24\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2020-09-24, presumably until 2020-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-24 08:30:00, ended at 2020-09-24 12:10:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Ostectomy, partial excision, fifth metatarsal head (bunionette) (separate procedure)\n\n### Condition\n- Essential hypertension\n- Pure hypercholesterolemia\n- Pain in right foot\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Eosinophilic asthma\n- Osteoporosis\n- Tailor's bunion\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-09-24, presumably until 2020-11-23, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every 6 hours as needed\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-09-24, presumably until 2020-09-24\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-24, presumably until 2020-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-25 00:00:00, ended at 2020-09-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tailor's bunion\n- Pain in right foot\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-25, presumably until 2020-09-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-26 00:00:00, ended at 2020-09-26 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in right foot\n- Tailor's bunion\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-10-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-05 00:00:00, ended at 2020-10-05 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n- Uncomplicated mild persistent asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2020-10-06, presumably until 2021-02-09, with intended 3 refill(s). Instructions: Take by mouth every bedtime\n- levocetirizine dihydrochloride 5 MG Oral Tablet, started on 2020-10-06, presumably until 2021-07-05, with intended 3 refill(s). Instructions: TAKE ONE TABLET (5MG) BY MOUTH ONE TIME DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-08 09:35:08, ended at 2020-10-08 10:27:46\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Candidiasis of mouth\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Acute exacerbation of chronic obstructive airways disease\n\n### Drug\n- prednisone 1 MG Oral Tablet, started on 2020-10-08, presumably until 2020-12-07, with intended 0 refill(s). Instructions: 4 mg x 7 days, then 3 mg x 7 days, 2 mg x 7 days, 1 mg x 7 days\n- tiotropium 0.018 MG Inhalation Powder, through Inhalation, started on 2020-10-13, presumably until 2020-10-15, with intended 3 refill(s). Instructions: 1 Plunkett (18 mcg total) by Inhalation route daily\n- fluconazole 150 MG Oral Tablet, started on 2020-10-08, presumably until 2020-12-07, with intended 0 refill(s). Instructions: 150mg orally once and may repeat one tablet in 72 hour if not improved\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-09 00:00:00, ended at 2020-10-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clotrimazole 10 MG Oral Lozenge, through Oral route, started on 2020-10-09, presumably until 2021-01-26, with intended 3 refill(s). Instructions: take 1 Lozenge (10 mg total) by mouth 5 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-13 00:00:00, ended at 2020-10-13 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Degenerative disorder of macula\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Chronic kidney disease\n- Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in right foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-10-23, presumably until 2020-11-23, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2020-10-23, presumably until 2020-11-02, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH DAILY AS NEEDED \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 09:51:00, ended at 2020-10-26 12:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Postoperative state\n- Metatarsal bone fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-26 09:51:03, ended at 2020-10-26 12:26:39\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tailor's bunion\n- Primary diagnosis: Postoperative state\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 13:00:00, ended at 2020-10-26 14:02:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia in chronic kidney disease\n- Chronic kidney disease stage 3\n- Pain in right foot\n- Postoperative state\n- Uncomplicated severe persistent asthma\n- Tailor's bunion\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 14:03:00, ended at 2020-10-26 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 239 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.3 (ratio)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 147 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 97.0 (picogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 27 (milligram per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 73 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.0 (ratio)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 32 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 7.05 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 85.20 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 96 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-27 12:43:28, ended at 2020-10-27 13:54:28\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 15:51:11, ended at 2020-11-03 16:43:27\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2020-11-03, presumably until 2021-01-25, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-10 13:09:35, ended at 2020-11-10 14:05:34\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease\n- Chronic kidney disease stage 3A\n- Essential hypertension\n- Primary diagnosis: Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-20 00:00:00, ended at 2020-11-20 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-23 00:00:00, ended at 2020-11-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-11-23, presumably until 2021-11-23, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-25 00:00:00, ended at 2020-11-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-07 00:00:00, ended at 2020-12-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Tablet, through Oral route, started on 2020-12-07, presumably until 2020-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth every day\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2020-12-07, presumably until 2021-11-19, with intended 12 refill(s). Instructions: take 1 Tab (6.25 mg total) by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-08 11:45:37, ended at 2020-12-08 12:18:16\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Cellulitis\n- Chronic sinusitis\n- Chronic obstructive lung disease\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2020-12-08, presumably until 2020-12-18, with intended 0 refill(s). Instructions: take 1 Cap (500 mg total) by mouth 3 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-14 08:30:00, ended at 2020-12-14 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Dysphonia\n- Hammer toe\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Metatarsal bone fracture\n- Closed bimalleolar fracture\n- Metatarsalgia\n- Acquired hallux varus\n- Pain in right foot\n- Postoperative state\n- Tailor's bunion\n- Chronic frontal sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-15 00:00:00, ended at 2020-12-15 12:19:53\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2020-12-15, presumably until 2021-01-04, with intended 0 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-22 00:00:00, ended at 2020-12-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2020-12-23, presumably until 2021-01-06, with intended 0 refill(s). Instructions: TAKE TWO TABLETS BY MOUTH DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-22 00:00:00, ended at 2020-12-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, started on 2020-12-23, presumably until 2022-01-20, with intended 12 refill(s). Instructions: TAKE 1 TABLET (20MEQ) BY MOUT HEVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-01 00:00:00, ended at 2021-01-01 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2021-01-05, presumably until 2021-02-08, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN, APPOINTMENT NEEDED BEFORE NEXT REFILL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-02 00:00:00, ended at 2021-01-02 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2021-01-04, presumably until 2021-01-04, with intended 0 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-04 00:00:00, ended at 2021-01-04 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-04, presumably until 2021-02-09, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-06 00:00:00, ended at 2021-01-06 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2021-01-06, presumably until 2021-04-15, with intended 0 refill(s). Instructions: take 1.5 Tabs (75 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-25 00:00:00, ended at 2021-01-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated moderate persistent asthma\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2021-01-25, presumably until 2021-01-27, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-26 08:44:00, ended at 2021-01-26 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 72 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 20.0 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.11 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 89.00 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.22 (milligram per milligram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte sedimentation rate: 11 (millimeter per hour)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Acquired hallux varus\n- Hammer toe\n- Metatarsalgia\n- Non-rheumatic aortic sclerosis\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-26 09:16:50, ended at 2021-01-26 10:35:10\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic aortic sclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-26 10:42:23, ended at 2021-01-26 12:24:26\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated severe persistent asthma\n- Osteoporosis\n- Non-rheumatic aortic sclerosis\n- Uncomplicated moderate persistent asthma\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-27 00:00:00, ended at 2021-01-27 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated moderate persistent asthma\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2021-01-27, presumably until 2021-02-09, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-03-21 01:58:00, ended at 2014-03-29 16:27:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.6 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Cholesterol [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 338 (milligram per deciliter)\n- Osmolality of Urine: 574 (milliosmole per kilogram)\n- Thrombin time: 15.7 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 229 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.31 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.25 (milli-international unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Body height: 5' 4\" (inch (US))\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 83 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.3 (percent)\n- Prothrombin time (PT): 16.0 (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.3 (nanogram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 61 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 9.82 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 4.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 357 (thousand per microliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 94 (milligram per deciliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 12.4 (microgram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 55 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 25 (millimeter per hour)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n\n### Procedure\n- Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities\n- Magnetic resonance angiography, head; without contrast material(s)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes\n- Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time int\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete\n- Radiologic examination, chest; single view, frontal\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n- Hospital discharge day management; more than 30 minutes\n- Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professio\n- Nerve conduction studies; 5-6 studies\n- Occupational therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Magnetic resonance angiography, neck; without contrast material(s)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Lumbar puncture\n- Open biopsy of cranial or peripheral nerve or ganglion\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Collection of venous blood by venipuncture\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Open biopsy of soft tissue\n- Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and prepari\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Acute renal failure syndrome\n- Arteritis\n- Diffuse cerebrovascular disease\n- Acquired deformity of ankle AND/OR foot\n- Altered mental status\n- Congestive heart failure\n- Disorder of brain\n- Eosinophil count raised\n- Eruption\n- Hyperkalemia\n- Cardiomegaly\n- Cerebral ischemia\n- Disorder of lower extremity\n- Disorder of posterior pituitary\n- Granulomatosis with polyangiitis\n- Hypo-osmolality and or hyponatremia\n- Polyarteritis nodosa\n- Primary diagnosis: Visual field defect\n- Disorder of skeletal muscle\n- Essential hypertension\n- Primary cardiomyopathy\n- Anemia in chronic kidney disease\n- First degree atrioventricular block\n- Renal function tests abnormal\n- Spontaneous ecchymosis\n- Organic mental disorder\n- Abnormal findings on diagnostic imaging of skull and head\n- Backache\n- Cardiomyopathy associated with another disorder\n- Chronic diastolic heart failure\n- Chronic kidney disease\n- Disorder of nervous system\n- Herpes simplex without complication\n- Electrocardiogram abnormal\n- Mononeuritis\n- Subarachnoid hemorrhage\n\n### Drug\n- ramipril 5 MG Oral Capsule, through Oral route, started on 2014-03-21, presumably until 2014-03-23\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-21\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2014-03-25, presumably until 2014-05-14, with intended 0 refill(s). Instructions: 3 mL by Nebulization route every 4 hours as needed for Bronchospasm/Wheezing.\n- calcium carbonate 625 MG / cholecalciferol 125 UNT Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2023-01-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2014-03-22, presumably until 2017-12-26, with intended 0 refill(s). Instructions: 2 Sprays by Nasal route daily.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2014-03-23, presumably until 2014-05-14, with intended 0 refill(s). Instructions: 40 mg by Intravenous route daily.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-03-22, presumably until 2014-07-31, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed (pain or fever).\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-03-21, presumably until 2014-03-21\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2014-03-21, presumably until 2014-03-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-03-24, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- citalopram 20 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-23\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2014-03-23, presumably until 2015-03-29, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 12 hours as needed.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, through Subcutaneous route, started on 2014-03-21, presumably until 2014-05-14, with intended 0 refill(s). Instructions: inject 0.5 mL subcutaneous (under the skin) every 8 hours.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2014-03-23, presumably until 2014-07-31, with intended 0 refill(s). Instructions: take 1 Singhal by mouth every bedtime.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2014-03-27, presumably until 2014-03-29\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2014-03-24\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2014-03-24, presumably until 2014-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every Monday, Wednesday and Friday.\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2014-03-25, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2014-03-29, presumably until 2014-03-29\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-03-26, presumably until 2014-03-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-23, presumably until 2014-03-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-03-26, presumably until 2014-03-26\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2014-03-29, presumably until 2014-05-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2014-03-21, presumably until 2014-03-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-03-25 00:00:00, ended at 2014-03-25 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-03-25 00:00:00, ended at 2014-03-25 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nerves, muscles, tendons, and fascia of lower leg, ankle, and foot; not otherwise specified\n\n### Condition\n- Muscle weakness\n\n### Drug\n- cefazolin 1000 MG Injection, started on 2014-03-25, presumably until 2014-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-03-25, presumably until 2014-03-25\n- midazolam 1 MG/ML Injectable Solution, started on 2014-03-25, presumably until 2014-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-09 10:06:18, ended at 2014-04-09 16:27:50\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-24 11:44:00, ended at 2014-04-24 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-04-24, presumably until 2014-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-24, presumably until 2014-04-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-04-24, presumably until 2014-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-24 15:16:36, ended at 2014-04-24 15:16:45\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-14 00:00:00, ended at 2014-05-14 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 2.1EF(MOD-sp4) (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-14 09:16:31, ended at 2014-05-14 10:23:33\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2014-05-14, presumably until 2014-09-04, with intended 6 refill(s). Instructions: take 4 Tabs by mouth daily.\n- carvedilol 12.5 MG Oral Tablet, through Oral route, started on 2014-05-14, presumably until 2015-01-06, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-14 09:30:00, ended at 2014-05-14 10:28:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n\n### Condition\n- Localized swelling, mass and lump, trunk\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-14 10:29:00, ended at 2014-05-14 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.13 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.17 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-05-27 11:59:00, ended at 2014-05-27 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.5\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-05-27, presumably until 2014-05-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-05-27, presumably until 2014-05-27\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-05-27, presumably until 2014-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-05-27 12:40:23, ended at 2014-05-27 12:41:49\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-06-11 00:00:00, ended at 2014-06-11 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arteritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-26 09:44:00, ended at 2014-06-26 10:55:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 12.65 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 36 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Ulcerative colitis\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-26 10:56:00, ended at 2014-06-26 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.488\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Ulcerative colitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-06-26\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-06-26, presumably until 2014-06-26\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-06-26, presumably until 2014-06-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-26 12:33:34, ended at 2014-06-26 12:34:17\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Ulcerative colitis\n\n### Drug\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2014-06-26, presumably until 2014-10-14, with intended 3 refill(s). Instructions: take 40 mg by mouth daily.\n- prednisone 5 MG Oral Tablet, started on 2014-06-26, presumably until 2014-07-31, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- cyclophosphamide 25 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-08-01, with intended 1 refill(s). Instructions: take 4 Tabs by mouth daily.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2014-06-26, presumably until 2014-10-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 09:56:00, ended at 2014-07-31 11:17:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.60 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 240 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 12.59 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 34 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.1 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Age related macular degeneration\n- Cataract\n- Presbyopia\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-31 10:22:03, ended at 2014-07-31 11:10:54\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2018-09-06, with intended 0 refill(s). Instructions: take 81 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-31 11:18:00, ended at 2014-07-31 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 10 (milligram per gram)\n- Albumin [Mass/volume] in Urine: 10 (milligram per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-05 09:30:00, ended at 2014-08-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2014-08-05, presumably until 2014-08-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-08-05, presumably until 2014-08-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2014-08-05, presumably until 2014-08-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-08-05 14:28:42, ended at 2014-08-05 17:01:53\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Arteritis\n- Inflammatory and toxic neuropathy\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-18 00:00:00, ended at 2014-08-18 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-08-18, presumably until 2014-09-04, with intended 3 refill(s). Instructions: take 2 tablets by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-04 00:00:00, ended at 2014-09-04 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-09-04, presumably until 2014-11-11, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- prednisone 10 MG Oral Tablet, started on 2014-09-04, presumably until 2014-11-06, with intended 6 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-22 00:00:00, ended at 2014-09-22 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-14 11:53:00, ended at 2014-10-14 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 17 (milligram per gram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 335 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.90 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cataract\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-14 15:17:41, ended at 2014-10-14 16:01:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- 0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Ma..., through Intramuscular route, started on 2014-10-14, presumably until 2014-10-15, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time.\n- ciprofloxacin 250 MG Oral Tablet, through Oral route, presumably until 2014-11-11, with intended 0 refill(s). Instructions: take  by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-04 00:00:00, ended at 2014-11-04 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute myocardial infarction of anterior wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-05 00:00:00, ended at 2014-11-05 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-05 12:34:00, ended at 2014-11-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Erythrocyte sedimentation rate: 13 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.23 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 92.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.2 (thousand per microliter)\n- Albumin/Creatinine [Mass Ratio] in Urine: 9 (milligram per gram)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 294 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- MCV [Entitic volume] by Automated count: 92.7 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-05 13:51:43, ended at 2014-11-05 14:20:57\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation\n\n### Condition\n- Primary diagnosis: Cataract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-11-06 00:00:00, ended at 2014-11-06 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2014-11-06, presumably until 2015-01-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. Taper as instructed by MD.\n- prednisone 5 MG Oral Tablet, started on 2014-11-06, presumably until 2015-01-06, with intended 3 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-11-10 00:00:00, ended at 2014-11-10 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- chondroitin sulfates, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- chondroitin 4-sulfate, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- cefazolin 1000 MG Injection, started on 2014-11-10, presumably until 2014-11-10\n- 1 ML epinephrine 1 MG/ML Injection, started on 2014-11-10, presumably until 2014-11-10\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-11-10, presumably until 2014-11-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-10 11:50:00, ended at 2014-11-10 14:31:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- One stage extracapsular extraction of lens and insertion of prosthetic intraocular lens\n- Aspiration of cataract by phacoemulsification\n\n### Condition\n- Visual field defect\n- Hypermetropia\n- Presbyopia\n- Cataract\n- Asthma\n- Gastroesophageal reflux disease\n- Age related macular degeneration\n- Cardiac arrhythmia\n- Chronic kidney disease\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- moxifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-11-10, presumably until 2014-11-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-11 13:56:14, ended at 2014-11-11 14:39:52\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2014-11-11, presumably until 2015-01-06, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-18 10:24:00, ended at 2014-11-18 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 19 (milligram per gram)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Neutrophils [#/volume] in Blood by Automated count: 7.61 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.4 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 331 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Urine: 11 (milligram per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.25 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-12-15 00:00:00, ended at 2014-12-15 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hyaluronate, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- chondroitin sulfates, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- povidone-iodine 50 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- chondroitin 4-sulfate, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- cefazolin 1000 MG Injection, started on 2014-12-15, presumably until 2014-12-15\n- 1 ML epinephrine 1 MG/ML Injection, started on 2014-12-15, presumably until 2014-12-15\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-12-15, presumably until 2014-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-15 11:18:00, ended at 2014-12-15 14:40:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Aspiration of cataract by phacoemulsification\n- Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation\n- One stage extracapsular extraction of lens and insertion of prosthetic intraocular lens\n\n### Condition\n- Asthma\n- Chronic kidney disease\n- Cataract\n- Heart failure\n- Disorder of kidney and/or ureter\n- Granulomatosis with polyangiitis\n- Age related macular degeneration\n- Allergic disposition\n- Chronic sinusitis\n- Allergic rhinitis\n- Gastroesophageal reflux disease\n\n### Drug\n- tropicamide 10 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-12-15, presumably until 2014-12-15\n- phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- moxifloxacin 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- ketorolac tromethamine 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n- tetracaine hydrochloride 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2014-12-15, presumably until 2014-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-12-24 00:00:00, ended at 2014-12-24 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-24 12:07:00, ended at 2014-12-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.76 (thousand per microliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 43 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 305 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Age related macular degeneration\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-06 09:29:01, ended at 2015-01-06 10:29:13\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n- Intraocular pressure of right eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Age related macular degeneration\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-01-06 11:18:21, ended at 2015-01-06 12:06:39\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Age related macular degeneration\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-01-06, presumably until 2015-04-30, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- prednisone 1 MG Oral Tablet, started on 2015-01-06, presumably until 2015-05-05, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- prednisone 5 MG Oral Tablet, started on 2015-01-06, presumably until 2015-03-27, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n- carvedilol 6.25 MG Oral Tablet, through Oral route, presumably until 2016-10-20, with intended 0 refill(s). Instructions: take 6.25 mg by mouth 2 times a day with meals \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-10 00:00:00, ended at 2015-02-10 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 10:04:24, ended at 2015-02-10 12:34:34\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n\n### Condition\n- Eruption\n- Primary diagnosis: Chronic rhinitis\n- Chronic sinusitis\n- Asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 14:51:30, ended at 2015-02-10 16:38:58\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Chronic rhinitis\n- Eruption\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-02-10 16:11:09, ended at 2015-02-10 17:15:16\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-03 00:00:00, ended at 2015-03-03 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 09:01:58, ended at 2015-03-03 10:32:17\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of right eye: 11 (millimeter mercury column)\n- Intraocular pressure of left eye: 13 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Age related macular degeneration\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 11:10:19, ended at 2015-03-03 13:37:55\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Granulomatosis with polyangiitis\n- IgE-mediated allergic asthma\n- Primary diagnosis: Allergic rhinitis due to pollen\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-03-03, presumably until 2015-05-05, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-03 12:47:00, ended at 2015-03-03 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.1 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Acute myocardial infarction of anterior wall\n- Cerebral infarction due to embolism of cerebral arteries\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-03 15:08:13, ended at 2015-03-03 16:51:51\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-03-25 00:00:00, ended at 2015-03-25 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2015-04-16, presumably until 2015-06-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-27 00:00:00, ended at 2015-03-27 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2015-03-31, presumably until 2015-08-25, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-04-17 00:00:00, ended at 2015-04-17 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 12.5 MG Oral Tablet, started on 2015-04-17, presumably until 2015-04-17, with intended 6 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE A DAY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-04-30 00:00:00, ended at 2015-04-30 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Allergic rhinitis due to animal hair and dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-04-30, presumably until 2015-06-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-05-05 00:00:00, ended at 2015-05-05 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-05 09:35:00, ended at 2015-05-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 18 (milligram per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 129.70 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.73 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.7 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCV [Entitic volume] by Automated count: 94.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 216 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypokalemia\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-05-05 10:09:27, ended at 2015-05-05 10:55:28\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypokalemia\n\n### Drug\n- potassium chloride 25 MEQ Effervescent Oral Tablet, through Oral route, started on 2015-05-05, presumably until 2016-02-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-06-24 10:42:00, ended at 2015-06-24 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 10.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Creatinine [Mass/volume] in Urine: 32.50 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-24 12:52:33, ended at 2015-06-24 14:33:10\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 1\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-06-24 14:50:21, ended at 2015-06-24 15:40:13\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n- Allergic rhinitis due to animal hair and dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-06-24, presumably until 2015-08-25, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-07 00:00:00, ended at 2015-07-07 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-21 10:22:00, ended at 2015-07-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.06 (million per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 79.1 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 11 (millimeter per hour)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.74 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 257 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Granulomatosis with polyangiitis\n- Chronic sinusitis\n- Chronic kidney disease stage 1\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-07-21 13:38:44, ended at 2015-07-21 14:47:40\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2015-07-21, presumably until 2016-05-19, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n- cephalexin 500 MG Oral Capsule, through Oral route, presumably until 2015-07-21, with intended 0 refill(s). Instructions: take by mouth 4 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-25 10:45:00, ended at 2015-08-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Erythrocyte sedimentation rate: 9 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.7 (picogram)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Creatinine [Mass/volume] in Urine: 55.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.85 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of muscle\n- Allergic rhinitis due to animal hair and dander\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-25 11:35:10, ended at 2015-08-25 12:35:45\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis due to pollen\n- Asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2015-08-25, presumably until 2016-08-24, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-25 14:05:22, ended at 2015-08-25 15:02:39\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Body height: 5' 4\" (inch (US))\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.04 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Allergic rhinitis due to animal hair and dander\n- Primary diagnosis: Disorder of muscle\n- Granulomatosis with polyangiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2015-08-25, presumably until 2016-04-20, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, started on 2015-08-25, presumably until 2015-12-23, with intended 1 refill(s). Instructions: Taper as prescribed by MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-26 00:00:00, ended at 2015-08-26 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Granulomatosis with polyangiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-09-28 00:00:00, ended at 2015-09-28 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-12 00:00:00, ended at 2015-11-12 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-11-17 00:00:00, ended at 2015-11-17 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-18 10:21:00, ended at 2015-11-18 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.2 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.6 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 168 (picogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 120.7 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.83 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-18 11:04:02, ended at 2015-11-18 11:46:02\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-23 10:30:00, ended at 2015-12-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 8 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: <0.10 (milligram per milligram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 255 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 123.8 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.64 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of bone\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-23 11:24:15, ended at 2015-12-23 11:52:17\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Disorder of bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-01-05 00:00:00, ended at 2016-01-05 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-04 14:12:49, ended at 2016-02-04 16:12:30\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-04 16:10:44, ended at 2016-02-04 16:53:21\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, presumably until 2019-04-30, with intended 0 refill(s). Instructions: take 20 mEq by mouth 2 times a day Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-19 00:00:00, ended at 2016-04-19 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-20 11:37:00, ended at 2016-04-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 59.99 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.40 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 292 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Osteoporosis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-20 12:00:20, ended at 2016-04-20 12:18:01\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2016-04-20, presumably until 2016-09-20, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 1 MG Oral Tablet, started on 2016-04-20, presumably until 2016-09-19, with intended 2 refill(s). Instructions: Take 3mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-29 00:00:00, ended at 2016-04-29 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-05-18 00:00:00, ended at 2016-05-18 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-19 10:46:24, ended at 2016-05-19 12:06:35\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 60 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, started on 2016-05-19, presumably until 2017-04-12, with intended 0 refill(s). Instructions: Take 2 tablets by mouth initially then 1 tablet by mouth following each loose stool. Not to exceed 8 tablets per day\n- 1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection, through Intramuscular route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: inject 1,440 Units into a muscle One Time\n- azithromycin 500 MG Oral Tablet, through Oral route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 3 days\n- typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution, through Intramuscular route, started on 2016-05-19, presumably until 2016-05-19, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time\n- atovaquone 250 MG / proguanil hydrochloride 100 MG Oral Tablet, through Oral route, started on 2016-05-19, presumably until 2017-01-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily Take one tablet daily, starting 1-2 days prior to travel to malarious area. Continue daily while in malarious area and for 7 days after leaving area\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-19 13:25:31, ended at 2016-05-19 14:01:55\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2016-05-19, presumably until 2016-10-10, with intended 6 refill(s). Instructions: 1 Spray by Nasal route 2 times a day\n- fexofenadine hydrochloride 180 MG Oral Tablet, through Oral route, presumably until 2018-09-06, with intended 0 refill(s). Instructions: take by mouth\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-09 00:00:00, ended at 2016-06-09 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-09 15:45:46, ended at 2016-06-09 16:14:23\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypokalemia\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-06-13 00:00:00, ended at 2016-06-13 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-14 00:00:00, ended at 2016-07-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-14 12:20:00, ended at 2016-07-14 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 287 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Creatinine [Mass/volume] in Urine: 32.09 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-14 14:04:01, ended at 2016-07-14 14:32:54\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-07-14, presumably until 2016-09-19, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-07-14, presumably until 2016-10-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-08-09 00:00:00, ended at 2016-08-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-06 00:00:00, ended at 2016-09-06 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-15 00:00:00, ended at 2016-09-15 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2016-09-15, presumably until 2016-09-28, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-16 00:00:00, ended at 2016-09-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Urine: 24 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Globulin [Mass/volume] in Serum: 2.1 (gram per deciliter calculated)\n- Lymphocytes [#/volume] in Blood by Automated count: 199 (cells per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 21 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10635 (cells per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Protein [Mass/volume] in Urine: 5 (milligram per deciliter)\n- Bacteria [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Basophils [#/volume] in Blood by Automated count: 0 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 445 (cells per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 208 (milligram per gram of creatinine)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 2.0 (calculated)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- MCV [Entitic volume] by Automated count: 94.3 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.13 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.05 (milligram per deciliter)\n- Epithelial cells.squamous [#/area] in Urine sediment by Microscopy high power field: NONE SEEN (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 421 (cells per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hyaline casts [#/area] in Urine sediment by Microscopy low power field: NONE SEEN (per low powered field)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.9 (percent)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 8.6 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-19 00:00:00, ended at 2016-09-19 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Essential hypertension\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-09-19, presumably until 2017-04-12, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-20 00:00:00, ended at 2016-09-20 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2016-09-20, presumably until 2017-01-19, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2016-09-28, presumably until 2017-01-19, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-30 00:00:00, ended at 2016-09-30 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-10-10 00:00:00, ended at 2016-10-10 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, started on 2016-10-10, presumably until 2017-01-19, with intended 3 refill(s). Instructions: SPRAY 1 SPRAY NASALLY 2 TIMES A DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-14 00:00:00, ended at 2016-10-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-20 12:33:00, ended at 2016-10-20 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 18.05 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.6 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- MCV [Entitic volume] by Automated count: 93.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.39 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-20 14:20:04, ended at 2016-10-20 14:56:33\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-28 00:00:00, ended at 2016-10-28 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-11 00:00:00, ended at 2016-11-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-12 00:00:00, ended at 2016-11-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2016-11-14, presumably until 2017-01-19, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-14 00:00:00, ended at 2016-12-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-14 11:39:00, ended at 2016-12-14 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.30 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCV [Entitic volume] by Automated count: 94.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.9 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.8 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 10.31 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-14 14:17:25, ended at 2016-12-14 15:07:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-19 10:48:04, ended at 2017-01-19 10:48:30\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis due to pollen\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray, through Inhalation, started on 2017-01-19, presumably until 2017-12-26, with intended 3 refill(s). Instructions: 1 Spray by Inhalation route 2 times a day as needed (rhinitis)\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-01-19, presumably until 2017-07-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- beclomethasone dipropionate 0.08 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-01-19, presumably until 2017-04-12, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-19 14:07:24, ended at 2017-01-19 14:50:33\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-01-19, presumably until 2017-04-12, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n- prednisone 1 MG Oral Tablet, started on 2017-01-19, presumably until 2017-04-12, with intended 3 refill(s). Instructions: Take 4mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-07 00:00:00, ended at 2017-02-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-09 00:00:00, ended at 2017-02-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-02-14, presumably until 2017-03-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-09 11:18:15, ended at 2017-02-09 12:28:04\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.913\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-09 12:38:08, ended at 2017-02-09 13:15:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Disorder of nasal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-02-14 00:00:00, ended at 2017-02-14 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2017-02-23, presumably until 2017-02-23, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-03-21 00:00:00, ended at 2017-03-21 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-03-21, presumably until 2017-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-12 10:51:00, ended at 2017-04-12 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 26.74 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Erythrocyte sedimentation rate: 14 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 10.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 284 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Osteoporosis\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-12 11:17:25, ended at 2017-04-12 12:11:15\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.795\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2017-04-12, presumably until 2018-01-03, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 7 days\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2017-01-04, presumably until 2017-08-10, with intended 0 refill(s). Instructions:   </br>1 Puff Aerosol, INH, BID, 6 gm, 0, Maintenance\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-04-12 14:58:04, ended at 2017-04-12 15:24:37\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-04-12, presumably until 2017-07-17, with intended 1 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n- prednisone 1 MG Oral Tablet, started on 2017-04-12, presumably until 2017-09-05, with intended 3 refill(s). Instructions: Take 3mg PO daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-24 00:00:00, ended at 2017-05-24 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-05-31 00:00:00, ended at 2017-05-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n\n### Drug\n- levalbuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2017-05-31, presumably until 2017-12-26, with intended 0 refill(s). Instructions: 3 mL by Nebulization route 4 times a day as needed\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2017-05-31, presumably until 2017-06-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 7 days\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2017-05-31, presumably until 2018-02-01, with intended 1 refill(s). Instructions: 2 mL by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-07 00:00:00, ended at 2017-06-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2017-06-07, presumably until 2018-06-07, with intended 1 refill(s). Instructions: TAPER AS PRESCRIBED BY DR\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-07-17, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily Or as directed by MD.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-06-12, presumably until 2017-09-05, with intended 0 refill(s). Instructions: Take as directed by MD for tapering\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-12 00:00:00, ended at 2017-06-12 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-06-13, presumably until 2017-06-13, with intended 6 refill(s). Instructions: TAKE 4 TABLETS ORALLY DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 12:56:20, ended at 2017-06-15 15:15:34\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Allergic rhinitis due to pollen\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-15 14:25:08, ended at 2017-06-15 15:08:23\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Exacerbation of mild persistent asthma\n- Allergic rhinitis due to pollen\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-06-16 00:00:00, ended at 2017-06-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-06-22 00:00:00, ended at 2017-06-22 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2017-06-22, presumably until 2017-06-22, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-06 00:00:00, ended at 2017-07-06 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-07-06, presumably until 2017-12-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2017-07-17, presumably until 2017-09-05, with intended 0 refill(s). Instructions: TAKE 2 TABS BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-07-17 00:00:00, ended at 2017-07-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2017-07-17, presumably until 2017-07-18, with intended 1 refill(s). Instructions: TAPER AS PRESCRIBED BY MD\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-07-18 00:00:00, ended at 2017-07-18 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-07-18, presumably until 2018-01-04, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-08-02 00:00:00, ended at 2017-08-02 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-10 11:38:00, ended at 2017-08-10 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 11.83 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.22 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.63 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-10 13:51:08, ended at 2017-08-10 15:20:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2017-01-04, presumably until 2018-09-06, with intended 0 refill(s). Instructions: 1 Cris Burt, Oliver, every 12 hours, PRN, as needed for pain, 0, Maintenance\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-08-10, presumably until 2017-12-26, with intended 11 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-01-04, presumably until 2019-10-22, with intended 0 refill(s). Instructions: take 3.125 mg by mouth daily as needed\n- citalopram 10 MG Oral Tablet, through Oral route, presumably until 2019-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-08-22, presumably until 2018-08-22, with intended 1 refill(s). Instructions: TAKE 1 TAB BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-24 15:25:49, ended at 2017-08-24 16:47:09\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 00:00:00, ended at 2017-08-25 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on nose and accessory sinuses; not otherwise specified\n\n### Condition\n- Heart failure\n- Transient cerebral ischemia\n- Deviated nasal septum\n- Hypertrophy of nasal turbinates\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- cefazolin 1000 MG Injection, started on 2017-08-25, presumably until 2017-08-25\n- remifentanil 2 MG Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-08-25, presumably until 2017-08-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-08-25, presumably until 2017-08-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-08-25 00:00:00, ended at 2017-08-25 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-08-25, presumably until 2017-08-25\n- fluorescein dilaurate, through Intraocular route, started on 2017-08-25, presumably until 2017-08-25\n- epinephrine 1 MG/ML Injectable Solution, through Intravenous route, started on 2017-08-25, presumably until 2017-08-25\n- fluorescein, through Intraocular route, started on 2017-08-25, presumably until 2017-08-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-25 05:47:00, ended at 2017-08-25 12:19:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- Replacement of Nasal Septum with Autologous Tissue Substitute, Open Approach\n- Submucous resection inferior turbinate, partial or complete, any method\n- Excision of Nasal Turbinate, Percutaneous Approach\n- Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed\n- Nasal/sinus endoscopy, surgical, with maxillary antrostomy\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Computer Assisted Procedure of Head and Neck Region\n- Excision of Right Sphenoid Sinus, Percutaneous Endoscopic Approach\n- Excision of Left Ethmoid Sinus, Percutaneous Endoscopic Approach\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Nasal/sinus endoscopy, surgical, with sphenoidotomy\n- Repair Right Maxillary Sinus, Percutaneous Endoscopic Approach\n- Excision of Left Sphenoid Sinus, Percutaneous Endoscopic Approach\n- Excision of Right Frontal Sinus, Percutaneous Endoscopic Approach\n- Repair Left Maxillary Sinus, Percutaneous Endoscopic Approach\n- Septoplasty or submucous resection, with or without cartilage scoring, contouring or replacement with graft\n- Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)\n- Excision of Left Frontal Sinus, Percutaneous Endoscopic Approach\n- Excision of Right Ethmoid Sinus, Percutaneous Endoscopic Approach\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Degenerative disorder of macula\n- Deviated nasal septum\n- Hypertrophy of nasal turbinates\n- Osteoporosis\n- Seasonal allergic rhinitis\n- Presbyopia\n- Allergic rhinitis\n- Disorder of nasal cavity\n- Chronic sinusitis\n- Disorder of kidney and/or ureter\n- Essential hypertension\n- Heart failure\n- Uncomplicated asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 12:31:57, ended at 2017-09-05 13:01:26\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to animal dander\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2018-01-04, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 15:21:00, ended at 2017-09-05 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of nasal cavity\n- Allergic rhinitis due to animal dander\n- Disorder of bone\n- Chronic sinusitis\n- Osteoporosis\n- Uncomplicated asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 13:12:56, ended at 2017-09-28 14:17:14\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure)\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-12 11:00:00, ended at 2017-10-12 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.1 (percent)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 332 (picogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 94.2 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 11.11 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.6 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 24.94 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Hypo-osmolality and or hyponatremia\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 11:34:28, ended at 2017-10-12 12:34:37\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.992\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Hypo-osmolality and or hyponatremia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 13:54:53, ended at 2017-10-12 15:07:57\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Eosinophilic asthma\n- Allergic rhinitis due to pollen\n- Chronic maxillary sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-10-12, presumably until 2017-10-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-12 15:15:57, ended at 2017-10-12 16:10:38\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.99\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2017-10-19 00:00:00, ended at 2017-10-19 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n- Acute asthma\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2017-10-19, presumably until 2017-12-26, with intended 0 refill(s). Instructions: Take 20 mg PO Qday x 7 days, then 10 mg PO Qday x 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-02 12:54:42, ended at 2017-11-02 13:31:24\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Allergic rhinitis due to pollen\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Disorder of nasal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-26 12:07:41, ended at 2017-12-26 12:43:08\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Allergic rhinitis due to pollen\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated mild persistent asthma\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-12-26, presumably until 2018-10-09, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2017-12-26, presumably until 2018-02-01, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2017-12-26, presumably until 2018-10-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2017-12-26, presumably until 2019-01-01, with intended 3 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-12-26, presumably until 2019-03-07, with intended 3 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-26 13:09:03, ended at 2017-12-26 14:24:20\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 14:27:00, ended at 2017-12-26 14:49:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 51.71 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- IgE [Units/volume] in Serum or Plasma by Immunoassay: 19 (kilounit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <6 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.57 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-26 14:50:00, ended at 2017-12-26 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Uncomplicated asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-01-03 00:00:00, ended at 2018-01-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2018-01-03, presumably until 2018-03-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-03 00:00:00, ended at 2018-01-03 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperparathyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-04 12:55:22, ended at 2018-01-04 13:29:56\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-04 15:01:13, ended at 2018-01-04 16:10:33\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-01-04, presumably until 2018-03-21, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-01-04, presumably until 2018-03-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-01 11:22:54, ended at 2018-02-01 12:51:04\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Allergic rhinitis due to pollen\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic maxillary sinusitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n\n### Drug\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2018-02-01, presumably until 2018-09-06, with intended 3 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2018-02-01, presumably until 2018-09-06, with intended 1 refill(s). Instructions: 2 mL by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-01 13:32:31, ended at 2018-02-01 14:52:49\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Mononeuritis multiplex\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-10 00:00:00, ended at 2018-03-10 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2018-03-12, presumably until 2019-03-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 10:25:18, ended at 2018-03-21 10:50:18\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis\n- Allergic rhinitis due to animal dander\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-03-21, presumably until 2018-07-19, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-03-21, presumably until 2018-07-19, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 11:12:00, ended at 2018-03-21 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.30 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Urine: <5.0 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.27 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Erythrocyte sedimentation rate: 6 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 282 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Creatinine [Mass/volume] in Urine: 60.51 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 8 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.17 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.13 (milligram per milligram)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- IgE [Units/volume] in Serum or Plasma by Immunoassay: 16 (kilounit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- MCV [Entitic volume] by Automated count: 93.5 (femtoliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 182 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Osteoporosis\n- Allergic rhinitis\n- Hyperparathyroidism\n- Allergic rhinitis due to animal dander\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 11:22:44, ended at 2018-03-21 12:13:39\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 10:49:00, ended at 2018-04-24 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Chronic sinusitis\n- Chronic maxillary sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-24 14:54:36, ended at 2018-04-24 16:30:41\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Primary diagnosis: Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-05-09 00:00:00, ended at 2018-05-09 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-26 13:43:37, ended at 2018-06-26 14:46:12\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2018-07-12, presumably until 2018-07-12, with intended 0 refill(s). Instructions: TAKE 2 TABLETS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-19 14:18:37, ended at 2018-07-19 14:45:47\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-10-11, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-07-19, presumably until 2018-10-11, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-19 15:26:30, ended at 2018-07-19 16:01:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Exacerbation of mild persistent asthma\n- Allergic rhinitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-14 11:59:13, ended at 2018-08-14 13:15:54\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-04 00:00:00, ended at 2018-09-04 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe, started on 2018-09-05, presumably until 2018-09-05, with intended 0 refill(s). Instructions: LA:[000000]:05/18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-06 12:58:46, ended at 2018-09-06 14:41:57\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cerebral infarction\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Visual field defect\n\n### Drug\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2019-03-20, with intended 0 refill(s). Instructions: take 81 mg by mouth every morning with breakfast Takes 2-3 a day for pain \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-06 14:15:00, ended at 2018-09-06 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Cerebral infarction\n- Visual field defect\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-10-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-21 00:00:00, ended at 2018-09-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-09-21, presumably until 2018-09-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-08, presumably until 2018-10-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-08 00:00:00, ended at 2018-10-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-08, presumably until 2018-10-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-09 00:00:00, ended at 2018-10-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Anemia in chronic kidney disease\n- Primary diagnosis: Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-09 00:00:00, ended at 2018-10-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to pollen\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2018-10-09, presumably until 2019-01-31, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 10:40:45, ended at 2018-10-11 11:28:07\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Allergic rhinitis\n- Primary diagnosis: Exacerbation of mild persistent asthma\n- Acute upper respiratory infection\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 12:08:12, ended at 2018-10-11 12:34:03\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-11 14:10:39, ended at 2018-10-11 14:36:43\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2019-01-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2019-01-24, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-12 00:00:00, ended at 2018-10-12 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Visual field defect\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-15 00:00:00, ended at 2018-10-15 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-10-18, presumably until 2018-10-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 4 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-24 00:00:00, ended at 2018-10-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2018-10-29, presumably until 2019-01-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levofloxacin 750 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 14 days\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2018-12-13, presumably until 2019-12-13, with intended 1 refill(s). Instructions: TAKE 2 TABLETS EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-07 00:00:00, ended at 2018-12-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 11:00:00, ended at 2018-12-12 14:56:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 58.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Chronic kidney disease\n- Cerebral infarction\n- Anemia in chronic kidney disease\n- Valvular endocarditis\n- Visual field defect\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 14:57:00, ended at 2018-12-12 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Protein [Mass/volume] in Urine collected for unspecified duration: 13.0 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.15 (milligram per milligram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.0 (ratio)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 255 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 88.78 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 5 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 152 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.14 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.93 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.8 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 108.0 (picogram per milliliter)\n- Platelets [#/volume] in Blood by Automated count: 259 (thousand per microliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-01 10:43:30, ended at 2019-01-01 12:48:12\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic pansinusitis\n- Uncomplicated mild persistent asthma\n- Primary diagnosis: Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2019-01-01, presumably until 2020-02-04, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-01-01, presumably until 2019-04-04, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-01 12:52:22, ended at 2019-01-01 15:15:25\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Uncomplicated asthma\n- Chronic sinusitis\n- Primary diagnosis: Loss of sense of smell\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, started on 2019-01-01, presumably until 2019-03-20, with intended 11 refill(s). Instructions: Use 1 ampule as directed BID.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-24 14:46:39, ended at 2019-01-24 15:22:41\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-01-29, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-06-18, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-29 00:00:00, ended at 2019-01-29 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-01-29, presumably until 2019-08-13, with intended 1 refill(s). Instructions: take 2 Tabs by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-31 00:00:00, ended at 2019-01-31 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Allergic rhinitis due to pollen\n\n### Drug\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2019-01-31, presumably until 2020-03-02, with intended 3 refill(s). Instructions: 2 Sprays by Nasal route daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-12 15:03:19, ended at 2019-02-12 16:29:50\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dysphonia\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-07 11:37:58, ended at 2019-03-07 12:21:35\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Chronic rhinitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- fexofenadine hydrochloride 60 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-03-20, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2019-03-07, presumably until 2019-05-13, with intended 11 refill(s). Instructions: 1 Spray by Nasal route 2 times a day Use in each nostril as directed\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-07-29, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-07 15:33:11, ended at 2019-03-07 17:03:08\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-19 12:17:38, ended at 2019-03-19 14:02:29\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n- Disorder of the larynx\n\n### Drug\n- nystatin 100000 UNT/ML Oral Suspension, through Oral route, started on 2019-03-19, presumably until 2019-05-13, with intended 3 refill(s). Instructions: take 5 mL by mouth 4 times a day\n- fluconazole 150 MG Oral Tablet, started on 2019-03-19, presumably until 2019-03-20, with intended 0 refill(s). Instructions: 150mg orally once and may repeat one tablet in 4 days if symptoms persist.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 07:23:00, ended at 2019-03-20 15:22:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance angiography, head; without contrast material(s)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 07:23:00, ended at 2019-03-20 15:22:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Hypertrophic condition of skin\n- Essential hypertension\n- Osteoporosis\n- Pain in right foot\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- gadobenate, through Intravenous route, started on 2019-03-20, presumably until 2019-03-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-20 09:56:33, ended at 2019-03-20 10:25:36\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2019-03-20, presumably until 2020-03-04, with intended 3 refill(s). Instructions: take 1 Tab (70 mg total) by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-20 13:31:38, ended at 2019-03-20 15:07:49\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Hypertrophic condition of skin\n- Primary diagnosis: Pain in right foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-03-20, presumably until 2019-03-20, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (81 mg total) by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-20 15:23:00, ended at 2019-03-20 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-03-26 00:00:00, ended at 2019-03-26 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-03-27, presumably until 2019-03-27, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-04 11:42:40, ended at 2019-04-04 12:33:34\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.81\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-04 14:09:00, ended at 2019-04-04 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.63 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.11 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 282 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.17 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 30.13 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.0 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 5.0 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.1 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-24 00:00:00, ended at 2019-04-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-04-30 00:00:00, ended at 2019-04-30 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2019-05-01, presumably until 2019-09-23, with intended 12 refill(s). Instructions: take 1 Packet (20 mEq total) by mouth daily Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-30 12:05:26, ended at 2019-04-30 15:57:31\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 0.6 to 1.0 cm\n\n### Condition\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n- Neoplasm of uncertain behavior of skin\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-30 13:14:52, ended at 2019-04-30 14:18:49\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.81\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated moderate persistent asthma\n- Dysphonia\n- Neoplasm of uncertain behavior of skin\n- Senile hyperkeratosis\n- Neoplastic disease of uncertain behavior\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-13 10:55:27, ended at 2019-05-13 12:12:51\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- olopatadine 1 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-05-08, presumably until 2019-05-08, with intended 0 refill(s). Instructions: Instill 1 drop to both eyes as needed\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-05-13, presumably until 2019-05-13, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2019-04-14, presumably until 2019-05-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-13 12:15:00, ended at 2019-05-13 12:29:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Tailor's bunion\n- Pain in right foot\n- Talipes planus\n- Acquired hallux varus\n- Essential hypertension\n- Pain in left foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-13 12:30:00, ended at 2019-05-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in left foot\n- Pain in right foot\n- Localized, primary osteoarthritis of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-15 00:00:00, ended at 2019-05-15 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-05-15, presumably until 2020-05-11, with intended 3 refill(s). Instructions: 2 Puffs by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-18 10:57:51, ended at 2019-06-18 12:08:03\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2019-06-18, presumably until 2019-10-09, with intended 3 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n- gabapentin 100 MG Oral Capsule, through Oral route, presumably until 2019-08-13, with intended 0 refill(s). Instructions: take 100 mg by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-09 11:00:00, ended at 2019-07-09 11:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-16 00:00:00, ended at 2019-07-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-17 00:00:00, ended at 2019-07-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n\n### Drug\n- levocetirizine dihydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-07-29, presumably until 2019-12-25, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-13 10:36:00, ended at 2019-08-13 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.16 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 295 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 26.70 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.4 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: <4.0 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Bunion\n- Follicular cysts of skin and subcutaneous tissue\n- Low back pain\n- Pain of left knee region\n- Chronic pain\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-13 13:18:06, ended at 2019-08-13 13:37:04\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pain\n- Primary diagnosis: Follicular cysts of skin and subcutaneous tissue\n- Low back pain\n- Pain of left knee region\n- Bunion\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-08-13, presumably until 2019-09-20, with intended 2 refill(s). Instructions: take 1 Tab (50 mg total) by mouth as needed for pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-13 14:05:12, ended at 2019-08-13 14:51:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2019-08-13, presumably until 2020-02-04, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-26 00:00:00, ended at 2019-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- valacyclovir 1000 MG Oral Tablet, through Oral route, started on 2019-08-26, presumably until 2019-08-27, with intended 2 refill(s). Instructions: take 2 Tabs (2,000 mg total) by mouth 2 times a day for 1 day PRN cold sores\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-09-05 00:00:00, ended at 2019-09-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-12 09:26:05, ended at 2019-09-12 14:45:38\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- valacyclovir 1000 MG Oral Tablet, started on 2019-08-30, presumably until 2019-09-13, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-12 11:31:14, ended at 2019-09-12 13:11:07\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cerebral infarction\n- Eosinophilic asthma\n- Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-13 07:30:00, ended at 2019-09-13 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Supraventricular tachycardia\n- Cerebral infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-09-20 00:00:00, ended at 2019-09-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2019-09-20, presumably until 2019-10-25, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every bedtime as needed for pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-09-23, presumably until 2020-04-07, with intended 12 refill(s). Instructions: take 20 Tabs by mouth every day\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2019-09-23, presumably until 2019-09-23, with intended 12 refill(s). Instructions: take 1 Packet (20 mEq total) by mouth daily Every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-09 00:00:00, ended at 2019-10-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-09 08:15:00, ended at 2019-10-09 11:14:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Osteoarthritis of knee\n- Acquired genu valgum\n- Pain of left knee region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-09 08:55:12, ended at 2019-10-09 09:27:51\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.811\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2019-10-09, presumably until 2020-02-04, with intended 3 refill(s). Instructions: take 2 Tabs (2 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-09 11:15:00, ended at 2019-10-09 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Osteoporosis\n- Disorder of bone\n- Pain in thoracic spine\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Acquired hallux varus\n- Pain of left knee region\n- Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-09 15:03:15, ended at 2019-10-09 15:53:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in thoracic spine\n- Primary diagnosis: Shoulder joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic pansinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-10-17, presumably until 2019-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-21 00:00:00, ended at 2019-10-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2019-10-22, presumably until 2020-04-07, with intended 12 refill(s). Instructions: take 1 Tab (3.125 mg total) by mouth daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-25 00:00:00, ended at 2019-10-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2019-10-28, presumably until 2019-12-05, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pansinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-10-29, presumably until 2019-11-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-04 00:00:00, ended at 2019-11-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 09:50:06, ended at 2019-11-05 10:25:56\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 11:12:09, ended at 2019-11-05 12:04:23\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Uncomplicated severe persistent asthma\n- Chronic rhinitis\n- Primary diagnosis: Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 12:22:32, ended at 2019-11-05 14:38:39\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-05 13:22:35, ended at 2019-11-05 14:31:38\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease\n- Primary diagnosis: Chronic kidney disease stage 3\n- Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-05 13:50:00, ended at 2019-11-05 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: 15 (milligram per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 20 (milligram per gram)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 74.10 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.99 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Dysphonia\n- Anemia in chronic kidney disease\n- Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-08 00:00:00, ended at 2019-11-08 08:07:41\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-25 00:00:00, ended at 2019-11-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2019-11-25, presumably until 2019-12-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-02 00:00:00, ended at 2019-12-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2019-12-05, presumably until 2019-12-10, with intended 1 refill(s). Instructions: 3 mL (1.25 mg total) by Nebulization route every 4 hours as needed for Bronchospasm/Wheezing (cough)\n- prednisone 5 MG Oral Tablet, started on 2019-12-05, presumably until 2020-02-04, with intended 0 refill(s). Instructions: Take 10 mg x 1 week, then 5 mg x 1 week\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2019-12-05, presumably until 2020-02-20, with intended 2 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-05 00:00:00, ended at 2019-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2019-12-05, presumably until 2020-01-22, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-10 00:00:00, ended at 2019-12-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2019-12-10, presumably until 2021-02-09, with intended 1 refill(s). Instructions: 1 Dose by Injection route every 4 hours as needed Use as directed\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2019-12-10, presumably until 2020-01-09, with intended 1 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-11 08:59:06, ended at 2019-12-11 09:45:31\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute sinusitis\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Acute bronchitis\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-11 10:29:00, ended at 2019-12-11 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Melanocytic nevus of trunk\n- Acute sinusitis\n- Disorder of immune function\n- Hyperpigmentation of skin\n- Melanocytic nevus of lower limb\n- Temporomandibular joint disorder\n- Scar conditions and fibrosis of skin\n- Essential hypertension\n- Acute bronchitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n- Melanocytic nevus of upper limb\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-11 12:17:22, ended at 2019-12-11 13:40:55\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Scar conditions and fibrosis of skin\n- Hyperpigmentation of skin\n- Primary diagnosis: Melanocytic nevus of lower limb\n- Disorder of immune function\n- Primary diagnosis: Melanocytic nevus of trunk\n- Primary diagnosis: Melanocytic nevus of upper limb\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Senile hyperkeratosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-19 00:00:00, ended at 2019-12-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n\n### Drug\n- levocetirizine dihydrochloride 5 MG Oral Tablet, started on 2019-12-25, presumably until 2020-10-06, with intended 10 refill(s). Instructions: TAKE ONE TABLET (5MG) BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-01-22, presumably until 2020-02-29, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated mild persistent asthma\n- Eosinophilic asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2020-01-22, presumably until 2020-07-21, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-04 09:13:00, ended at 2020-02-04 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 264 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 20 (milligram per gram)\n- Basophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.96 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 6.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 39.80 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocyte sedimentation rate: 5 (millimeter per hour)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 73.8 (picogram per milliliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.15 (milligram per milligram)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.08 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Dysphonia\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 09:50:25, ended at 2020-02-04 10:17:09\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Laryngoscopy, flexible or rigid telescopic, with stroboscopy\n\n### Condition\n- Primary diagnosis: Dysphonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 10:45:37, ended at 2020-02-04 12:08:30\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Joint pain\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 12:20:34, ended at 2020-02-04 13:04:58\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-05-19, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-13 00:00:00, ended at 2020-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Reduced mobility\n- Primary diagnosis: Closed fracture of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-13 00:00:00, ended at 2020-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture of lower leg\n- Primary diagnosis: Loss of consciousness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-20 12:15:00, ended at 2020-02-20 13:41:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Closed bimalleolar fracture\n- Closed fracture of lower leg\n- Arthralgia of the ankle and/or foot\n- Closed fracture of fibula\n- Closed fracture of medial malleolus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-20 13:42:00, ended at 2020-02-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; 2 views\n\n### Condition\n- Closed fracture of lateral malleolus\n- Closed fracture of lower leg\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-21 00:00:00, ended at 2020-02-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nonunion of fracture\n- Primary diagnosis: Closed bimalleolar fracture\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2020-02-21, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for open procedures on bones of lower leg, ankle, and foot; not otherwise specified\n\n### Condition\n- Closed fracture of lateral malleolus\n- Sprain of deltoid ligament of ankle\n- Sprain of ankle\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- cefazolin 1000 MG Injection, started on 2020-02-27, presumably until 2020-02-27\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- ketamine 100 MG/ML Injectable Solution, started on 2020-02-27, presumably until 2020-02-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- 30 ML ropivacaine hydrochloride 5 MG/ML Injection, started on 2020-02-27, presumably until 2020-02-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-02-27 00:00:00, ended at 2020-02-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed\n- Manual application of stress performed by physician or other qualified health care professional for joint radiography, including contralateral joint if indicated\n- Open treatment of distal tibiofibular joint (syndesmosis) disruption, includes internal fixation, when performed\n\n### Condition\n- Closed fracture of lateral malleolus\n- Sprain of ankle\n- Sprain of deltoid ligament of ankle\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-02-27 07:19:00, ended at 2020-02-29 13:20:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Left ventricular Ejection fraction: 61.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Body height: 5' 2\" (inch (US))\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n\n### Procedure\n- Repair Right Ankle Bursa and Ligament, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Reposition Right Fibula with Internal Fixation Device, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n\n### Condition\n- Chronic congestive heart failure\n- Hypertensive heart failure\n- Pain\n- Closed bimalleolar fracture\n- Primary diagnosis: Loss of consciousness\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated asthma\n- Essential hypertension\n- First degree atrioventricular block\n- Illness\n- Persistent pain following procedure\n- Chronic systolic heart failure\n- Gastroesophageal reflux disease without esophagitis\n- Closed fracture of lower leg\n- Sprain of deltoid ligament of ankle\n- Electrocardiogram abnormal\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- albuterol 0.83 MG/ML Inhalation Solution, through Inhalation, started on 2020-02-28, presumably until 2020-02-29\n- calcium carbonate 625 MG / cholecalciferol 125 UNT Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-02-27, presumably until 2020-02-27\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2020-02-27, presumably until 2020-03-10, with intended 0 refill(s). Instructions: take 2 Caps (200 mg total) by mouth 2 times a day as needed for Constipation\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-28\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-02-29, presumably until 2020-02-29\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-02-28, presumably until 2020-03-10, with intended 1 refill(s). Instructions: take 1 Packet (17 g total) by mouth daily as needed\n- 8 HR acetaminophen 650 MG Extended Release Oral Tablet, through Oral route, started on 2020-02-28, presumably until 2020-03-10, with intended 0 refill(s). Instructions: take 1 Tab (650 mg total) by mouth every 6 hours\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2020-02-28, presumably until 2020-02-29\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-02-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-02-27, presumably until 2020-02-28\n- carboxymethylcellulose sodium 5 MG/ML Ophthalmic Solution, through Intraocular route, started on 2020-02-28, presumably until 2020-02-29\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-02-27, presumably until 2020-04-07, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed for Pain\n- 30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2020-02-29, presumably until 2020-02-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-02 00:00:00, ended at 2020-03-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-04 00:00:00, ended at 2020-03-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n\n### Drug\n- alendronic acid 70 MG Oral Tablet, through Oral route, started on 2020-03-04, presumably until 2021-05-21, with intended 3 refill(s). Instructions: take 1 Tab (70 mg total) by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-10 09:00:00, ended at 2020-03-10 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Closed fracture of medial malleolus\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-16 00:00:00, ended at 2020-03-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in left foot\n- Pain in right foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-04-07 10:41:24, ended at 2020-04-07 12:14:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic pansinusitis\n- Primary diagnosis: Eosinophilic asthma\n- Chronic rhinitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-04-07 12:40:59, ended at 2020-04-07 13:56:39\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed bimalleolar fracture\n- Primary diagnosis: Loss of consciousness\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-04-07, presumably until 2020-12-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2020-04-07, presumably until 2020-10-23, with intended 0 refill(s). Instructions: take 1 Tab (3.125 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-07 13:56:18, ended at 2020-04-07 13:56:28\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Loss of consciousness\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-08 00:00:00, ended at 2020-04-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-13 00:00:00, ended at 2020-04-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-20 00:00:00, ended at 2020-04-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-04-28, presumably until 2020-05-26, with intended 0 refill(s). Instructions: TAKE ONE TABLET ORALLY DAILY AT BEDTIME AS NEEDED FOR PAIN\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-23 09:50:00, ended at 2020-04-23 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Closed fracture of lateral malleolus\n- Tailor's bunion\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-24 00:00:00, ended at 2020-04-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed bimalleolar fracture\n- Arthralgia of the ankle and/or foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-09 00:00:00, ended at 2020-05-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2020-05-11, presumably until 2020-08-11, with intended 2 refill(s). Instructions: INHALE TWO PUFFS BY MOUTH TWICE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-15 00:00:00, ended at 2020-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Arthralgia of the ankle and/or foot\n- Closed bimalleolar fracture\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 00:00:00, ended at 2020-05-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2020-05-19, presumably until 2020-12-23, with intended 1 refill(s). Instructions: take 2 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-05-26, presumably until 2020-06-02, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2020-05-25, presumably until 2020-06-01, with intended 5 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-26 00:00:00, ended at 2020-05-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n- Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-01 00:00:00, ended at 2020-06-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 5 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-01, presumably until 2020-06-16, with intended 5 refill(s). Instructions: 0.5 mL (2.5 mg total) by Inhalation route every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-02 00:00:00, ended at 2020-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-06-02, presumably until 2020-07-13, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-04 00:00:00, ended at 2020-06-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-16 09:23:00, ended at 2020-06-16 15:41:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Eosinophilic asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Late effect of fracture of lower extremities\n- Melanocytic nevus\n- Postoperative state\n- Closed bimalleolar fracture\n- Supraventricular tachycardia\n- Arthralgia of the ankle and/or foot\n- Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 11:49:33, ended at 2020-06-16 13:26:49\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nasal cavity\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-16, presumably until 2020-06-25, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n- mupirocin 0.02 MG/MG Nasal Ointment, through Nasal route, started on 2020-06-16, presumably until 2020-06-18, with intended 0 refill(s). Instructions: by Nasal route 2 times a day\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2020-06-16, presumably until 2020-06-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 13:05:45, ended at 2020-06-16 15:41:51\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Melanocytic nevus\n- Primary diagnosis: Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 14:48:32, ended at 2020-06-16 15:36:44\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-16 15:42:00, ended at 2020-06-16 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Protein [Mass/volume] in Urine collected for unspecified duration: 9.0 (milligram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.12 (milligram per milligram)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 4 - 5 (per high power field)\n- Creatinine [Mass/volume] in Urine: 77.29 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-17 00:00:00, ended at 2020-06-17 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-18 00:00:00, ended at 2020-06-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of nasal cavity\n\n### Drug\n- mupirocin 0.02 MG/MG Nasal Ointment, through Nasal route, started on 2020-06-18, presumably until 2020-08-21, with intended 0 refill(s). Instructions: by Nasal route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-19 00:00:00, ended at 2020-06-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- albuterol 0.83 MG/ML Inhalation Solution, started on 2020-06-19, presumably until 2021-11-19, with intended 0 refill(s). Instructions: USE ONE VIAL BY INHALATION ROUTE EVERY 4 HOURS AS NEEDED FOR COUGH/WHEEZE\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-25 00:00:00, ended at 2020-06-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated severe persistent asthma\n\n### Drug\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-25, presumably until 2020-08-20, with intended 3 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-25 00:00:00, ended at 2020-06-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-06-25, presumably until 2020-07-07, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-02 00:00:00, ended at 2020-07-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Localized infection of skin AND/OR subcutaneous tissue\n- Primary diagnosis: Bacterial infectious disease\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2020-07-02, presumably until 2020-08-27, with intended 1 refill(s). Instructions: Apply to affected areas BID x 5-7 days until improved\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-02 00:00:00, ended at 2020-07-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-07 11:06:14, ended at 2020-07-07 16:16:38\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated mild persistent asthma\n- Primary diagnosis: Eosinophilic asthma\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-07-07, presumably until 2020-08-17, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n- prednisone 5 MG Oral Tablet, started on 2020-07-07, presumably until 2020-07-09, with intended 0 refill(s). Instructions: Take 20 mg by mouth x 5 days, 15 mg x 5 days, 10 mg x 5 days, 5 mg x 5 days\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2020-07-07, presumably until 2020-11-03, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-09 00:00:00, ended at 2020-07-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-09 00:00:00, ended at 2020-07-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2020-07-09, presumably until 2020-07-21, with intended 0 refill(s). Instructions: Take 20 mg by mouth x 5 days, 15 mg x 5 days, 10 mg x 5 days, 5 mg x 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-10 00:00:00, ended at 2020-07-10 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-07-13, presumably until 2020-10-23, with intended 2 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-14 12:46:03, ended at 2020-07-14 13:10:35\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eosinophilic asthma\n- Recurrent acute sinusitis\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Acute pansinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-21 00:00:00, ended at 2020-07-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated mild persistent asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2020-07-21, presumably until 2020-10-06, with intended 11 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-21 00:00:00, ended at 2020-07-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2020-07-21, presumably until 2020-08-13, with intended 0 refill(s). Instructions: 30 mg x 7 days, 20 mg x 7 days, 10 mg x 7 days, 5 mg x 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperlipidemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-10 00:00:00, ended at 2020-08-10 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 120 ACTUAT budesonide 0.16 MG/ACTUAT / formoterol fumarate 0.0045 MG/ACTUAT Metered Dose Inhaler, started on 2020-08-11, presumably until 2021-01-26, with intended 0 refill(s). Instructions: INHALE TWO PUFFS BY MOUTH TWICE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-13 11:05:59, ended at 2020-08-13 15:45:04\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Eosinophilic asthma\n- Uncomplicated severe persistent asthma\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2020-08-13, presumably until 2020-12-07, with intended 0 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-17 00:00:00, ended at 2020-08-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated severe persistent asthma\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, through Inhalation, started on 2020-08-17, presumably until 2020-08-20, with intended 0 refill(s). Instructions: 3 mL by Nebulization route as needed\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2020-08-20, presumably until 2021-05-21, with intended 1 refill(s). Instructions: 3 mL by Inhalation route every 6 hours as needed (cough/wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-18 00:00:00, ended at 2020-08-18 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Arthralgia of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-20 00:00:00, ended at 2020-08-20 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, started on 2020-08-20, presumably until 2020-08-21, with intended 0 refill(s). Instructions: 3mL mixed with budesonide by inhalation route BID PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-08-20 10:05:43, ended at 2020-08-20 11:13:04\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic pansinusitis\n- Spasm\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Blood chemistry abnormal\n- Primary diagnosis: Disorder of bone\n- Lymphocytopenia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-20 10:45:00, ended at 2020-08-20 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, ankle; complete, minimum of 3 views\n\n### Condition\n- Arthralgia of the ankle and/or foot\n- Metatarsalgia\n- Pain in right foot\n- Postoperative state\n- Closed bimalleolar fracture\n- Closed fracture of lateral malleolus\n- Acquired hallux varus\n- Hammer toe\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-21 00:00:00, ended at 2020-08-21 08:04:46\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pure hypercholesterolemia\n- Eosinophilic asthma\n- Primary diagnosis: Insomnia\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- 0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 M..., through Intramuscular route, started on 2020-08-21, presumably until 2020-08-21, with intended 0 refill(s). Instructions: inject into a muscle\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2020-08-21, presumably until 2021-08-21, with intended 12 refill(s). Instructions: take 1 Tab (3 mg total) by mouth every bedtime as needed (insomnia)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-21 00:00:00, ended at 2020-08-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 9 MG/ML Inhalation Solution, started on 2020-08-21, presumably until 2020-12-07, with intended 3 refill(s). Instructions: 3mL mixed with budesonide by inhalation route BID PRN cough\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-24 00:00:00, ended at 2020-08-24 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Allergic rhinitis due to pollen\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-24 00:00:00, ended at 2020-08-24 10:20:37\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Candidiasis of mouth\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2020-08-27, presumably until 2020-12-07, with intended 0 refill(s). Instructions: APPLY TO THE AFFECTED AREA(S) TWICE DAILY FOR 5 TO 7 DAYS UNTIL IMPROVED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-08 11:04:53, ended at 2020-09-08 12:09:27\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Lymphocytopenia\n- Uncomplicated severe persistent asthma\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-10 11:26:40, ended at 2020-09-10 13:35:18\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary diagnosis: Tailor's bunion\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-17 00:00:00, ended at 2020-09-17 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-09-17, presumably until 2020-12-07, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Open bimalleolar fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-23 00:00:00, ended at 2020-09-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-23 11:15:00, ended at 2020-09-23 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, maxillofacial area; without contrast material\n\n### Condition\n- Dysphonia\n- Pain in right foot\n- Chronic pansinusitis\n- Disorder of bone\n- Spasm\n- Lymphocytopenia\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Tailor's bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-09-24 00:00:00, ended at 2020-09-24 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2020-09-24, presumably until 2020-09-24\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-09-24, presumably until 2020-09-24\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-09-24, presumably until 2020-09-24\n- bupivacaine hydrochloride 5 MG/ML Injectable Solution, started on 2020-09-24, presumably until 2020-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-24 08:30:00, ended at 2020-09-24 12:10:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Ostectomy, partial excision, fifth metatarsal head (bunionette) (separate procedure)\n\n### Condition\n- Essential hypertension\n- Pure hypercholesterolemia\n- Pain in right foot\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Eosinophilic asthma\n- Osteoporosis\n- Tailor's bunion\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-09-24, presumably until 2020-11-23, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every 6 hours as needed\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-09-24, presumably until 2020-09-24\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-24, presumably until 2020-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-09-25 00:00:00, ended at 2020-09-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Tailor's bunion\n- Pain in right foot\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-25, presumably until 2020-09-26, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-09-26 00:00:00, ended at 2020-09-26 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in right foot\n- Tailor's bunion\n\n### Drug\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2020-09-26, presumably until 2020-10-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-05 00:00:00, ended at 2020-10-05 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic rhinitis\n- Uncomplicated mild persistent asthma\n\n### Drug\n- montelukast 10 MG Oral Tablet, started on 2020-10-06, presumably until 2021-02-09, with intended 3 refill(s). Instructions: Take by mouth every bedtime\n- levocetirizine dihydrochloride 5 MG Oral Tablet, started on 2020-10-06, presumably until 2021-07-05, with intended 3 refill(s). Instructions: TAKE ONE TABLET (5MG) BY MOUTH ONE TIME DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-08 09:35:08, ended at 2020-10-08 10:27:46\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Candidiasis of mouth\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Acute exacerbation of chronic obstructive airways disease\n\n### Drug\n- prednisone 1 MG Oral Tablet, started on 2020-10-08, presumably until 2020-12-07, with intended 0 refill(s). Instructions: 4 mg x 7 days, then 3 mg x 7 days, 2 mg x 7 days, 1 mg x 7 days\n- tiotropium 0.018 MG Inhalation Powder, through Inhalation, started on 2020-10-13, presumably until 2020-10-15, with intended 3 refill(s). Instructions: 1 Plunkett (18 mcg total) by Inhalation route daily\n- fluconazole 150 MG Oral Tablet, started on 2020-10-08, presumably until 2020-12-07, with intended 0 refill(s). Instructions: 150mg orally once and may repeat one tablet in 72 hour if not improved\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-09 00:00:00, ended at 2020-10-09 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- clotrimazole 10 MG Oral Lozenge, through Oral route, started on 2020-10-09, presumably until 2021-01-26, with intended 3 refill(s). Instructions: take 1 Lozenge (10 mg total) by mouth 5 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-13 00:00:00, ended at 2020-10-13 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Degenerative disorder of macula\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Chronic kidney disease\n- Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pain in right foot\n- Primary diagnosis: Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-22 00:00:00, ended at 2020-10-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2020-10-23, presumably until 2020-11-23, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-10-23 00:00:00, ended at 2020-10-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2020-10-23, presumably until 2020-11-02, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH DAILY AS NEEDED \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 09:51:00, ended at 2020-10-26 12:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Pain in right foot\n- Postoperative state\n- Metatarsal bone fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-26 09:51:03, ended at 2020-10-26 12:26:39\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tailor's bunion\n- Primary diagnosis: Postoperative state\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 13:00:00, ended at 2020-10-26 14:02:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia in chronic kidney disease\n- Chronic kidney disease stage 3\n- Pain in right foot\n- Postoperative state\n- Uncomplicated severe persistent asthma\n- Tailor's bunion\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-26 14:03:00, ended at 2020-10-26 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 239 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.3 (ratio)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 147 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Parathyrin.intact [Mass/volume] in Serum or Plasma: 97.0 (picogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 27 (milligram per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 73 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 2.0 (ratio)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Microalbumin/Creatinine [Mass Ratio] in Urine: 32 (milligram per gram)\n- Neutrophils [#/volume] in Blood by Automated count: 7.05 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 85.20 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 96 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Anemia in chronic kidney disease\n- Chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-10-27 12:43:28, ended at 2020-10-27 13:54:28\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-03 15:51:11, ended at 2020-11-03 16:43:27\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic sinusitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2020-11-03, presumably until 2021-01-25, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-11-10 13:09:35, ended at 2020-11-10 14:05:34\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 1.417\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease\n- Chronic kidney disease stage 3A\n- Essential hypertension\n- Primary diagnosis: Anemia in chronic kidney disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-20 00:00:00, ended at 2020-11-20 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-11-23 00:00:00, ended at 2020-11-23 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-11-23, presumably until 2021-11-23, with intended 0 refill(s). Instructions: take 1 Tab (50 mg total) by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-25 00:00:00, ended at 2020-11-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in right foot\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-07 00:00:00, ended at 2020-12-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Tablet, through Oral route, started on 2020-12-07, presumably until 2020-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth every day\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2020-12-07, presumably until 2021-11-19, with intended 12 refill(s). Instructions: take 1 Tab (6.25 mg total) by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-12-08 11:45:37, ended at 2020-12-08 12:18:16\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Primary diagnosis: Uncomplicated severe persistent asthma\n- Cellulitis\n- Chronic sinusitis\n- Chronic obstructive lung disease\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2020-12-08, presumably until 2020-12-18, with intended 0 refill(s). Instructions: take 1 Cap (500 mg total) by mouth 3 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-14 08:30:00, ended at 2020-12-14 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Dysphonia\n- Hammer toe\n- Chronic sinusitis\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Metatarsal bone fracture\n- Closed bimalleolar fracture\n- Metatarsalgia\n- Acquired hallux varus\n- Pain in right foot\n- Postoperative state\n- Tailor's bunion\n- Chronic frontal sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-15 00:00:00, ended at 2020-12-15 12:19:53\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2020-12-15, presumably until 2021-01-04, with intended 0 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-22 00:00:00, ended at 2020-12-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, started on 2020-12-23, presumably until 2021-01-06, with intended 0 refill(s). Instructions: TAKE TWO TABLETS BY MOUTH DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-12-22 00:00:00, ended at 2020-12-22 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- potassium chloride 20 MEQ Extended Release Oral Tablet, started on 2020-12-23, presumably until 2022-01-20, with intended 12 refill(s). Instructions: TAKE 1 TABLET (20MEQ) BY MOUT HEVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-01 00:00:00, ended at 2021-01-01 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- tramadol hydrochloride 50 MG Oral Tablet, started on 2021-01-05, presumably until 2021-02-08, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH AT BEDTIME AS NEEDED FOR PAIN, APPOINTMENT NEEDED BEFORE NEXT REFILL\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-02 00:00:00, ended at 2021-01-02 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2021-01-04, presumably until 2021-01-04, with intended 0 refill(s). Instructions: take 1 Tab (25 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-04 00:00:00, ended at 2021-01-04 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-04, presumably until 2021-02-09, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-06 00:00:00, ended at 2021-01-06 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n\n### Drug\n- azathioprine 50 MG Oral Tablet, through Oral route, started on 2021-01-06, presumably until 2021-04-15, with intended 0 refill(s). Instructions: take 1.5 Tabs (75 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-25 00:00:00, ended at 2021-01-25 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Uncomplicated moderate persistent asthma\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2021-01-25, presumably until 2021-01-27, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-26 08:44:00, ended at 2021-01-26 23:59:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 72 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 20.0 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.11 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 89.00 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.22 (milligram per milligram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte sedimentation rate: 11 (millimeter per hour)\n- MCV [Entitic volume] by Automated count: 93.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Pulmonary disease due to allergic granulomatosis angiitis\n- Acquired hallux varus\n- Hammer toe\n- Metatarsalgia\n- Non-rheumatic aortic sclerosis\n- Localized, primary osteoarthritis of the ankle and/or foot\n- Pain in right foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-26 09:16:50, ended at 2021-01-26 10:35:10\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 2\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic aortic sclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2021-01-26 10:42:23, ended at 2021-01-26 12:24:26\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pulmonary disease due to allergic granulomatosis angiitis\n- Uncomplicated severe persistent asthma\n- Osteoporosis\n- Non-rheumatic aortic sclerosis\n- Uncomplicated moderate persistent asthma\n- Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-27 00:00:00, ended at 2021-01-27 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Uncomplicated moderate persistent asthma\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2021-01-27, presumably until 2021-02-09, with intended 1 refill(s). Instructions: 2 mL (0.5 mg total) by Inhalation route 2 times a day\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "b683f88bc101cd0b5ef4926f40a5b15e4ec57da197b188dcddb595d1e2eee06b", "prompt_hash": "23576c70692d12b5df6b0ef85e31cf48fff96ee6abb638f85075230e4c4a23ab", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 9, "doc": {"person_id": 115969679, "visit_occurrence_id": 168311949, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2020-12-05 07:12:00", "visit_end_datetime": "2020-12-05 07:38:00", "visit_length_in_hours": 0.43333333333333335, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-05 07:12:00, ended at 2020-12-05 07:38:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 43.8 (percent)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.7 (second)\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 120 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 11.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 191 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.87 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Chronic kidney disease\n- Aortic aneurysm\n- Prediabetes\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 903, "patient_first_visit_date": "2018-11-26 00:00:00", "patient_last_visit_date": "2023-01-22 12:58:51", "end_obs_date": "2021-12-05", "hypertension_type": "new", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 8, "cumulated_visit_num": 8, "cumulated_approximate_token_count": 1809, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-26 00:00:00, ended at 2018-11-26 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Primary diagnosis: Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-13 09:25:00, ended at 2019-04-13 10:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Thoracic aortic aneurysm without rupture\n- Non-rheumatic heart valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-13 11:00:00, ended at 2019-04-13 23:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 54.5 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 14:35:00, ended at 2019-04-15 23:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Thoracic aortic aneurysm without rupture\n- Disorder of body system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-05 00:00:00, ended at 2019-06-05 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Primary diagnosis: Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-15 00:00:00, ended at 2020-11-15 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary diagnosis: Aortic aneurysm\n- Aortic incompetence, non-rheumatic\n- Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Aortic incompetence, non-rheumatic\n- Aortic aneurysm\n- Chronic kidney disease\n- Prediabetes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-05 07:12:00, ended at 2020-12-05 07:38:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 43.8 (percent)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.7 (second)\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 120 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 11.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 191 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.87 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Chronic kidney disease\n- Aortic aneurysm\n- Prediabetes\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-26 00:00:00, ended at 2018-11-26 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Primary diagnosis: Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-13 09:25:00, ended at 2019-04-13 10:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Thoracic aortic aneurysm without rupture\n- Non-rheumatic heart valve disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-13 11:00:00, ended at 2019-04-13 23:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 54.5 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 14:35:00, ended at 2019-04-15 23:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Thoracic aortic aneurysm without rupture\n- Disorder of body system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-05 00:00:00, ended at 2019-06-05 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-rheumatic heart valve disorder\n- Primary diagnosis: Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-15 00:00:00, ended at 2020-11-15 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary diagnosis: Aortic aneurysm\n- Aortic incompetence, non-rheumatic\n- Thoracic aortic aneurysm without rupture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Aortic incompetence, non-rheumatic\n- Aortic aneurysm\n- Chronic kidney disease\n- Prediabetes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-05 07:12:00, ended at 2020-12-05 07:38:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.85 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.5 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 43.8 (percent)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.7 (second)\n- Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin: 120 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 11.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 191 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.87 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Aortic incompetence, non-rheumatic\n- Chronic kidney disease\n- Aortic aneurysm\n- Prediabetes\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Chronic kidney disease within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of chronic_kidney_disease means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["Yes"]], "filtered_resps": ["Yes"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "be173e4ba8c42a508c9b2bc82dcd44ebdae050daabdb9fa283d77af517a5a26e", "prompt_hash": "e8b575a86be67a3cc4d09d7eaaff131d1846d78a9cc5cf932394fa94e1daae48", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 1.0, "f1_gu_yn": [1, 1], "recall_gu_yn": [1, 1]}
